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Abstract 
Multiple sclerosis (MS) is a chronic disease of the human central nervous system 
(CNS)  in  which  repeated  episodes  of  inflammatory  demyelination  result  in 
formation of persistently demyelinated plaques of gliotic scar tissue associated 
with varying degrees of axonal loss.   MS is now considered a “complex trait” 
that is triggered in genetically susceptible individuals by environmental factors.  
The disease is also considered to contain an autoimmune component where both 
the  adaptive  and  innate  immune  systems  have  been  implicated  in  disease 
pathogenesis.  There has been a steady accumulation of circumstantial evidence 
from  both  clinical  and  experimental  studies  that  implicate  a  role  for 
autoantibody dependent mechanisms.  However this issue remains controversial 
in the absence of formal evidence that patients actually develop a pathogenic 
autoantibody response.  The aim of this thesis was to resolve this question.   
 
To do this we developed an in vitro bioassay based on a dissociated myelinating 
culture system from embryonic rat spinal cord.  We demonstrated that this in 
vitro system could reproduce many features of in vivo myelinated axons.  To 
validate  this  model  as  a  viable  screening  assay  characterised  complement 
mediated autoantibody responses using a series of monoclonal antibodies and 
anti-sera.  Due to their significance in the literature we focussed in particular on 
the  MOG  specific  and  Nfasc  specific  responses  and  comprehensively 
demonstrated that our bioassay offered a robust screening strategy in which to 
detect pathogenic antibody responses in the presence and absence of exogenous 
complement.   
 
To  determine  whether  we  could  use  our  model  to  detect  pathogenic 
autoantibody  responses  in  MS  patients,  we  purified  the  IgG  fraction  from  a 
cohort of MS patients (n=20), OND (n=10) and healthy controls (n=13).  Using this 
patient  purified  IgG  we  demonstrated  a  MS  specific  demyelinating  activity, 
which was present in ~50% of samples screened.  However in 10% of patients 
demyelination occurred secondary to pronounced axonal injury.  These effects 
were dependent on exogenous complement and were unique to the MS cohort.  
Pathogenic antibody responses tended to be most prevalent in those patients 
with an aggressive disease course.  In addition to complement mediated CNS 
injury we also demonstrated that this pathogenic MS IgG could disrupt myelin 
formation in developing myelinating cultures.  Attempts to define the specificity 
revealed that this was heterogeneous, however in one MS patient we discovered 
that  Nfasc155  provided  a  dominant  antigen  for  pathogenic  autoantibody 
responses.    
 
Together these data provide formal demonstration that MS is associated with 
pathogenic autoantibody responses.  This has significant long term consequences 
for the clinical management of the disease.   
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 1 
1  Introduction 
1.1 Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic disease of the human central nervous system 
(CNS)  in  which  repeated  episodes  of  inflammatory  demyelination  result  in 
formation of persistently demyelinated plaques of gliotic scar tissue associated 
with varying degrees of axonal loss (review: Steinman et al., 2001). MS affects 
approximately  100,000  people  in  the  UK  and  its  incidence  in  Scotland 
(approximately 200 per 100,000) is among the highest worldwide (Handel et al., 
2011).  It is typically diagnosed between the ages 20 and 40 and is a leading 
cause  of  non-traumatic  neurological  disability  in  young  adults.  It  not  only 
severely compromises the quality of life of the patient and their families, but 
also has far wider adverse socioeconomic effects, costing the UK economy in 
excess  of  £1.5  billion  (review:  Kolbelt  et  al.,  2000;  review:  Trisolini  et  al., 
2010).   
The  macroscopic  neuropathological  changes  associated  with  MS  were  first 
described by Carswell in 1838 (Murray, 2009), but it was only formally defined as 
a clinical entity thirty years later by Charcot who named it “sclerose en plaques” 
(Charcot, 1868).  Over a century later it is accepted the diverse symptoms of MS 
are associated with perivascular inflammatory infiltrates, demyelination, axonal 
loss and astrogliosis in the brain and spinal cord (review: Frohman et al., 2006), 
but there is still no fully effective treatment for this devastating condition.  
MS  is  now  considered  a  “complex  trait”  that  is  triggered  in  genetically 
susceptible individuals by environmental factors (review: Sospedra and Martin, 
2005). The complexity of the genetic component is evident from familial studies 
and more recently genome wide genetic screens.  Monozygotic twins have a 20-
35% increased risk of developing MS and first degree family members of patients 
have a 2 - 5% increased risk (Haines et al., 2002; Dyment et al., 2004). This can 
be attributed predominantly to the effects of specific HLA-DR and –DQ alleles 
that  confer  a  greater  risk  of  developing  the  disease  (Haines  et  al.,  2002; 
Barcellos  et al.,  2003),  although  an increasing  number  of other  susceptibility 
genes are now being identified that include contribution from specific IL7R and 2 
IL2R  alleles  (Hafler  et  al.,  2007).    However  relatively  low  concordance  for 
clinically  definite  MS  in  monozygotic  twins  implies  additional  environmental 
factors must be involved in its aetiology. Numerous environmental factors are 
implicated  in  the  pathogenesis  of  MS  including  viral  infections,  smoking  and 
vitamin D deficiency but as yet no single factor has been identified that acts a 
trigger for disease in genetically susceptible individuals (review: Handel et al., 
2010).   
The  clinical  classification  of  MS  patients  largely  relies  on  the  disease  course 
[Figure 1.1].  The majority of MS patients develop initially a relapsing remitting 
form of the disease (RRMS), characterised by the appearance of new symptoms 
or  the  worsening  of  existing  symptoms,  followed  by  periods  of  recovery.  
Relapses vary in severity and duration and periods of remission may be relatively 
transient or last for many months or even years.  If 10 to 20 years after the 
initial  diagnosis,  symptoms  have  not  progressed  and  there  is  little  disability, 
patients may be classified as having benign MS.  However, most RRMS patients 
eventually develop secondary progressive MS (SPMS) which is characterised by a 
progressive  worsening  of  symptoms  in  the  absence  of  clearly  defined  acute 
relapses; an estimated 65% of RRMS patients will develop SPMS within 15 years of 
disease onset (Koch et al., 2008).  The other major clinical variant is primary 
progressive  MS  (PPMS)  which  occurs  in  approximately  15%  of  cases  of  MS 
patients.  This is characterised by a progressive increase in clinical deficits from 
onset  of  disease  and  lacks  any  superimposed  relapses  or  remissions.    PPMS 
differs from the other MS subtypes in a number of ways; men are as likely to 
develop primary progressive disease as women, disease onset is usually later in 
life  (mid-30s  to  early  40s),  initial  disease activity  is  often  in  the  spinal  cord 
although there is later brain involvement and is characterised by severe atrophy 
and axonal degeneration (Review: Sospedra and Martin, 2005).  
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Figure 1.1:  The four major MS subtypes 
There are four major MS subtypes.  The most common of which is relapsing remitting MS 
(RRMS).  The majority of patients with RRMS go on develop secondary progressive disease 
characterised by the progressive worsening of symptoms.  However if there is little to no 
disease progression or neurological deficit then the patient is classed as having benign MS.  
In  ~15%  of  all  MS  cases  present  with  primary  progressive  disease  mediated  by  gradual 
deterioration without superimposed relapses or periods of recovery.  Figure adapted from 
Lublin and Reingold (1996).   
The introduction  of  sensitive  magnetic resonance  imaging  (MRI)  protocols  has 
shown  that  the  pathomechanisms  responsible  for  disease  progression  in  PPMS 
and SPMS differ from those associated with relapses in patients with RRMS. In 
early  relapsing  remitting  disease  the  development  of  clinical  deficits  is 
associated with an ongoing inflammatory process in the CNS as defined by the 
presence of gadolinium enhancing lesions by MRI. Disease-modifying agents that 
significantly  reduce  the  relapse  rate  also  suppress  the  development  of 
gadolinium  enhancing  lesions  in  RRMS.  Intriguingly,  not  only  is  little  or  no 
inflammatory activity detected by MRI in the brains of patients with established 
progressive  forms  of  the  disease  and  SPMS,  but  disease  modifying  anti-
inflammatory  agents  also  appear  to  have  no  appreciable  effect  on  the 
progressive  accumulation  of  disability  (Bradl  and  Lassmann,  2009).    These 
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observations indicate that different mechanisms can contribute to the formation 
of chronically demyelinated plaques of scar tissue  in the CNS, the end stage 
pathology of the disease. This interpretation is supported by immunopathological 
studies describing four distinct lesion types in different MS patients (Lucchinetti 
et al., 2000).  
There are also a number of other diseases that mimic clinical, neuroradiological 
and pathological features of MS but which are clearly distinct clinical entities. 
These  include  acute  disseminated  encephalitis  (ADEM),  a  post-infectious 
inflammatory  demyelinating  disease  and  neuromyelitis  optica  (NMO)  an 
inflammatory  demyelinating  disease  triggered  by  a  primary  autoimmune 
response to directed against aquaporin-4 which is expressed by astrocytes in the 
CNS.  More problematic are patients diagnosed with clinically isolated syndrome 
(CIS) classified by the presence of a single demyelinating event at disease onset 
often will subsequently go onto develop RRMS but cannot be given this diagnosis 
at presentation (Polman et al., 2005). 
Understanding how demyelination and axonal injury occur in MS is essential if we 
are  to  treat  the  disease  efficiently,  but  our  understanding  of  the 
pathomechanistic  basis  of  MS  remains  limited  despite  fifty  years  of  intense 
research.  There  is  circumstantial  evidence  for  the  involvement  of  an 
autoimmune  component,  but  whether  MS  is  an  autoimmune  disease  per  se 
remains controversial. For many years it was assumed MS was a purely a CD4
+ T 
cell  mediated  disease.  This  hypothesis  was  based  on  the  identification  of 
particular HLA class II haplotypes as susceptibility genes and the demonstration 
that  MHC  class  II  restricted  T  cells  specific  for  myelin  antigens  could  induce 
experimental  allergic  encephalomyelitis  (EAE),  an  MS-like  disease  in 
experimental animals (review: Zamvil and Steinmann, 1990). Over the past 75 
years  EAE  has  provided  a  powerful  tool,  enhancing  our  understanding  of 
neuroinflammatory  disease  mechanisms  (review:  Gold  et  al.,  2006).    Two 
approved  immunomodulating  therapies  for  MS,  glatiramer  acetate  and 
natalizumab,  were  developed  from  initial  studies  in  EAE  (Sela  et  al.,  1990; 
Yednock  et  al.,  1992).    Nonetheless,  the  “T-cell  centric”  view  of  MS 
pathogenesis is now regarded as an oversimplification and it is now accepted 
that  in  addition  to  T  cell  dependent  inflammation  other  pathomechanisms 
contribute to lesion formation.  5 
There  has  been  a  steady  accumulation  of  circumstantial  evidence  from  both 
clinical  and  experimental  studies  that  implicate  a  role  for  autoantibody 
dependent  mechanisms.  However,  in  the  absence  of  formal  evidence  that 
patients  actually  develop  a  pathogenic  autoantibody  response,  the 
clinical/pathological significance of autoantibodies remains controversial. This is 
the question addressed in this thesis. The following sections will therefore focus 
on reviewing the evidence that MS is associated with a pathologically significant 
autoantibody  response,  rather  than  on  the  details  of  purely  T  cell  and/or 
monocyte dependent mechanisms that could contribute to disease development. 
 
1.2 The broad spectrum of autoantibody mediated 
diseases 
Early in the last century Ehrlich introduced the concept of “horror autotoxicus”, 
the  generation  of  antibodies  against  self  antigens.  However  Ehrlich  also 
described that “by certain contrivances” these self-reactive autoantibodies were 
unable to mediate disease. This led to the belief that autoimmune disease could 
not  occur,  a  dogma  that  persisted  well  into  the  mid-1950s,  when  it  was 
challenged by the discovery of pathogenic antibodies in experimental thyroid 
disease  (Witebsky  et  al.,  1957;  Commentary:  Silverstein,  2001).  Over  the 
following 50 years a  broad spectrum of autoantibody mediated diseases have 
been  identified  that  can  affect  almost  every  tissue  in  the  body,  either  by 
targeting tissue-specific autoantigens, as is the case in Addison’s disease and 
Myasthenia  Gravis  or  recognition  of  tissue  non-specific  targets  such  double 
stranded DNA in patients with systemic lupus erythematosus (SLE) (Wellmann et 
al., 2005).  A number of autoantibody mediated diseases of the CNS have also 
been  identified  including  Morvan’s  syndrome  and  Neuromyelitis  Optica  [Table 
1.1]. Although autoantibody mediated diseases are very diverse with respect to 
antigen  specificity,  target  and  mode  of  action  they  do  exhibit  a  number  of 
commonalities  including  gender  bias  (generally  with  a  higher  prevalence  in 
females),  genetic  predisposition  and  the  involvement  of  an  environmental 
component in their aetiology. 6 
Table 1.1: A selection of human autoimmune diseases mediated by autoantibodies (either 
completely or partly).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Systemic
Autoantibodies DNA, nuclear proteins, 
erythrocytes and 
platelets
Systemic lupus 
erythematosus (SLE)
Autoantibodies Various antigens.  
Salivary gland, kidney , 
liver and thyroid are 
commonly targeted
Sjogren’s Syndrome
Autoantibodies Type IV collagen Goodpasture’s Disease
Autoantibodies 
(stimulating)
Thyroid stimulating 
hormone receptor 
(TSH-R)
Grave’s Disease
Autoantibodies 
(blocking)
Thyroid stimulating 
hormone receptor 
(TSH-R)
Thyroid proteins and 
cells 
Hashimoto’s Thyroiditis
Autoantibodies
T cells
Acetylcholine receptor 
(AChR)
Muscle specific Kinase
(MUSK)
Myasthenia Gravis 
Autoantibodies Voltage-gated 
potassium channel 
(VGKC)
Morvan’s Syndrome
Autoantibodies
T cells
Aquaporin-4 (astrocyte 
end foot)
Neuromyelitis Optica
Autoantibodies Voltage-gated 
potassium channel 
(VGKC)
Neuromyotonia
Autoantibodies
Immune complexes
Connective tissue, 
immunoglobulin
Rheumatoid arthritis
Autoantibodies 21 hydroxylase Addison’s Disease
Organ-specific 
Immune response Self-antigen Disease
Systemic
Autoantibodies DNA, nuclear proteins, 
erythrocytes and 
platelets
Systemic lupus 
erythematosus (SLE)
Autoantibodies Various antigens.  
Salivary gland, kidney , 
liver and thyroid are 
commonly targeted
Sjogren’s Syndrome
Autoantibodies Type IV collagen Goodpasture’s Disease
Autoantibodies 
(stimulating)
Thyroid stimulating 
hormone receptor 
(TSH-R)
Grave’s Disease
Autoantibodies 
(blocking)
Thyroid stimulating 
hormone receptor 
(TSH-R)
Thyroid proteins and 
cells 
Hashimoto’s Thyroiditis
Autoantibodies
T cells
Acetylcholine receptor 
(AChR)
Muscle specific Kinase
(MUSK)
Myasthenia Gravis 
Autoantibodies Voltage-gated 
potassium channel 
(VGKC)
Morvan’s Syndrome
Autoantibodies
T cells
Aquaporin-4 (astrocyte 
end foot)
Neuromyelitis Optica
Autoantibodies Voltage-gated 
potassium channel 
(VGKC)
Neuromyotonia
Autoantibodies
Immune complexes
Connective tissue, 
immunoglobulin
Rheumatoid arthritis
Autoantibodies 21 hydroxylase Addison’s Disease
Organ-specific 
Immune response Self-antigen Disease7 
1.2.1 Criteria for recognising autoantibody mediated disease 
Demonstrating that autoantibody-dependent mechanisms are involved in disease 
pathogenesis  is  complicated  by  the  presence  of  pathologically  irrelevant 
autoautoantibodies within the normal repertoire, and their potential expansion 
following tissue damage. So what criteria should be used to decide whether an 
autoantibody  response  plays  a  significant  role  in  disease  pathogenesis?    Koch 
proposed  a  set  of  postulates  to  identify  pathogens  responsible  for  a  specific 
disease. These were adapted by Witebsky and subsequently Rose (Witebsky et 
al., 1957; Rose and Bona, 1993) as criteria to identify pathogenic autoantibodies 
actively  involved  in  disease  development.    For  an  antibody  to  be  universally 
accepted as pathogenic most if not all of the following criteria must be fulfilled. 
a: It must be present in most patients. 
b: It must be present at the site of injury. 
c: Passive transfer antibody should reproduce the clinical/pathological 
characteristics of the disease. 
d: Immunisation with antigen induces disease and autoantibody 
production in experimental animals. 
e: Demonstration of pathogenic antibody activity using target cells. 
f:  Reduction of antibody levels ameliorates the disease. 
Table 1.2 summarises antibody mediated autoimmune diseases fulfilling these 
criteria for pathogenic antibodies, of which myasthenia gravis is the best known, 
whilst neuromyelitis optica, an inflammatory demyelinating disease reproducing 
some of the features of MS illustrates the difficulties of using the Witebsky/Rose 
criteria to define a pathologic autoantibody response in CNS disease.  
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Table 1.2: A selection of autoimmune diseases which fulfil the some if not all criteria for 
pathogenic autoantibodies.   
There  are  a  number  of  autoimmune  diseases  both  organ-specific  (neurological  and  non-
neurological) and systemic which can be described as pathogenic autoantibody mediated using a 
series of postulates which define pathogenic activity.  ND= not done or unknown.  
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1.3 Myasthenia Gravis 
Myasthenia  Gravis  (MG)  is  characterised  by  severe  muscle  weakness  and 
fatiguability due to autoimmune destruction of the post synaptic membrane at 
the neuromuscular junction (NMJ) leading to a loss of muscle innervation.  The 
disease  can  affect  any  muscle  (except  the  heart)  and  can  be  fatal  if  the 
respiratory muscles become paralysed (known as myasthenic crisis).  Research 
into the potential role of autoantibodies in MG pathogenesis began over 50 years 
ago when Simpson first introduced the concept of “antibodies to an endplate 
protein”  (Simpson,  1960).    This  endplate  protein  was  later  identified  as  the 
acetylcholine receptor (AChR) (Patrick and Lindstrom, 1973; Lindstrom et al., 
1976).  MG  is  regarded  the  “textbook”  example  of  an  autoantibody  mediated 
disease and one which satisfies all six criteria listed previously.   
a: Autoantibodies are frequently present in patients. 
Antibodies to AChR are present in ~80% of MG patients and were seldom found in 
healthy controls or in association with in other diseases (Lindstrom et al., 1976).  
A subset of MG which lack anti-AChR antibodies (~40%) have been shown to have 
high  titres  of  antibodies  against  muscle  specific  kinase  (MUSK)  (Hoch  et  al., 
2001; Evoli et al., 2003).  
b: Detection of antibody at the site of injury. 
Injury at the neuromuscular junction has been associated with deposition of IgG 
and  complement  activation  products  (C3  and  MAC)  at  the  post  synaptic 
membrane (review: Engel, 1984).  Injury is accompanied by a loss of AChR either 
via internalisation or via shedding (Fambrough et al., 1973).   
c: Reproduction of disease features by passive transfer of autoantibodies. 
Transfer  of  MG  patient  IgG  confers  a  MG-like  disease  in  mice.    Mice  with 
experimental  MG  reproduced  clinical  pathology  with  a  marked  loss  of  AChR 
expression at the NMJ.  Electrophysiology confirmed that disruption of the NMJ 
was accompanied by a loss of muscle innervation (Toyka et al., 1977).   10 
Antibodies are also able to mediate pathology via maternal transfer across the 
placenta.  The majority of women with MG give birth to healthy babies or with 
minor transient MG.  Unfortunately in a small number of cases children are born 
with arthrogryposis, a severe congenital disorder resulting in lifelong disability.  
Barnes et al. demonstrated that these severe birth defects were due to high 
maternal antibody titres against the foetal specific form of the AChR.  Passive 
transfer of this patient serum into pregnant mice resulted in antibody-mediated 
arthrogryposis in the offspring (Barnes et al., 1995).     
d: Immunisation with antigen induces disease and autoantibody production. 
Rabbits  injected  with  purified  AChR  develop  experimental  MG  the  clinical 
symptoms  greatly  improved  upon  intravenous  injection  of  edrophonium  (an 
acetyl-choline esterase inhibitor) (Patrick and Lindstrom 1973).   
e: Demonstration of pathogenic antibody activity using target cells. 
Serum or IgG purified from MG patients downregulates expression of AChR on 
cultured muscle cells (Review: Drachmann, 2003).   
f: Reduction of antibody levels ameliorates the disease. 
MG patients respond well to therapies such as plasma exchange or intravenous 
IgG that remove pathogenic immunoglobulins from the blood which correlates 
with a marked improvement in clinical symptoms (Newsom-Davies, 1979).   
Robb et al, observed a reduction in clinical severity in MG in response to immune 
suppression  using  azathioprine  and  prednisolone  which  corresponded  to  a 
marked reduction in AChR antibody titre (unpublished observations by Robb et 
al.,  communicated  by  Dr  C.  Buckley,  European  School  of  Neuroimmunology, 
October 2010).   
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1.4 Neuromyelitis Optica  
Neuromyelitis optica (NMO) was first described over a century ago by Allbutt 
who reported a patient with a "sympathetic disorder of the eye" after an acute 
episode  of  myelitis  (Allbutt,  1870).  The  disease  was  further  characterised  by 
Devic (1894) and is now also known as Devic’s disease.  NMO is classified as an 
inflammatory demyelinating disease characterised by a selective involvement of 
the spinal cord and optic nerve and which typically spares the brain.  MRI studies 
of the spinal cord reveal extensive central longitudinal lesions which results in 
severe disability and respiratory failure in those patients with lesions affecting 
the  brain  stem  whilst  optic  neuritis  may  be  unilateral  or  bilateral.    It  was 
assumed for many years that NMO was simply a rare anatomical variant of MS.  In 
fact an optic-spinal variant of MS, which accounts for 15-40% of all MS cases in 
Japan (Misu et al., 2002; Kira et al., 2003) shares many common features with 
NMO.  However the identification of NMO-Ig as a specific biomarker for NMO lead 
to it being identified as a distinct disease entity (Lennon et al., 2004; [Table 
1.3].  The  antigenic  target  of  NMO-Ig  is  aquaporin-4  (AQP-4)  (Lennon  et  al., 
2005).  AQP-4 is the major water channel expressed by astrocytes in the CNS 
where it is preferentially localised within astrocytic end feet at the blood-brain 
barrier.  Knockout studies in mice demonstrate AQP-4 is involved in maintaining 
the integrity of the blood brain barrier and loss of this protein causes the blood 
brain  barrier  to  become  hyper-permeable  allowing  free  translocation  of 
molecules in to the CNS (Zhou et al., 2008).  NMO is the first proven example of 
an autoantibody mediated disease of the CNS that results in extensive loss of 
myelin, despite not fulfilling all of the Witesbsky/Rose citeria.   
•  Passive  transfer  of  disease  by  NMO-Ig  requires  permeablisation  of  the 
blood brain barrier (Bradl et al., 2009). 
•  Active  immunisation  of  rodents  with  AQP-4  does  not  induce  disease 
(Kalluri et al., 2011).  
These  points  demonstrate  the  problems  of  strictly  applying  Witebsky/Rose 
criteria to CNS disorders.   
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Table 1.3: The key features of NMO and MS 
Although MS and NMO are inflammatory demyelinating diseases of the CNS, comparison of the 
key features of both diseases reveals significant differences in their pathology and aetiology.   
 
 
 
 
 
 
 
 
 
a: Autoantibodies are frequently present in patients. 
The presence of NMO-IgG in the serum of patients of NMO patients was first 
described  in  2004  by  Lennon  et  al.  using  an  indirect  immunofluorescence 
staining by applying patient serum to murine CNS tissue.  The staining pattern of 
NMO-IgG is unique, outlining CNS microvessels, pia, subpia and Virchow-Robin 
spaces.  From a cohort of 45 patients with clinically definite NMO, 73% were 
seropositive  for  NMO  IgG.    In  contrast,  NMO-IgG  was  only  detected  in  2%  of 
classic MS patient samples screened (n=20).  Interestingly, in the small group of 
Japanese patients with Asian optic-spinal MS, 58% were seropositive for NMO-IgG 
(Lennon et al., 2004).  A range of AQP-4 specific assays are also now available 
and that identify AQP-4 specific autoantibodies in most patients with clinically 
confirmed NMO (McKeon et al., 2009).   
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b: Detection of antibody at the site of injury. 
Binding of NMO-IgG to AQP-4 to astrocytes at the blood brain barrier has been 
demonstrated in both murine (Lennon et al., 2005) and primate CNS sections 
(Vincent et al., 2008).  In each case NMO-IgG binding patterns show a linear 
perivascular localisation in the white matter and granular layer.  This staining 
pattern is unique to NMO-IgG and a subset of patients with optic-spinal MS but is 
not observed in classic MS samples (Lennon et al., 2004; Roemer et al., 2007; 
Vincent et al., 2008).  Histopathological analysis of NMO autopsy samples shows 
perivascular  inflammatory  demyelinating  lesions  associated  with  extensive 
deposition  of  immunoglobulins  and  complement  activation  products  at  the 
perivascular  rim  or  in  a  rosette  pattern  surrounding  vessels.    These  lesions 
correlate  to  significant  vascular  fibrosis  (Lucchinetti  et  al.,  2002).    Lesion 
formation  is  accompanied  by  loss  of  AQP-4  expression  irrespective  of  lesion 
localisation  or  the  extent  of  necrosis  or  demyelination.    In  early  spinal  cord 
lesions, demyelination is preceded by loss of AQP-4.  In MS, significant AQP-4 
loss was only detectable in inactive MS lesions (Roemer et al., 2007).  
c: Reproduction of disease features by co-transfer of autoantibodies. 
In MG the antigenic target is readily accessible to circulating antibody, but this 
is not the case for CNS antigens, which are sequestered behind the blood brain 
barrier (BBB). It is well established that the BBB will normally inhibit entry of 
antibody  into  the  CNS,  and  as  a  consequence  circulating  CNS  specific 
autoantibodies will cause no clinical or pathological deficits in healthy animals 
(Litzenburger  et  al.,  1998).    However,  the  pathogenic  potential  of  NMO 
associated autoantibodies can be demonstrated either by direct injection in to 
the CNS (Saadoun et al., 2011: in press) or passive transfer into animals with EAE 
(Bradl et al., 2009). In the latter case NMO patient-derived autoantibodies not 
only  exacerbated  clinical  disease  but  also  resulted  in  formation  of  NMO-like 
lesions characterised by immune complex deposition, AQP-4 and astrocyte loss 
and inflammatory cell infiltrates. Similar observations were made in adoptive 
transfer  studies  using  patient-derived  AQP-4  specific  monoclonal  antibodies 
(Bennett et al., 2009). 
 14 
Transfer  of  immunoglobulins  purified  from  NMO  patients  into  rats  with  EAE 
mediated  by  encephalogenic  MBP  specific  T  cells  augments  clinical  disease.  
Associated  histopathology  demonstrates  the  formation  of  NMO-like  lesions 
characterised  by  immune  complex  deposition,  AQP-4  and  astrocyte  loss 
accompanied by extensive immune cell infiltrates (Bradl et al., 2010).  These 
observations  replicate  those  reported  previously  when  transferring  an  AQP-4 
specific monoclonal antibody into rats with T cell mediated EAE (Bennett et al., 
2009).   
d: Immunisation with antigen induces disease and autoantibody production. 
There is as yet no formal AQP-4 based in vivo animal model of NMO, although 
some rodent models of MOG-induced EAE do exhibit notable NMO-like pathology 
(i.e.  lesions  restricted  to  spinal  cord  and  optic  nerve)  (Stefferl  et  al.,  1999; 
Krishnamoorthy et al., 2006; Bettelli et al., 2006). Immunisation of mice with a 
full  length  AQP-4  peptide  or  peptides  corresponding  to  immunogenic  T  cell 
epitopes did not induce spinal cord injury or optic neuritis (Kalluri et al., 2011). 
This lack of observed pathology may be due to dependence on conformational 
epitopes similar to that described in some forms of MOG induced EAE (Stefferl et 
al., 1999). Although active immunisation with AQP-4 peptides is insufficient to 
induce injury, it has been reported that immunisation is capable of producing 
high titre AQP-4 anti-sera in rodents (Review: Graber et al., 2008). 
e: Demonstration of pathogenic antibody activity using target cells. 
Binding of NMO-IgG to astrocytic AQP-4 can be shown both in vivo and in vitro 
using cultured astrocytes. In active NMO lesions there is a loss of perivascular 
GFAP+  astrocytes  (Misu  et  al.,  2007),  but  the  exact  mechanism  leading  to 
astrocyte  loss  remains  unclear, although  incubation of  rat  astrocytes  in  vitro 
with  NMO-Ig  mediates  complement  dependent  lysis  (Kinoshita  et  al.,  2009). 
Using  an  in  vitro  BBB  model  Vincent  et  al.  demonstrated  that  incubation  of 
astrocytes in culture with NMO-IgG caused internalisation of AQP-4 and enhanced 
BBB permeability (Vincent et al., 2008). However, it still remains unclear how 
autoantibodies  that  attack  the  end  feet  of  astrocytes  trigger  demyelination. 
Incubation  of  co-cultures  of  astrocytes  and  oligodendrocytes  with  NMO-IgG 
resulted in major astrocyte dysfunction and a marked loss of oligodendrocytes. 15 
This observation was reproduced in ex vivo optic nerve tissue preparations.  One 
potential mechanism may due to increased glutamate cytotoxicity, as incubation 
of  treated  co-cultures  with  a  NMDA  receptor  antagonist  partially  protected 
oligodendrocyes (Marignier et al., 2010). 
f: Reduction of antibody levels ameliorates the disease. 
Antibody depleting therapies such as plasma exchange are useful in the clinical 
management of NMO (Keegan et al., 2002) as is B cell depletion (Cree et al., 
2005). Immune modulation using rituximab, azathioprine and cyclophosphamide 
is  associated  with  reduced  AQP-4  antibody  titres  and  reduced  relapse  rates. 
Conversely, a three fold increase in AQP-4 antibody titres was detected shortly 
before relapse (Jarius et al., 2008).  
In  conclusion,  the  demonstration  that  antibody-dependent  mechanisms  were 
involved in NMO and the identification of AQP-4 as a target for this response 
radically  improved  the  clinical  management  of  NMO.  If it  can be  shown  that 
autoantibody mediated mechanisms contribute to the pathogenesis of MS, it is 
likely that this will result in a similar improvements in disease diagnosis and 
treatment. 
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1.5 Antibody involvement in multiple sclerosis- the 
supporting evidence 
1.5.1 The presence of oligoclonal bands in the CSF 
It has been known since the 1940s that MS is associated with elevated levels of 
intrathecal immunoglobulins within the CSF (Kabat et al., 1948). Resolution of 
patient CSF Ig by agarose gel isoelectric focusing (IEF) produces an oligoclonal 
banding pattern completely distinct from the polyclonal “smear” obtained when 
analysing serum IgG (Johnson et al., 1977). Oligoclonal bands (OCB) are present   
in the CSF in a majority of MS patients and are considered a diagnostic hallmark 
of the disease. Despite their presence in the majority of patients, the banding 
pattern and specificity varies (Andersson et al., 1994). The significance of this 
heterogeneity remains unclear. There is evidence to suggest that OCBs may be 
useful  relevant  prognostic  biomarkers  as  OCB-negative  MS  patients  tend  to 
follow  a  benign  disease  course  (Farrell  et  al.,  1985).  Conversely,  in  a 
retrospective study, elevated intrathecal IgG synthesis and number of OCBs were 
correlated with a progressive disease course (Avasarala et al., 2001), although a 
more  recent  study  failed  to  validate  this  observation  (Koch  et  al.,  2007) 
therefore  their true value is  difficult  to  determine. In  RRMS the  presence of 
oligoclonal  IgM  in  the  CSF  of  RRMS  patients  is  indicative  of  an  increased 
probability of developing secondary progressive disease (Villar et al., 2002) and 
enhanced  intrathecal  IgM  production  was  associated  with  rapid  disease 
progression  (Villar  et  al.,  2003).  However  once  again,  other  groups  failed  to 
replicate these findings as they were not confirmed by an independent study 
(Schneider et al., 2007), so the value of these CSF measurements as informative 
biomarkers remains controversial and their clinical relevance obscure. 
 
1.5.1.1  Source of oligoclonal bands  
B cells and antibodies do not normally cross the intact BBB to any significant 
extent. However, at sites of inflammation not only are B cells are recruited into 
the CNS, but passive diffusion of serum proteins into the lesion is also greatly 
increased due to localised damage to the BBB. B cells were first described in the 17 
CNS of MS patients by Prineas, who detected ectopic lymphoid-like structures in 
some autopsy samples (Prineas, 1979). These follicle-like aggregates of B cells 
are reported to be a relatively common finding in SPMS, where they are localised 
within the meninges. Moreover, their presence correlates with a more aggressive 
disease course (Serafini et al., 2004; Magliozzi et al., 2007). The presence of 
these follicles, together with the observation that synthesis of individual OCB 
can persist for many years, suggests the CNS in MS provides niches that support 
sustained  B  cell  survival  and  differentiation  (review:  Meinl  et  al.,  2006). 
Unfortunately there is as yet no formal evidence that OCB IgG is actually derived 
from B cells within these aggregates. However, analysis of the IgG CSF proteome 
revealed that this overlapped with the IgG transcriptome obtained from a single 
representative of clonally expanded CSF B cell populations in individual patients 
(Obermeier  et  al  2008).  This  formally  demonstrates  that  at  least  some  OCB 
components are derived from clonally expanded CNS B cell populations in MS. 
However it must be stressed that OCB are not specific for MS, and ectopic B cell 
follicles are also present at sites of chronic inflammation in other autoimmune 
diseases such as rheumatoid arthritis (Revew: Aloisi and Pujol-Borrell, 2006). 
 
1.5.1.2  Potential specificities of OCBs in MS 
As stated above, the presence of OCB in CSF is not unique to MS, but is also 
common in infectious diseases of the CNS such as measles encephalitis (Vandvik 
and  Norrby,  1973),  Lyme  neuroborreliosis  (Halperin  et  al.,  1989)  and 
neurosyphilis (Pedersen et al., 1982).  In these cases OCB are generally directed 
against the causative pathogen, which lead to numerous attempts to identify a 
pathogen-specific OCB response in MS patients.  Some OCB associated with MS do 
actually recognise common pathogens such as the measles, rubella and varicella-
zoster  viruses  (Sindic  et  al.,  1994)  or  Chlamydia  pneumoniae  (Derfuss  et  al., 
2001).  However  these  specificities  are  normally  associated  with  minor  OCB 
components and are generally considered to represent a sample of the patient’s 
immunological/infectious  history  (Reiber  et  al.,  1998).  The  failure  of  these 
studies  to  identify  prominent  intrathecal  B  cell  responses  to  pathogens 
stimulated speculation that OCB associated with MS were directed against CNS 
autoantigens.  However,  no  study  has identified a  verified  autoimmune  target 
(see Owens et al., 2009; reviewed in Sospedra and Martin, 2005).  18 
1.5.2 Evidence from histopathogical studies of MS lesions 
One  of  the  most  recent  influential  contributions  to  our  understanding  of  the 
pathogenesis of MS was an immunopathological study performed by Lucchinetti 
and  colleagues.    The  study  was  the  product  of  extensive  international 
collaboration that allowed the authors access to a large collection of biopsy and 
autopsy  samples  from  actively  demyelinating  MS  lesions  (Lucchinetti  et  al., 
2000).  Although this study was extensively criticised as the majority of biopsy 
samples came from patients with clinically or radiologically atypical disease who 
may  not  therefore  be  representative  of  “classic”  cases  of  MS  (Poser  et  al., 
2000), nevertheless, it is still of great interest and significance.  Lesions were 
classified using a number of criteria including the phenotype of cells infiltrating 
the  lesion,  presence  of  complement  activation  products  (C9neo)  and 
immunoglobulin deposition [Table 1.4].  Type I lesions were characterised by 
extensive  demyelination  associated  with  infiltrating  macrophages/microglia, 
whilst  the  most  common  type  II  was  characterised  by  deposition  of 
immunoglobulins  and  C9neo  at  the  site  of  myelin  injury.    The least  common 
lesion patterns observed were type III and type IV lesions.  These lesions were 
not  associated  with  immune  mediated  demyelination  via  macrophages  or 
antibodies/complement but were reminiscent of viral or toxin induced models of 
demyelination.    Interestingly,  signs  of  remyelination  were  reported  only  in 
association with immune mediated/ inflammatory lesion (types I and II). 
Most importantly, this study demonstrated that while MS is not only clinically but 
also  pathologically  heterogeneous,  in  any  one  patient  the  pattern  of 
demyelination in active lesions seems to be homogeneous. This observation has 
major implications for the clinical management of MS.  In particular, the study 
highlighted the possibility that humoral mechanisms play a significant role in 
lesion formation in the majority of patients (as high as 50%); suggesting that 
targeting  this  arm  of  the  immune  response  could  provide  significant  clinical 
benefits.    
This study has been extremely influential in developing our understanding of MS, 
but its findings remain controversial.  The concept that demyelination in MS may 
be mediated by several different effector pathways was challenged by Breij et 19 
al.  who  analysed  actively  demyelinating  lesions  in  autopsy  material  from  39 
patients.  In this study all cases of active demyelination were associated with 
complement activation products, immunoglobulins and phagocytic macrophages. 
This supports the hypothesis that humoral mechanisms play a significant role in 
demyelination  and  calls  into  question  the  involvement  of  other  effector 
mechanisms (Breij et al., 2006).  However deposition of immunoglobulins and 
complement within CNS many not be unique to MS lesions.  Analysis of autopsy 
samples  from  25  MS  and  24  OND  patients  failed  to  identify  any  specific 
association  between  MS  and  deposition  of  immunoglobulins  and  complement 
activation products in the CNS.  The authors interpreted their observations as 
evidence  that  white  matter  injury  in  general  is  associated  with  complement 
activation irrespective of the identity of the disease (Barnett et al., 2009). 
 
Table 1.4:  Heterogeneous characteristics of MS lesions as described by Lucchinetti et al. 
(2000). 
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1.5.3 The efficacy of B cell/ antibody targeted therapies 
Most therapeutic agents routinely used in MS such as corticosteroids, interferons 
and  Tysabri  target  the  inflammatory  component  of  the  disease.  These 
treatments provide a significant clinical benefit in patients with RRMS but do not 
specifically  target  antibody/humoral  pathomechanisms.  However,  as  our 
understanding  of  MS  pathogenesis  has  advanced  there  is  more  interest  in 
exploring the potential role of antibodies and B cells as therapeutic targets.  
1.5.3.1  Plasma exchange 
Plasma exchange is an extracorporeal therapy designed to remove and replace 
plasma from the patient’s blood. For many years it has been used with great 
success  in  treating  a  wide  range  of  autoantibody  mediated  diseases  such  as 
myasthenia gravis, SLE and Guillain-Barre syndrome.  However, plasma exchange 
is not a widely accepted therapy for MS.  This is despite clinical studies dating 
back  to  the  1990s  that  suggest  ~45%  of  MS  patients  with  acute  steroid  non-
responsive exacerbations disease may benefit from therapeutic plasma exchange 
(TPX; Rodriguez et al., 1993; Weinshenker et al, 2001).  In view of the reported 
pathological heterogeneity of MS it is unlikely that TPX would be beneficial in all 
patients.    This  concept  is  supported  by  a  recent  retrospective  study  which 
demonstrated the therapeutic potential of plasma exchange correlated with the 
presence  of  immunoglobulin  and  complement  activation  products  in  biopsied 
lesions (Keegan et al., 2005).   C9neo immunoreactivity is a defining feature of 
pattern II type lesions as defined by Lucchinetti, Lassmann and colleagues and 
only these patients benefited significantly from TPX (Keegan et al., 2005). 
1.5.3.2  B cell depletion therapies  
Following  these  observations  suggesting  that  humoral  pathomechanisms  may 
drive  disease  activity  in  at  least  some  patients,  several  clinical  studies  were 
initiated to investigate whether depletion of B cells might also prove beneficial 
(Review: Cross and Waubant, 2011).  The agent of choice for these studies was 
Rituximab, a monoclonal chimeric antibody that selectively targets and depletes 
CD20+ B cells and which is already licensed to treat lymphoma and rheumatoid 
arthritis.      A  recent  phase  II  trial  of  Rituximab  in  relapsing-remitting  MS 21 
indicated substantial clinical benefit (Hauser et al., 2008).  A single infusion of 
Rituximab resulted in a rapid and sustained depletion of B cells (> 24 weeks) 
associated with dramatic reductions in both the total number of MRI lesions and 
the  number  of  newly  appearing  gadolinium  enhancing  lesions  in  the  brain 
compared to controls.  This decrease in lesion activity/load was accompanied by 
a reduction in clinical disease activity as determined by the relapse rate.  This 
rapid response was unexpected CD20 is not expressed by plasma cells and it 
occurred before there was any significant effect on serum immunoglobulin levels 
(Hauser  et  al.  2008).    An  independent  study  also  failed  to  demonstrate  any 
effect of Rituximab on CSF IgG levels, rate of synthesis or removal of oligoclonal 
bands (Cross et al., 2006).  These observations indicate that the pathogenic role 
of B cells in MS extends beyond their role as a source of autoantibodies, but at 
present how B cell depletion modulates the inflammatory response in the CNS 
remains unclear.  Rituximab has also been trialled in PPMS and in parallel with 
the  findings  in  RRMS  it  also  suppressed  inflammatory  disease  activity  as 
determined by MRI (Hawker et al., 2009).  
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1.6 Myelinated axons- the target of autoantibodies in MS  
The studies outlined above suggest antibody-dependent mechanisms contribute 
to  disease development  in  some  patients with  MS,  but  the  specificity  of this 
response remains obscure.  As demyelination is the most obvious pathological 
feature  of  MS  it  was  assumed  that  any  clinically  significant  autoantibody 
response  would  be  directed  against  a  CNS  myelin-specific  autoantigen.    This 
concept was supported by numerous studies in EAE that identified several myelin 
associated antigens as targets for autoantibody mediated demyelination in vivo 
(review:  McLaughlin  and  Wucherpfennig,  2008).    The  spectrum  of  potential 
targets  is  actually  wider,  as  it  is  now  recognised  that  axon-specific 
autoantibodies may also contribute to disease development (Mathey et al., 2007; 
review: Derfuss et al., 2010).  Yet of the numerous potential targets identified 
over the past four decades, none were ultimately found to be MS specific [Table 
1.5].    Indeed,  it  is  rash  to  assume  that  all  autoantibody  responses  are 
pathogenic,  as  an  increasing  body  of  evidence  demonstrates  that  some 
components of the autoantibody repertoire can actually stimulate remyelination 
in vivo  (review: Schwab et al., 2004; Reindl et al., 2003; Mi et al., 2007).  
Nonetheless, it remains possible that an MS-specific autoantibody response will 
be identified and that this in turn will provide new diagnostic/prognostic tools to 
improve disease management.  This section reviews this concept, focusing on 
recent  advances  in  our  understanding  of  the  MOG-specific  autoantibody 
response.   
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Table 1.5:  Antibodies to myelin and other CNS autoantigens implicated in MS 
Decades of MS research  have  yielded a number of potential  targets for autoantibodies  in  MS.  
These  antibody  responses  have  varying  functions  in  disease.    Some  are  described  as  being 
involved in mediating disease pathogenesis (MOG, Nfasc, GalC) and whereas others are thought 
to  be  involved  in  promoting  remyelination  and  repair  (Lingo-1,  heat  shock  proteins,  Nogo-A).  
Antibody  responses  have  also  been  reported  as  potential  prognostic  markers  (neurofilament, 
phosphatidyl choline).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathey et al., 2007 Axoglial adhesion molecule.  Abs to both Nfasc155 and 
Nfasc186 isoforms are present in MS serum.  
Neurofascin
Ehling et al., 2004
Silber et al., 2002
Abs present in MS patient sera and CSF; titre correlates 
with disease progression and MRI activity.
Neurofilament
Niehaus et al., 2000 OPC surface antigen, abs found in MS patient CSF  AN-2 (NG-2)
Walsh and Murray 1998 Abs present in MS patient sera and CSF (~74) CNPase
Menge et al., 2005
Menon et al., 1997
Abs found in RRMS (~40) patient serum but much less in 
CIS (~8)
GalC
Acarin et al., 1996
Sadatipour et al., 1998
Kanter et al., 2006
GD1a, GM3 and sulphatide abs present in sera and CSF 
of MS patients.  More frequent in patients with chronic 
progressive disease
Gangliosides
Lolli et al., 2005
Schwartz et al., 2006
Abs against CSF114(Glc) & Glc(alpha1,4)Glc(alpha) 
present in MS patient sera
Glycopeptides
Selmaj et al., 1992
Cid et al., 2005
Antigens expressed by OPCs, antibodies may inhibit 
remyelination
HSP 60 & HSP90
Mi et al., 2007 Nogo receptor interacting protein.  Potential role in 
axonal survival and remyelination.  
Lingo-1
Baig et al., 1991
Moller et al., 1989
Abs present in MS patient CSF, potential correlation with 
disease progression
MAG
Schmidt et al., 2001
Egg et al., 2001
Reindl et al., 1999
Olsson et al., 1990 
Cruz et al., 1987
Antibodies present in sera and CSF of MS patients (~25-
58)
MBP
Genain et al., 1999
Berger et al., 2003
Kuhle et al., 2007
The major focus of MS autoantigen research.  Abs 
present in MS lesions.  Antibodies present in sera and 
CSF of MS patients (~0-80).  Serum anti-MOG abs in 
CIS patients predictive for chronic disease
MOG
Reindl et al., 2003 Neurite outgrowth inhibitor.  Abs in serum and CSF of 
patients with RRMS and other acute neurological 
diseases.  
Nogo-A
Bronstein et al., 1999
Aslam et al., 2010
Abs found in CSF of MS patients.  Does not bind to 
native antigen.  
OSP 
Villar et al., 2002
Villar et al., 2005
Oligoclonal IgM present in MS patient CSF, potential 
correlation with disease progression  
Phosphatidylcholine
Sun et al., 1991a
Warren et al., 1994
Abs and specific B cells in the CSF of MS patients PLP
Mayo et al., 2002 Protein complex involved in processing and chaperone 
function.  Abs present in serum and CSF of MS patients 
(~66).  
Proteosome
Banki et al., 1994 Abs present in MS patient serum and CSF Transaldolase
Archelos et al., 1998 OPC derived B cell epitope.
Abs found in MS CSF and sera (~50)
Alu repeats
Agius et al., 1999
Celet et al., 2000
Vojdani et al., 2003
Ab present in MS patient sera and CSF, potential link 
between antibody titre and relapse rate
Alpha-B-crystallin
References Significance in MS  Antigen
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1.6.1 Myelin oligodendrocyte glycoprotein (MOG) 
Myelin  oligodendrocyte  glycoprotein  (MOG)  is  a  CNS-specific  autoantigen 
sequestered  at  the  outer  surface  of  the  myelin  sheath  and  oligodendrocyte 
(Linington et al., 1988; Brunner et al., 1989; Kroepfl et al., 1996).  MOG was 
first identified as a dominant target for demyelinating autoantibodies in animals 
with  EAE  induced  by  immunisation  with  CNS  tissue  homogenates  in  Freunds 
complete  adjuvant  (Lebar  et  al.,  1986).  Subsequently  passive  transfer 
experiments demonstrated that anti-MOG antibodies augments disease severity 
and leads to extensive demyelination in animals with (Linington et al., 1988; 
Genain et al., 1995). These properties are attributed to the accessibility of the 
extracellular  IgV-like  domain  of  MOG  to  antibody  in  the  extracellular  milieu 
(Gardinier et al., 1992). Demyelination mediated by MOG-specific antibodies in 
these  EAE  models  is  associated  with  co-deposition  of  immunoglobulin  and 
complement activation products (Genain et al., 1999; Raine et al., 1999; Storch 
et  al.,  1998),  reproducing  the  immunopathology  of  pattern  II  MS  lesions  as 
defined by Lucchinetti and colleagues (Lucchinetti et al., 2000). It should be 
noted that transfer of antibodies recognising intracellular MBP epitopes does not 
induce widespread demyelination in EAE (Schluesener et al., 1987).   
These  animal  experiments  stimulated  a  plethora  of  studies  in  which  MOG-
specific  antibody  responses  were  investigated  in  MS  and  other  neurological 
diseases.  To  date  there  are  hundreds  of  papers  relating  to  the  MOG-specific 
response in MS were published the results of which may be summarised as being 
generally conflicting and controversial [Table 1.6]. Some studies report that MS 
is associated with elevated serum or CSF MOG-specific antibody titres (Sun et 
al., 1991; Lalive et al., 2006; Lindert et al., 1999; Gaertner et al., 2004) whilst 
others  find  no  significant  differences  between  MS  patients  and  patients  with 
other neurological inflammatory diseases or healthy controls (Haase et al., 2006; 
Reindl et al., 1999; Lampsona et al., 2004; Xiao et al., 1991;). The frequency of 
seropositive patients in these studies ranges from 0 to 88% in MS and 0 to 67% in 
healthy controls depending on the source of antigen and assay protocol.  The 
observation that MOG-specific antibodies were pathogenic in EAE also stimulated 
attempts to attribute some clinical significance to these responses detected in 
patients.  A  potential  prognostic  role  was  first  reported  by  Berger  et al.  who 25 
studied a cohort of 103 CIS patients and reported that those with high levels of 
serum anti-MBP and anti-MOG IgM were most likely to suffer relapses earlier and 
more frequently than seronegative patients (Berger et al., 2003). However these 
observations could not be reproduced in subsequent report using an identical 
protocol (Kuhle et al., 2007).  
In retrospect the lack of reproducibility between studies reflects a failure to 
accept that any autoantibody response that may play a primary role in disease 
pathogenesis has to recognise its target as it exists in vivo. In other words any in 
vitro assay to detect such responses should reproduce as closely as possible the 
targets  three-dimensional  structure,  post-translational  modifications  and 
membrane topology as they occur in vivo. Unfortunately this was not the case in 
the  majority  of  published  studies,  as  these  either  relied  on  using  denatured 
recombinant MOG expressed in E.coli or synthetic peptides in ELISA or Western 
blot based assays. The importance of retaining the native 3-D structure of MOG 
if  one  is  to  detect  pathogenic  i.e.  demyelinating  antibody  responses  is  now 
apparent from the crystal structure of MOG complexed with the Fab fragment of 
a demyelinating MOG-specific mAb. In both rodent and marmoset models of EAE 
demyelinating  MOG-specific  antibody  responses  are  directed  against 
conformational/discontinuous  epitopes  (Bourquin  et  al.,  2000;  Brehm  et  al., 
1999;  von  Budingen  et  al.,  2004).  A  demyelinating  response  which  is  not 
observed when animals are immunised with linear MOG derived peptides. These 
observations are consistent with the published crystal structure of the MOG/anti-
MOG Fab complex. This demonstrated the demyelinating MOG-specific mAb 8-
18C5 recognised a discontinuous and conformation-dependent epitope focused 
on  the  FG  loop  of  the  proteins  Ig-V  like  fold  (Breithaupt  et  al.,  2003). 
Subsequently  it  was  confirmed  this  conformation-dependent  epitope  is  the 
immunodominant target of the demyelinating MOG-specific response in several 
strains of mice and the Dark Agouti rat (Breithaupt et al., 2008). In vitro it is 
also essential to retain the correct conformation of MOG to detect pathogenic 
MOG-specific antibodies targeting the oligodendrocyte surface (Lolli et al., 2005; 
Marta et al., 2005). 
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To identify potentially pathogenic responses in MS patients a number of groups 
adopted cell based assay systems that use mammalian cell lines manipulated to 
express MOG on their surface (Haase et al., 2006; Gaertner et al., 2004; Lalive 
et al., 2006; Zhou et al., 2006). Theoretically these cell based assays will detect 
antibodies  against  native  MOG  embedded  in  a  membrane  which  will  go 
undetected  by  other  methods.  Crucially  this  approach  detects  MOG-specific 
antibodies in only a small percentage of patients indicating that it is unlikely to 
be  the  dominant  target  for  demyelinating  antibodies  in  MS.  A  conclusion 
supported  by  the  failure  of  fluid  phase  assays  using  correctly  folded  and 
glycosylated recombinant MOG preparations to detect high affinity MOG-specific 
antibodies in patient sera (Lampsona et al., 2004; O’Connor et al., 2005).  
Nonetheless  MOG-specific  antibodies  are  present  in  acutely  demyelinating  MS 
lesions where they are associated with myelin debris (Genain et al., 1999), and 
can be recovered from MS autopsy samples (O’Connor et al., 2005).  In the latter 
study  in  50%  of  the  MS  cases  these  antibodies  were  highly  specific  for  MOG 
compared to 13% in non-MS controls and exhibited higher affinities for MOG than 
antibodies isolated from the patients serum or CSF. The clinical significance of 
these MOG-specific autoantibody responses is still to be determined in classical 
forms of MS, but there is increasing evidence that the presence of antibodies to 
the  native  antigen  may  define  a  specific  subset  of  patients  with  paediatric 
inflammatory demyelinating disease.  
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Table 1.6: Overview of selected publications investigating serum antibody responses (IgG) 
to MOG in patients with adult-onset MS 
There have been numerous contributions over the past 20 years to determine the frequency of 
antibody responses against MOG in patients with adult-onset MS.  Some studies have reported 
elevated  MOG  specific  autoantibody  responses  in  MS  patients  but  other  reports  suggest  no 
significant  difference  between  MS  and  other  neurological  diseases  or  healthy  controls.    The 
reported frequencies of α-MOG responses in MS patients range from 0-82% depending on the 
method of detection and antigen source used in each study.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MS: 54
Controls: 22
MS: 37
Controls: 37
Western Blot 
Recombinant human MOG 
Ig domain expressed in 
E.coli
Lindert et al., 
1999
Elevated in MS 
compared to controls
MS: 75
Non-MS: 20
ELISA 
recombinant human native 
MOG expressed by 
mammalian cells
Gaertner et 
al., 2004
MS: 3
Non-MS: 0
MS: 14
Non-MS: 8
Liquid phase 
radioimmunoassay 
recombinant human MOG 
(refolded in vitro by 
mammalian cells)
O’Connor et 
al., 2005
Elevated in CIS and 
RRMS but less 
frequent in SPMS and 
absent in PPMS
MS: 92
CIS: 36
HC: 37
FACS 
recombinant human MOG 
expressed by mammalian 
cells
Lalive et al., 
2006
MS: 0
ONND: 0
MS: 30
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MOG purified from human 
myelin 
Xiao et al., 
1991
MS: 82
HC: 67
MS: 6
HC: 0
MS: 17
HC: 9
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synthetic MOG peptides
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recombinant human MOG 
expressed on mammalian 
cells
Haase et al., 
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MS: 38
ONID: 53
ONND: 3
RA: 10
MS: 130
ONID: 32
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RA: 10
Western Blot 
Recombinant human MOG 
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recombinant human MOG in 
vitro translation
Lampsona et 
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MOG purified from human 
myelin
Sun et al., 
1991b
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1.6.1.1  MOG antibody responses in paediatric demyelinating diseases 
Paediatric MS defined as having disease onset before the age of 16 is thought to 
represent between 2 to 5% of all MS cases (Chitnis et al., 2009), although it’s 
precise incidence is unclear. In the majority of cases (>90%) the disease follows 
a relapsing remitting disease course, but tends to be more aggressive than its 
adult-onset equivalent being characterised by higher relapse rates (Gorman et 
al.,  2009)  and  rapid  accumulation  of  neurological  disability  (Renoux  et  al., 
2007). Unlike adult onset disease, paediatric MS has no strong gender bias (pre 
puberty)  and  is  present  across  many  ethnic  groups  (review:  Banwell  et  al., 
2011).  
In contrast to previous reports on adult-onset MS, paediatric MS is associated 
with  a  far  higher  frequency  of  patients  seropositive  for  MOG-specific 
autoantibodies as determined using cell based assays.  This was demonstrated 
beautifully  by  McLaughlin  et  al.  (2009)  using  a  FACS  based  assay  with  MOG 
transfectants  to  compare  the  frequency  of  anti-MOG  antibody  responses  in 
paediatric and adult-onset MS patients with appropriate age matched controls 
for  each  group.    Within  the  adult  cohort  there  was  no  significant  difference 
between those donors with or without MS (4% and 5% respectively), whereas. 21% 
of paediatric MS cases were seropositive compared to only 6% of age matched 
OND controls (McLaughlin et al., 2009). 
Intriguingly  the  major  differential  diagnosis  for  paediatric  MS  is  acute 
disseminated encephalomyelitis (ADEM) and these patients also exhibit elevated 
responses to MOG in both cell and fluid phase based immunoassays.  Early in 
disease it is extremely difficult to distinguish between the two diseases.  ADEM 
is a demyelinating disease of the CNS which usually has a monophasic disease 
course  and  is  most  prevalent  in  children  but  can  also  occur  in  adults.  The 
incidence of ADEM is estimated at approximately 1 per 100,000 and in 50 - 75% 
of  cases,  disease  onset  occurs  shortly  after  a  viral  or  bacterial  infection  or 
vaccination (review: Menge et al., 2005) which lead to speculation that MOG-
specific responses in these patients may occur by virtue of molecular mimicry.  
Cross reactive pathogenic antibody responses between viral and myelin antigens 
have been previously demonstrated experimentally involving mimicry between 
MOG and rubella virus (Besson-Duvanel et al., 2001). 29 
Over the past five years significant progress has been made in cataloguing MOG-
specific  antibody  responses  in  children  with  MS  and  ADEM  [Table  1.7].    The 
reported frequencies vary from 2 to 21% for paediatric MS and 18 to 54% for 
ADEM.    These  variations  probably  reflect  technical  differences  in  the  assays 
employed  by  different  groups  of  researchers,  including  the  selection  of  the 
threshold  used  to  define  a  positive  response.    However  it  is  becoming 
increasingly clear that not only does this particular antibody response define a 
specific  subset  of  young  patients  with  MS,  but  may  also  provide  a  useful 
diagnostic biomarker to help differentiate patients with ADEM from those with 
other  acute  encephalopathies  (Lalive  et  al.,  2011).    Yet  it  has  still  to  be 
demonstrated  whether  these  MOG-specific  antibodies  actively  contribute  to 
disease  pathogenesis  by  exacerbating  demyelination,  as  would  be  anticipated 
from studies in EAE.  
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Table 1.7: Overview of selected publications investigating serum antibody responses (IgG) 
to MOG in paediatric MS and ADEM 
Within the last 5 years there have been a small number of reports demonstrating that children with 
MS or ADEM have elevated titres of MOG specific autoantibodies.  The pathogenic significance of 
these autoantibody responses has not been yet demonstrated.   
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1.6.2 Myelin lipids as MS autoantigens 
Myelin  proteins  are  generally  considered  the  most  probable  target  for 
pathogenic  autoantibodies  in  MS.    However,  ~70%  of  the  myelin  sheath  is 
composed of lipid (Norton, 1984) and historically lipid-specific autoantibodies  
have  also  been  investigated  as  causative  agents  in  the  context  of  immune-
mediated demyelination, in particular antibodies recognising myelin associated 
glycosphingolipids such as galactocerebroside and sulphatide.    
1.6.2.1  Galactocerebroside 
Galactocerebroside  (GalC)  is  a  major  component  of  the  myelin  sheath, 
accounting  for  about  25%  of  myelin  lipid.    GalC  is  integrated  into  the  outer 
surface  of  the  membrane  bilayer  where  it  is  accessible  to  antibody  in  the 
extracellular milieu.  Historically there are a number of publications implicating 
GalC-specific antibodies in the pathogenesis of immune mediated demyelination 
in EAE (Raine et al., 1981; Fierz et al., 1988) but their significance in MS remains 
obscure (Rostami et al., 1987; Kanter et al., 2006).  However, it was recently 
reported that GalC-specific antibodies provide a stage specific biomarker in that 
they were detected preferentially in patients with RRMS compared to CIS, SPMS, 
PPMS and other neurological diseases (Menge et al., 2005). 
1.6.2.2  Sulphatide 
In addition to GalC, myelin is also enriched in sulphatide (3-O-sulphogalactosyl 
ceramide; Sulph).  This glycolipid is present in the outer leaflet of the myelin 
bilayer where it can bind Sulph-reactive antibodies if present in the extracellular 
compartment.    Intriguingly  not  only  are  elevated  levels  of  Sulph-specific 
antibodies  present  in  the  CSF  of  patients  with  MS compared  to  controls,  but 
active immunisation with Sulph or the passive transfer of a Sulph-reactive mAb 
exacerbates EAE (Kanter et al., 2006).  The later observation confirms that Sulph 
can provide a physiological target for autoaggression, but as yet whether Sulph-
reactive antibodies detected in patients are pathogenic remains unproven.  
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1.6.2.3  Other lipid specificities associated with MS  
The  presence  of  oligoclonal  IgM  bands  has  been  described  as  a  potential 
prognostic marker in MS (Villar et al., 2002). These IgM antibodies recognise a 
number of myelin lipids, in particular phosphatidylcholine were most frequently 
observed  in  patients  with  an  aggressive  disease  course  (Villar  et  al.,  2005). 
However as is the case for both GalC- and Sulph-specific responses there is no 
conclusive  evidence  that  these  responses  actively  contribute  to  immune 
mediated  demyelination.  Indeed  with  respect  to  antibodies  present  in  CSF 
repeated  studies  have  failed  to  demonstrate  these  are  able  to  bind  to 
oligodendrocytes (Lubetzki et al., 1986) or any major myelin antigen (Owens et 
al., 2009).    
  
1.6.3 Axonal/ neuronal autoantigens 
Although  MS  was  long  described  as  a  demyelinating  disease  characterised  by 
primary oligodendrocyte loss and demyelination in which there was extensive 
sparing of axons, it is now recognised that MS lesions are often associated with 
profound axonal loss.  Acute axonal injury as demonstrated by axonal swellings 
and enhanced immunoreactivity for beta-amyloid precursor protein (APP) is most 
pronounced  in  regions  of  active  inflammation  and  demyelination  and  is 
associated with varying degrees of axonal transection (Ferguson et al., 1997; 
Trapp et al., 1998).  The mechanisms involved are still being elucidated but 
there is now evidence suggesting these may involve an autoantibody-mediated 
component. Screening MS sera for reactivity to cell surface antigens expressed 
by neuronal cell lines identified neuronal reactivity in the sera of at least 70% of 
PPMS patients and in 25% of those with RRMS (Lily et al., 2004). The antigen 
specificity of these responses was not reported, but other studies have reported 
neurofilament,  ganglioside  and  neurofascin-specific  responses  in  some  MS 
patients.  
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1.6.3.1  Neurofilament  
It is suggested that autoantibodies recognising against the neurofilament light 
chain (NF-L) provide a biomarker for axonal injury. Increases in NF-L-specific 
antibody titres are present in the serum of patients with PPMS (Ehling et al., 
2004; Silber et al., 2002) and correlate with increased disability as scored using 
expanded disability status scale (EDSS; Silber et al., 2002) and brain atrophy as 
visualised by MRI (Eikelenboom et al., 2003).  
1.6.3.2  Gangliosides  
Gangliosides are glycosphingolipids which decorate the surface of both CNS and 
PNS  axons.    It  is  reported  that  pathogenic  autoantibody  responses  against 
gangliosides are associated with Bickerstaff’s encephalitis (GQ1b) (Odaka et al., 
2001), Miller-Fisher syndrome (GQ1b) (Chiba et al., 1992) and are also present in 
patients with Gullian-Barre syndrome (review: Willison and Yuki, 2002).  In MS 
the  situation  is  less  clear,  but  some  patients  do  develop  responses  to  GD1a 
(Acarin et al., 1996) and GM3 (Sadatipour et al., 1998).  These anti-ganglioside 
responses  tend  to  be  most  frequent  in  patients  with  progressive  disease 
(Sadatipour et al., 1998), but their pathophysiological relevance, if any, remains 
unknown.  
1.6.3.3  Neurofascin  
Neurofascin  (Nfasc)  is  cell  adhesion  molecule  of  the  L1  Ig  superfamily  which 
exists  as  two  major  isoforms,  Nfasc186  and  Nfasc155,  in  myelinated  fibres. 
These  are  structurally  and  functionally  distinct  [Figure  1.2].  Nfasc186  is  a 
neuronal product localized at the nodes of Ranvier and axonal initial segments 
(AIS)  where  it  interacts  with  voltage  gated  sodium  channels  and  cytoplasmic 
proteins such as ankyrin G and ßIV-Spectrin (Zhang et al., 1998a; Ratcliffe et al., 
2001).  In  contrast,  Neurofascin-155  (Nfasc155)  is  an  oligodendroglial  protein 
sequestered at septate-like junctions formed where the paranodal loops of the 
myelin  sheath  contact  the  axonal  surface.  Here  Nfasc155  interacts  with  an 
axonal  Caspr-Contactin  complex  to  form  electron  dense  assemblies 
characteristic of the paranodal junctional complex (Tait et al., 2000; Charles et 
al., 2002).   34 
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Figure 1.2: Nfasc exists as two structurally and functionally distinct isoforms.   
A:  Nfasc  155  (upper)  consists  of  six  immunoglobulin  (Ig)  and  4  fibronectin  (FN)  III  domains.  
Nfasc186 (lower) shares the same structure as Nfasc155 apart from the presence of an alternate 
FNIII domain and a mucin like domain.  Image modified from Tait et al., 2000.  B: Nfasc155 is 
expressed  by  the  oligodendrocyte  at  the  paranode  where  it  interacts  with  caspr-1/contactin.  
Nfasc186 is expressed by the axon at the node of Ranvier forming interactions with the voltage 
gated sodium channels and ankyrin G.  Image taken from Trapp and Kidd, 2000.  
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Nfasc  was  identified  as  a  candidate  autoantigen  in  MS  using  a  proteomics 
approach (Mathey et al., 2007) in which immunoreactivity of serum samples with 
myelin glycoproteins was screened by western blotting.  Approximately 20% of 
patients tested had significant antibody responses to a 150-180kDa protein which 
was subsequent identified as Nfasc.  Further characterisation by ELISA revealed 
that  ~30%  of  patients  had  high  titres  against  the  extracellular  domain  of 
Nfasc155 and that this response was most pronounced in patients with chronic 
progressive disease.  However, it should be noted that this response as detected 
by ELISA was not MS-specific as similar responses could also be identified in some 
patients  with  other  neurological  diseases,  as  well  as  healthy  controls.    The 
authors demonstrated that this Nfasc-reactive antibody repertoire contained a 
cross reactive component that recognised the extracellular domain of Nfasc186 
and Nfasc155 expressed on transfected cells.  Co-transfer studies in EAE using a 
pan-Nfasc specific mAb (A12/18.1) revealed the dominant pathological target for 
antibodies with this specificity in the inflamed CNS was Nfasc186 expressed at 
the  node  of  Ranvier.    In  vivo  antibody  recognition  of  Nfasc  at  the  node 
exacerbated  disease  severity  in  EAE  and  was  associated  with  complement 
deposition and axonal injury.  In vitro studies demonstrated acute conduction 
block  mediated  by  A12/18.1  in  hippocampal  slice  cultures  was  complement-
dependent (Mathey et al., 2007).  However, as yet these findings have not yet 
been reproduced using patient-derived Nfasc-specific antibodies therefore the 
exact role of this response in MS remains undefined. 
In  conclusion  autoantibodies  recognising  axonal  antigens  can  induce  primary 
axonal  injury  in  the  CNS,  but  whether  this  is  a  significant  factor  in  the 
pathogenesis of MS is still a matter of speculation. 
 
 
 
 
 36 
1.7 To what extent are autoantibodies involved in the 
pathogenesis of MS? 
The simple answer to this question is that we still do not know.  
Application  of  the  Rose-Witesby  to  MS  [Table  1.8]  suggests  that  if  a  myelin-
specific autoantibody response is involved then this is only the case in a subset 
of patients.  Specifically, it is important to note myelin-specific autoantibody 
responses are not MS specific, but are also observed in many other neurological 
disorders.  Similarly there is no consensus as to the pathological significance of 
complement activation products in the CNS.  With respect to third postulate 
“Induction of disease by passive transfer of antibodies” as far as I am aware 
there is no report of maternal transfer of disease in MS, as reported myasthenia 
gravis.  Moreover, the only study in which passive transfer of Ig is reported to 
exacerbate demyelination in vivo is flawed (Zhou et al., 2006).  Although the 
baseline burden of disease in this study was minimal, passive transfer of patient 
Ig failed to exacerbate clinical disease severity and although a minimal level of 
demyelination was detected the authors failed to confirm their supposition this 
pathology  was  mediated  by  a  MOG-specific  autoantibody  response.    The 
technical difficulties associated with this approach are apparent from studies 
investigating the pathogenic potential of AQP-4 specific autoantibodies in NMO 
(Bradl et al., 2009).  In this case reproducible exacerbation of disease severity 
and its pathological correlates in EAE was dependent on achieving circulating 
anti-AQP-4 titres similar to those seen in patients.  
In summary we are left in a quandary in that we suspect antibody-dependent 
mechanisms contribute to disease pathogenesis in a subset of patients but in the 
absence of any defined target we can neither identify these patients nor address 
the crucial question, “Is this response clinically relevant?”  One solution to this 
problem is to develop an in vitro assay that will identify those patients with a 
demyelinating or axopathic serum autoantibody response without requiring prior 
knowledge of its specificity.   The next section reviews contributions made in 
this direction over the past 70 years.   37 
Table 1.8:  To what extent do anti-myelin antibodies in MS patients fulfil the Rose-Witesby 
postulates?   
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1.8 In vitro studies of demyelinating disease 
1.8.1 Complement fixation assays 
In  vitro  studies  of  autoantibody  responses  associated  with  MS  began  over  80 
years ago.  In 1934 Sachs and Steiner conducted a novel study in which they 
measured the ability of MS brain extracts to activate complement in patient sera 
with  brain  extracts  from  patients  with  arteriosclerosis  as  a  negative  control. 
They defined a sample as positive if the serum selectively reacted with the MS 
brain extract but not the control.  Using this assay almost half the MS patients 
they  screened  were positive.    In  contrast  complement  fixing antibodies  were 
seldom  detected  in  OND  (<5%)  or  healthy  (<5%)  controls  (Sachs  and  Steiner, 
1934).  Over the next 30 years, attempts to confirm and expand these findings 
led to conflicting reports and divided opinions [Table 1.9].  Some laboratories 
reproduced these observations, the most prominent being the study by Raskin 
which used a similar complement fixation assay but  where Sachs and Steiner 
used a single antigen source, this study used MS and control brain extracts but 
also purified brain proteolipid fractions (Raskin, 1955).  The results of the two 
studies  were  in  broad  agreement  in  that  complement  fixing  activity  was 
consistently higher in patients with MS compared to controls. The studies are 
remarkable as they provide the first indication that MS may be associated with a 
serological response to CNS antigens.  However, this complement fixing activity 
was not MS-specific, an observation that suggests this approach to identify a 
clinically relevant response in patient sera was not ideal.  Indeed later studies 
criticised several technical aspects of these assays and using somewhat modified 
approaches were unable to reproduce the initial findings (MacLeod et al., 1962).  
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Table 1.9: A selection of studies investigating anti-CNS serological responses using an in 
vitro complement fixation assay 
 
 
 
 
 
 
 
 
 
1.8.2 Tissue culture studies of demyelination 
1.8.2.1  EAE and serum anti-myelin activity 
It was recognised in the late 1950’s that tissue culture models that reproduce 
the  topology  and  organisation  of  the  target  tissue  may  provide  an  elegant 
method to demonstrate the presence of pathogenic autoantibodies in vitro.  In 
the context of demyelinating diseases this approach was first used by Appel and 
Bornstein  who  demonstrated  sera  from  rabbits  with  EAE  induced  by 
immunisation  with  CNS  tissue  homogenates  in  Freunds  adjuvant  mediated 
complement dependant demyelination in rodent cerebellar cultures (Bronstein 
and Appel, 1961).  In a follow up study they demonstrated that demyelinating 
activity in EAE sera was found in the IgG2 fraction and could be abolished by 
absorption with brain tissue, but not with liver, lung or kidney tissue.  Moreover 
demyelination in this model was associated with antibodies binding to the myelin 
and oligodendrocyte surface (Appel and Bronstein, 1964). Demyelination induced 
using EAE sera not only spared axons but could be followed by remyelination, as 
demonstrated by removal of the pathogenic sera after the initial demyelinating 
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event  (Bornstein  and  Appel,  1961;  Raine  and  Bornstein,  1970).    Antibody-
mediated  demyelination  in  this  and  similar  model  systems  is  complement 
dependent  (Grundke-Iqbal  et al.,  1981)  and  associated  with  the  formation of 
membrane attack complex (C5b-C9) (Liu et al., 1983).  In addition to mediating 
complement-dependent  effects,  in  the  absence  of  complement  these  myelin-
reactive antiserum also block myelin formation in vitro (Bornstein, 1970).  
To identify the antigen(s) responsible for these pathological effects studies were 
performed using sera from animals immunised with purified CNS myelin antigens. 
In the case of MBP (Lebar et al., 1976; Seil et al., 1968; Kies et al.1973; Seil et 
al., 1975), PLP (Agrawal et al., 1984; Mithen et al., 1980; Seil and Agrawal, 
1980)  and  MAG  (Seil  et  al.,  1981)  no  in  vitro  demyelinating  or  myelination 
inhibiting  responses  were  detected,  whilst  anti-sera  from  animals  immunised 
with GalC (Fry et al., 1974; Hruby et al., 1977) or GM1/GM4 gangliosides (Roth 
et al., 1985) were demyelinating and in the absence of complement also blocked 
myelin formation.  
A similar approach in vitro was used to investigate the pathogenic potential of 
anti-sera raised against the axolemma enriched fraction derived from rat brain. 
These sera inhibited neuronal outgrowth and mediated destruction of mature 
axons  in  embryonic mouse  spinal  cord-dorsal  root  ganglion  cultures.  However 
axopathic activity was not detected in the spinal cord and was confined to axons 
within the dorsal root ganglion and the outgrowth zone (Bourdette et al., 1986; 
1988). Similarly an anti-serum to the ganglioside GM1 did not have axopathic 
activity  in  vitro  (Bourdette  et  al.,  1989).    Extensive  investigation  of  the 
axopathic  potential  of  serum  antibodies  is  lacking  but  is  certainly  warranted 
given the level of axonal injury observed in MS lesions. 
 
1.8.2.2  The identification of an in vitro demyelinating factor within MS serum 
The ability of sera from some patients with acute MS to mediate demyelination 
in vitro was first reported almost 50 years ago (Bronstein and Appel., 1965). 
Subsequent  studies  have  in  general  supported  this  initial  observation  [Table 
1.10] (Review: Caspary et al., 1977).  However, its clinical relevance remained 41 
controversial  largely  because  of  the  presence  of  demyelinating  activity  some 
healthy  controls  but  also  in  a  high  proportion  (~60%)  of  OND  patients,  in 
particular those with motor neurone disease (MND) (Bronstein and Appel., 1965; 
Hughes  and  Field  1967).  Attempts  to  reconcile  this  observation  with  the 
presence  of  secondary  demyelination  in  MND  patients  proved  controversial 
(Wolfgram and Myers, 1973; Horwich et al., 1974). 
It was assumed that this demyelinating activity was due to the presence of anti-
myelin antibodies.  This concept is supported by reports that the demyelinating 
activity  is  associated  with  the  serum  IgG  fraction  (Dowling  et  al.,  1968; 
Wolfgram  and  Duquette,  1976)  and  the  demonstration  that  absorption  of  IgG 
(IgG1, IgG2 and IgG4) using Staphylococcus aureus protein A results in a small 
but  significant  reduction  in  serum  demyelinating  activity  (Grundke-Iqbal  and 
Bornstein, 1979).  However interpretation of all these studies is complicated by 
reports  that  some  sera  contain  myelin-toxic  factors  that  are  both  IgG  and 
complement independent (Bradbury et al., 1984).  Nonetheless, ultrastructural 
studies of in vitro demyelination mediated by samples from some MS patients 
revealed that this phenomenon reproduces many of the features observed using 
an anti-myelin serum from animals with EAE (Raine et al., 1970; Raine et al., 
1973).  Attempts to define the specificity of this demyelinating activity suggest 
it may be directed against oligodendrocytes rather than myelin (Wolfgram and 
Duquette, 1976).  This concept was supported by the identification of antibodies 
that recognised cultured oligodendrocytes were identified in MS patients but not 
in  sera  from  patients  with  OND  or  healthy  controls  (Abramsky  et  al.,  1977). 
However, this staining of oligodendrocytes was later shown to be nonspecific 
(Traugott et al., 1979).  
In retrospect these studies demonstrate that myelinating cultures can provide a 
tool  to  identify  pathogenic  antibody  dependent  effects  in  vitro,  but  their 
application  as  a  screening  tool  not  only  requires  standardised  methods  to 
generate  purified  Ig  preparations  from  human  sera,  but  also  object 
methodologies to quantify myelin and/or axonal loss.  
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Table 1.10: A selection of studies demonstrating the presence of a factor in MS serum that 
can mediate demyelination in vitro.   
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1.9 Aims of this thesis  
A large body of circumstantial evidence implicates the involvement of antibody-
dependent mechanisms in the development of MS in some patients.  If this is the 
case then it has important clinical implications.  Complement inhibitors, plasma 
exchange and intravenous immunoglobulins are just some of the strategies now 
used to inhibit pathogenic events triggered by autoantibodies in other human 
diseases, and which in theory could also benefit some patients with MS.  
This defines the aim of my thesis which was to provide a definitive answer to the 
question: “Is MS associated with a pathogenic autoantibody response?”  
To achieve this goal it was necessary to:  
•  Determine  whether  myelinated  axonal  segments  within  an  in  vitro 
myelinating  culture  model  faithfully  reproduce  the  antigenic  profile  and 
molecular organisation of myelinated fibres in vivo.  
•  Validate  these  cultures  as  a  screening  tool  to  detect  and  quantify 
demyelinating and/or axopathic autoantibody responses in vitro. 
•  Use  the  resulting  bioassay  to  determine  the  frequency  of 
demyelinating/axopathic  IgG  responses  cohorts  of  patients  with  MS,  OND  and 
healthy controls. 
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2  Materials and methods 
2.1 Biochemical techniques 
2.1.1 ELISA 
ELISA was performed using 96-well polyvinyl ELISA plates (Costar).  Plates were 
coated with 10µg/ml of the appropriate antigen diluted in PBS overnight at 4°C.  
The following day plates were washed with ELISA wash buffer, blocked with 1% 
BSA in PBS for 1 hour at 37°C and after further extensive washing incubated with 
primary antibody or serum for 1 hour at 37°C.  Plates were washed again and 
secondary antibody conjugated to horse-radish peroxidase (HRP) was applied for 
45 min at 37°C.  Unbound conjugate was removed by washing and bound HRP   
was visualised using o-phenyldiamine (OPD) following incubation at RT in the 
dark and quenched with 4M H2SO4.  Absorbance was read at 492nm using a 96-
well plate reader Tecan Sunrise plate reader with Magellan software (Tecan, 
Switzerland).        
Table 2.11 ELISA secondary antibodies used in this study. 
Sigma (UK) HRP 1/3000 Mouse IgG Goat 
Southern Biotech (USA) HRP 1/3000 Rabbit IgG Goat 
Dako (Denmark) HRP 1/5000 Human IgG Goat 
Dako (Denmark) HRP 1/5000 Human IgM Goat 
Zymed labs (USA) HRP 1/5000 Human IgG1 Goat 
Zymed labs (USA) HRP 1/5000 Human IgG2 Goat 
Zymed labs (USA) HRP 1/5000 Human IgG3 Goat 
Zymed labs (USA) HRP 1/5000 Human IgG4 Goat 
Southern Biotech (USA) HRP 1/3000 Rat IgG Goat 
Source Conjugate Dilution  Isotype Host 
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2.1.2 SDS-PAGE 
SDS-PAGE was performed using the BioRad® Protean II apparatus according to 
manufacturer’s guidelines.  Gels were cast the previous day and kept overnight 
at 4°C.  The resolving and stacker gels were prepared to give the appropriate 
percentage.  The resolving gel was poured between two clean gel plates and 
overlaid  with  100%  butanol.    This  was  removed  once  the  resolving  gel  had 
polymerised  and  the  stacker  gel  mix  was  layered  onto  which  a  comb  was 
inserted to form sample wells.  Samples  were prepared by adding of sample 
buffer and boiling for 5 min before loading.   Gels were ran at 200V (constant 
voltage)  until  the  bromophenol  blue  dye  front  had  reached  the  end  of  the 
resolving gel (~55 min).    
2.1.3 Bicinchoninic acid assay 
To accurately determine protein concentrations a bicinchoninic acid assay (BCA) 
was performed using the Pierce ® BCA protein assay kit following manufacturer’s 
standard protocol. 
First  a  series  of  diluted  BSA  samples  were  prepared  at  2mg/ml,  1.5mg/ml, 
1mg/ml, 750µg/ml, 500µg/ml, 250µg/ml, 125µg/ml and 25µg/ml concentrations.  
Standards were applied to a 96 well microplate (Greiner) in triplicate.  Samples 
to be measured were diluted in series and applied also in triplicate.  To generate 
the  working  reagent  50  parts  BCA  reagent  A  (sodium  carbonate,  sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium hydroxide) 
was  mixed  with  1  part  BCA  reagent  B  (4%  cupric  sulfate)  mixed  thoroughly.  
After adding the working reagent to each well; the plate was incubated at 37°C 
for 30 min.  Absorbance was measured at 562nm using a 96-well plate reader 
Tecan Sunrise plate reader with Magellan software (Tecan, Switzerland).        
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2.2 Molecular biology techniques 
2.2.1 RNA extraction  
RNA was extracted using the RNeasy® plus micro kit (Qiagen) in accordance with 
the manufacturer’s standard protocol.   
Cells were lysed using the supplied lysis buffer and further disrupted using a 21 
gauge needle and a 1ml syringe.  Genomic DNA was removed from the lysate by 
binding to a gDNA eliminator column and centrifuging at 8000g for 0.5min.  The 
flow through was retained and mixed with 70% ethanol.  RNA was then isolated 
using RNeasy spin columns.  After loading columns were washed repeatedly with 
supplied  wash  buffers  and  80%  ethanol  at  8000g.    After  the  final  wash  step 
columns were transferred to new collection tubes can centrifuged at 10,000g for 
5 min.  The RNA was then eluted with 14µl Nuclease free water and stored at -
80°C until use.   
2.2.2 Primer design 
Primers  were  designed  using  primer3  (http://frodo.wi.mit.edu/primer3/) 
software.  Nfasc155 primers were designed for the unique fibronectin domain 
(FN3) (NM_001160313.1).  Primers for Nfasc186 were designed to recognise the 
sequence  encoding  the  mucin-like  domain  (NM_001160314.1)  sequences  were 
taken  from  NCBI  National  Centre  for  Biotechnology  Information  (National 
Institute for Health, USA).  Binding to target sequence was confirmed by BLAST 
(National Institute for Health, USA).   
Primers were ordered from Sigma-Aldrich and were made up 10µM with DEPC-
treated water on arrival.   
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2.2.3 cDNA synthesis 
RT-PCR was performed using the Superscript™ III First-Strand Synthesis System 
(Invitrogen, UK) following the manufacturers protocol.   
5µg  total  RNA  was  incubated  with  10mM  dNTP  mix  and  50ng/µl  random 
hexamers.    Primers  were  annealed  by  incubation  at  65°C  for  5  min.    The 
reaction was cooled by placing on ice for a minimum of 1 min.  Superscript™ III 
reverse transcriptase (200 U/µl) was then added to the reaction in the presence 
of  10x  RT  buffer,  25mM  MgCl2,  0.1M  Dithiothreitol  (DTT)  and    RNAse  OUT™ 
(40U/µl).  The reaction was well mixed, collected by brief centrifugation and 
incubated firstly for 10min at 25°C followed by 50min at 50°C.  The reaction was 
terminated  by  incubation  at  85°C  for  5min  and  chilled  on  ice.    After  brief 
centrifugation RNAse H was added to remove any residual RNA and incubated for 
20min at 37°C.  cDNA was stored at -20°C until further use.   
2.2.4 Q-PCR 
Q-PCR  reactions  were  prepared  using  SYBR®  green  master  mix  (2X)  (Applied 
Biosystems,  USA)  containing  pre  mixed  SYBR  green  dsDNA  reporter  dye,  PCR 
buffer, dNTPs and Taq polymerase.  Therefore each reaction consisted of 1X 
SYBR green reaction mix, 10µM each primer and 100ng cDNA and made up to 
20µl volume with dH2O.  Reactions were set up in MicroAmp® Fast Optical 96-
Well Reaction Plates (Applied Biosystems, USA).   
Q-PCR reactions were run and monitored using an Applied Biosystems 7900HT 
Fast Real-Time PCR system with Sequence Detection Systems software (version 
2.3).   
2.2.4.1  Cycling conditions 
95°C for 10min, (95°C for 15s, 60°C for 1min) x 40 cycles, 72°C for 5 min then 
melt curve analysis in a temp range of 75-99°C in 1°C increments. 48 
2.2.4.2  Quantification  
Changes in gene expression were quantified using the comparative Ct method 
(Livak  and  Schmittgen,  2001;  Schmittgen  and  Livak,  2008).  This  method 
compares  the  Ct  values  of  the  samples  of  interest  to  those  of  a  baseline  or 
control  sample.    The  Ct  values  of  both  the  sample  and  the  control  are  first 
normalised to a suitable housekeeping gene using the following equation.   
∆∆Ct= ∆Ct sample- ∆Ct reference 
From the ∆∆Ct value we can calculate the fold change in gene expression: 
Fold change= 1/(2
- ∆∆Ct) 
 
2.3 Myelin absorption studies 
2.3.1 Myelin purification 
Crude myelin was purified from whole rat brain using an abbreviated method 
based on that described by Norton and Podulso (1973).  
Wistar  rats  (female  ~3  weeks  old)  were  sacrificed  by  overdose  of  CO2, 
decapitated and the entire brain was removed, weighed and stored at -80°C.  
Tissues  were  homogenised  with  a  Dounce  homogeniser  in  approximately  20 
volumes (w/v) of 0.32M sucrose (10 strokes).  The homogenate was layered over 
25ml of 0.85M sucrose in SW38 centrifuge tubes (Beckmann) and centrifuged at 
75,000 g for 60 min.  The layers of crude myelin formed at the interface of the 
two sucrose solutions were collected with a Pasteur pipette.  Myelin layers were 
pooled and suspended in water by homogenisation and the final volume brought 
up to 180ml.  This suspension is centrifuged 75,000 g for 15 min the resulting 
supernatants were discarded.  Crude myelin pellets were subjected to osmotic 
shock by suspension in 180ml of water.  The solution was centrifuged at 12,000 g 
for 10 min and the supernatant was discarded.  This step was repeated once 
more ensure the removal of most small membrane fragments.   49 
In order to obtain purified myelin, pellets were combined and resuspended in 
0.32M  sucrose.    The  suspension  was  then  layered  over  0.85M  sucrose  and 
centrifuged at 75,000 g for 30 min.  The myelin was washed three times with 
water by centrifugation at 12,000 g for 10 min.  The pellet was resuspended in 
dH2O containing a protease inhibitor cocktail (Sigma, UK).  Purified myelin was 
stored  at  -80°C  and  its  purity  was  assessed  by  SDS-PAGE.    Myelin  protein 
concentration was measured using a BCA assay as described above.    
2.3.2 Myelin adsorption  
For myelin adsorption experiments 1µg monoclonal antibody or 100µg human IgG 
was  incubated  overnight  with  2mg  total  myelin  protein  in  1ml  PBS  at  4°C.  
Myelin and bound immunoglobulins were pelleted by centrifugation at 12,000 g 
and the resulting supernatant was tested for residual antibody binding by ELISA 
and pathogenic activity using the myelinating culture model.   
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2.4 Cell Culture Techniques 
2.4.1 Monoclonal antibody production 
2.4.1.1  A12/18.1, Z2 and 8-18C5 hybridoma 
Hybridoma cells were cultured in CELLine® cell culture flasks (BD biosciences) 
following manufacturer’s guidelines.  The media compartment was filled with 
200ml of the appropriate media and the cell compartment was inoculated with 
2x10
6  cells/ml  diluted  in  media.    Supernatant  was  harvested  from  the  cell 
compartment  after  7  days  and  twice  a  week  thereafter.    Supernatants  were 
centrifuged at 450 g and stored at -20 °C.  Antibody production was monitored 
by ELISA and purified from pooled supernatants by protein G chromatography as 
described below.   
2.4.2 Transfected cell lines 
Hela cells were transfected to express the extracellular domains of Nfasc155 and 
Nfasc186 (Mathey et al., 2007). 
Transfected  HeLa  cells  were  grown  in  the  presence  of  G418  to  prevent  the 
development on non-expressing cell populations. Cells were cultured in T75cm
3 
flasks and passaged 1:2 once the cells reached ~70% confluency.  For antibody 
treatment and immunocytochemistry 100,000 cells were plated onto uncoated 
13mm coverslips and were allowed to attach overnight.   
2.4.3 Neurosphere derived astrocytes 
Neurospheres  were  generated  based  on  protocols  described  by  Reynolds  and 
Weiss  (1996)  and  Zhang  et  al.  (1998b)  and  differentiated  into  astrocytes  as 
described by Sorenson et al. (2008).   51 
2.4.3.1  Isolation of the corpus striatum from postnatal rat brain 
Neurospheres were produced from the corpus striatum of P1 SD rats (less than 36 
hours  old).    Postnatal  pups  were  killed  by  i.p.  injection  of  euthathal  in 
accordance to UK Home Office guidelines.     
The brain was removed from the skull and placed in a petri dish in a dorsal 
orientation and separated into the two cerebral hemispheres by cutting at the 
corpus callosum with a scalpel (no. 22 blade).  The two hemispheres were then 
positioned  in  a  sagittal  orientation  [Figure  2.1].    The  region  containing  the 
striatum was isolated from the entire hemisphere by making an initial cut at the 
frontal  tip  of  corpus  callosum  followed  by  a  second  at  the  lateral  ventricle 
[Figure 2.1A].  The isolated section was then placed rostrally and the caudate 
nucleus of the striatum carefully removed using curved forceps (Dumont no. 5) 
and placed into a bijou containing 1ml L-15 media [Figure 2.1B].    
2.4.3.2  Production of neurospheres from rat striatum 
Isolated stria were dissociated by gentle trituration with a glass Pasteur pipette 
and centrifuged at 140 g for 5 min.  The resulting pellet was resuspended in 2ml 
NSM, added to an uncoated T75cm
2 cell culture flask (Corning) and the volume 
made  up  to  20mls  with  NSM.    The  flasks  were  supplemented  with  EGF 
(Peprotech) at a final concentration of 5ng/ml to promote sphere formation.  
Neurospheres  were  maintained  at  37°C/7%  CO2  and  fed  twice  per  week  by 
addition of 5ml NSM supplemented with 5ng/ml EGF.  After approximately 7 days 
the neurospheres were used to generate astrocytes. 
2.4.3.3  Generation of astrocyte monolayers from neurospheres 
Glass coverslips (13mm) (VWR) were coated with 13.3µg/ml poly-l-lysine (Sigma-
Aldrich,  Dorset,  UK)  for  a  minimum  of  1  hour  at  37°C.    After  coating  the 
coverslips were washed extensively with sterile water and placed into a 24 well 
plate (one coverslip/well) and left to air dry before use.    
Neurospheres were transferred into 50ml falcon tubes and centrifuged at 140 g 
for  5  min.    The  pellet  was  resuspended  in  2ml  DMEM  +  10%  FBS  by  gentle 52 
trituration with a glass Pasteur pipette.  The total volume was made up to 12ml 
with DMEM +10% FBS and 0.5ml was added to each well (~50,000 cells/ coverslip) 
after which additional media was added to obtain a total volume of 1ml/ well.  
Astrocytes were maintained at 37°C/7% CO2 until confluent (~7 days). 
 
 
Figure 2.1: Isolation of the striatum from postnatal rat brain 
A.  Sagittal section of rat brain from P1 SD rats.  To isolate the region containing the striatum two 
cuts were made. The first at the frontal tip of the corpus callosum and the second at the lateral 
ventricle (red dashed lines).  B.  When the isolated section is placed in a rostral orientation the 
striatum is easily visible (highlighted in blue) and can be carefully removed with curved forceps.  
Figures adapted from Budantsev et al., 2007 and Gammie et al., 2004.  Abbreviations: C, cerebral 
cortex;  cc,  corpus  callosum;  CE,  cerebellum;  CPu,  caudate-putamen  complex  (striatum);  H, 
hippocampus; Hy, hypothalamus; LV, lateral ventricle; OB, olfactory bulb; S, septum; Th, thalamus.   
 
2.4.4 Dissociated spinal cord cultures 
Myelinating  spinal  cord  cultures  were  generated  as  described  previously 
(Sorenson et al., 2008).   
2.4.4.1  Isolation of embryonic rat spinal cord 
SD rats were time mated and the day of plugging denoted as day E0.5.  In vitro 
myelinating cultures were generated from E15.5 embryos.   
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The  pregnant  female  was  sacrificed  by  overdose  of  CO2  followed  by  cervical 
dislocation in accordance to UK Home Office guidelines.  The abdominal skin and 
fur were sterilized using 70% ethanol.  The uterus was exposed by making a V-
shaped incision at the lower abdomen cutting through the skin and abdominal 
wall and was carefully removed and placed into ice cold HBSS.  
Embryos were dissected from the gravid uterus and decapitated approximately 
3mm rostral to the cervical flexure.  The cranial 5 to 6mm of skin covering the 
spinal cord was gently removed and the spinal cord extruded carefully into 1ml 
HBSS (without Ca
2+ and Mg
2+).  Great care was taken to remove all meninges and 
dorsal root ganglion. 
2.4.4.2  Production of myelinating spinal cord cultures 
Isolated  spinal  cords  were  mechanically  dissociated  by  light  chopping  with  a 
sterile scalpel (no. 22 blade) and collected in a 1ml of sterile HBSS (without 
Ca
2+and  Mg
2+).    The  tissue  was  further  dissociated  by  addition  of  100µl  10x 
trypsin and 100µl 1% collagenase for 15 min at 37°C.  Enzymatic activity was 
stopped by adding 2ml SD solution (soybean trypsin inhibitor with DNAse I) after 
which the tissue was titurated using a glass Pasteur pipette. 
The  suspension  was  then  centrifuged  at  200  g  for  5  min  after  which  the 
supernatant was removed and the cell pellet resuspended in 2ml plating media 
(PM).  A live cell count was performed using a haemocytometer and trypan blue 
and  the  cells  were  subsequently  diluted  in  PM  to  a  concentration  of  1.5x10
6 
cells/ml. 
Dissociated spinal cord cells (150,000 cells/ coverslip) were carefully plated onto 
coverslips  supporting  a  monolayer  of  neurosphere  derived  astrocytes.    Three 
coverslips were placed into a 35mm petri dish.  Cells were left to attach for 
approximately 2 hrs at 37°C after which 500µl DM+ and 250µl PM was carefully 
added to each petri dish.  Cultures were maintained for 28-30 days at 37°C/7% 
CO2 and fed three times per week with DM by removing half of the media and 
replacing it with fresh media.  After 12 DIV insulin was omitted from the culture 
media to promote myelination.   54 
2.5 Immunocytochemistry 
2.5.1 Antibodies 
Primary antibodies used throughout this work are detailed below [Table 2.2].  
Secondary antibodies; Alexa Fluor® 350 (blue),  Alexa Fluor® 488 (green) and 
Alexa Fluor® 565 (red) were purchased from Invitrogen (Paisley, UK) and used at 
a dilution of 1 in 400 throughout. 
2.5.2 Live staining of extracellular antigens  
Primary antibodies were diluted in ice cold DMEM and applied to coverslips for 
30  min  at  4°C  after  which  the  coverslips  were  washed  in  DMEM  and  the 
appropriate fluorochrome conjugated secondary antibody was added for 30 min 
at 4°C.  The coverslips were then washed in DMEM and fixed with 4% PFA for 15 
min (RT) and either co-labelled for intracellular antigens as described below or 
mounted in Vectashield (Vector labs).  However in some cases as noted in the 
text  PFA  fixation  was  performed  immediately  after  incubation  with  primary 
antibody or serum.   
2.5.3 Staining of intracellular antigens 
(a)  Cells were fixed with 4% PFA, washed in PBS and then permeabilised with 
0.5% Triton X-100 for 10min (RT) and blocked in blocking buffer for 60 min (RT).  
Fixed  and  permeablised  cells  were  incubated  overnight  at  4°C  with  primary 
antibody  diluted  in  blocking  buffer.    After  washing  with  PBS  an  appropriate 
fluorochrome  conjugated  secondary  antibody  was  added  for  45  min  (RT).  
Coverslips  were  then  washed  in  PBS  followed  by  dH2O  and  mounted  in 
Vectashield (Vector labs).        
(b)  In  order  to  conserve  particular  epitopes  it  was  necessary  to  fix  and 
permeablise the cells using methanol rather than Triton X-100.  In this case cells 
were fixed in 100% methanol for 10 min at -20°C, washed with PBS, blocked with 
blocking buffer for 60 min (RT).  Primary antibodies were diluted in blocking 
buffer at the appropriate dilution and applied for 60 min at RT or 4°C overnight.  55 
The  cells  were  then  washed  with  PBS  and  the  corresponding  fluorochrome 
conjugated secondary antibody added for 45 min (RT).  Coverslips were then 
washed in PBS followed by dH2O and mounted with Vectashield (Vector labs).        
Table 2.2: Primary antibodies used in this study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prof. E Meinl (Germany) Live/ Bouins 1/200 IgG Rabbit Nfasc155
Prof. P. Brophy (UK) Live 1/300 IgG Rabbit  Nfasc186
Sigma (UK) PFA 1/500 IgG1 Mouse Pan NaV
Dr E. Mathey Live 1/250 IgG Rat Pan Nfasc
Derfuss et al., 2009 Methanol 1/100 IgM Mouse 4D7 (TAG-1)
Derfuss et al., 2009 Methanol 1/100 IgG1 Mouse 3.1C12 (TAG-1)
Oligodendrocyte /Myelin
Linington et al., 1988 Live 1/200 IgG1 Mouse 8-18C5 (MOG)
Chemicon (Europe) PFA + Triton 1/100 IgG2a Mouse MBP
Sigma (UK) PFA + Triton 1/50 IgG Rabbit  GalC
Millipore (Europe) Live 1/200 IgM Mouse O4
Millipore (Europe) Live 1/200 IgG Rabbit  NG2
Antisera PFA + Triton 1/200 IgG Rabbit PLP
Abcam (UK) Methanol 1/500 IgG Rabbit PDGFRα
Piddlesden et al., 1993 Live 1/200 IgG2a Mouse Z2
Chemicon (Europe) PFA + Triton 1/100 IgG2a Mouse PLP
Prof. M Rasband (USA) Live 1/100 IgG2a Mouse A12/18.1
Node of Ranvier
Zymed labs (USA) Methanol 1/100 IgG1 Mouse AnkyrinG
Abcam (UK) Methanol 1/1000 IgG Rabbit Caspr
Millipore (Europe) Methanol 1/100 IgG1 Mouse NeuN
Neurons/Axons
Abcam (UK) PFA + Triton 1/1000 IgG1 Mouse SMI-31
Abcam (UK) Methanol 1/500 IgG Rabbit PGP9.5
Abcam (UK) Live 1/200 IgG2b Mouse CD11b/c
Miscellaneous 
Dako (Denmark) PFA + Triton 1/500 IgG Rabbit GFAP
Abcam (UK) Methanol 1/200 IgG1 Mouse ED1
Abcam (UK) Live 1/200 IgG1 Mouse MHC-II
Dako (Denmark) PFA 1/100 IgG2a Mouse MAC (C5b-C9)
PFA + Triton
Fixation
Yamamura et al., 1991 1/100 IgG Rat AA3 (PLP)
Notes Dilution Isotype Species Antibody
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2.5.4 Identification of Nfasc localisation in vitro  
2.5.4.1  Nfasc155  
Nfasc155 readily accessible for antibody binding was detected by live staining as 
described above using a rabbit polyclonal antibody specific for the unique FN-III 
domain of Nfasc155. 
To visualise Nfasc155 staining within paranodal structures it was necessary to 
disrupt the paranode using Bouins fixative.  Cells were fixed with 4% PFA for 10 
min, washed in PBS, fixed with Bouins fixative for 3 min and washed extensively 
with PBS.  Cells were blocked with blocking buffer for 60 min at RT.  Primary 
antibodies  were  diluted  in  blocking  buffer  at  the  appropriate  dilution  and 
applied for 60 min at RT or 4°C overnight.  The cells are then washed with PBS 
and the corresponding fluorochrome conjugated secondary antibody was added 
for 45 min at RT.  The coverslips were washed in PBS followed by dH2O and 
mounted with Vectashield (Vector labs).         
2.5.4.2  Nfasc 186/ Nfasc 155 
Nfasc186 and Nfasc155 readily accessible for antibody binding was detected by 
live staining as described above using a monoclonal antibody (A12/18.1) or a rat 
anti-sera, which recognises shared epitope(s) on both Nfasc155 and Nfasc186. 
2.5.5 Immunocytochemistry to detect complement activation 
The  reagent  routinely  used  in  our  department  to  visualise  MAC  is  a  mAb 
generated  against  human  C5b-C9  recognising  human  poly  C9.    It  has  been 
previously demonstrated that this antibody recognises rat poly C9 (Kallio et al., 
2000) however we needed to confirm this using our rat serum and antibodies.  
To do this I used transfected cell lines expressing high levels of antigen at the 
cell  surface  and  incubation  of  transfectants  with  10µg/ml  antibody  in  the 
presence of 1% FRS mediated complement cell death and MAC deposition on the 
cell surface within 1 hour of addition.   57 
2.5.5.1  Antibody treatment of transfectants 
Transfected HeLa cells were treated with antibody at concentration indicated in 
the text for 30 min and kept at 4°C to minimise antibody internalisation.  Fresh 
rat serum was then added to the cells and the cells were brought up to 37°C and 
incubated until fixation.   
Transfectants were fixed with 4% PFA.  Blocked for 1 hr in 1% BSA/ 10% normal 
goat serum/ 0.3M glycine at room temperature.  To detect residual antibody 
bound to the surface secondary antibody was added (Alexa Fluor 488, Invitrogen) 
for 45min at room temperature.  Cells were washed and mounted in Vectashield 
(Vectorlabs) with DAPI to visualize the nuclei. 
2.6 Image Capture and Analysis  
2.6.1  Image Capture 
All images for cell counting, quantification of axonal density and myelination 
were  taken  using  an  Olympus  BX51  fluorescent  microscope  (Olympus).    A 
minimum  for  thirty  images  were  analysed  per  condition  in  each  experiment.  
Images were taken in a semi-random fashion i.e. ten random images were taken 
per coverslip from myelinated regions.   
2.6.1.1  Quantification of axonal density 
Neurites were visualised by phosphorylated neurofilament staining (SMI-31) and a 
minimum of ten images were taken per coverslip (10X magnification). 
Using Image J (version 1.41o, National Institute of Health, USA) the image was 
split  into  three  separate  images  corresponding  to  the  red,  green  and  blue 
channels and the channel corresponding to SMI-31 staining was then converted to 
a black and white image. Axonal density was calculated as the number of SMI-
31+ pixels expressed as a percentage of the total number of pixels per field of 
view [Figure 2.2A]. 58 
2.6.1.2  Quantification of total myelin/ oligodendrocyte density 
Oligodendrocytes and their associated sheathes were visualised by staining for 
an oligodendrocyte/ myelin marker (e.g. MOG or PLP) and a minimum of ten 
images were taken per coverslip (10x magnification). 
Using Image J (version 1.41o, National Institute of Health, USA) the image was 
split  into  three  separate  images  corresponding  to  the  red,  green  and  blue 
channels and the channel corresponding to oligodendrocyte/ myelin staining was 
then converted to a black and white image.  Oligodendrocyte/myelin density 
was calculated as the number of positive pixels expressed as a percentage of the 
total number of pixels per field of view [Figure 2.2A]. 
2.6.1.3  Quantification of myelination   
As there is no specific myelin marker that differentiates completely between 
oligodendrocytes  and  myelin  sheathes  these  were  manually  highlighted  using 
Adobe Photoshop elements® (blue) [Figure 2.2B] and measured using a macro 
within Image J (written by John Annan) (Appendix).  To provide a measure of the 
extent of myelination the number of myelin positive pixels was divided by the 
number of SMI-31 pixels in the same field.   
2.6.1.4  Cell counting 
In order to quantify cell populations within cultures a minimum of 30 images 
were taken from three coverslips (20x magnification) and immunopositive cells 
associated  with  a  DAPI
+  nucleus  were  counted  using  the  ImageJ  cell  counter 
function (version 1.41o).  Cell counts were expressed as a percentage of the 
total number of DAPI
+ nuclei in the image at the same plane of focus.    
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Figure 2.2: Quantification of axonal density and myelination using Image J. 
A. To calculate axonal density images were split into their individual colour channels using Image J 
software.  The channel corresponding to SMI-31 (red) was converted into a black and white image 
and the axonal density was calculated as the number of SMI-31+ pixels within a field of view (10X 
magnification)  and  expressed  as  a  percentage.    The  same  approach  was  adopted  in  order  to 
calculate the total density of myelin/oligodendrocytes by focusing on the green channel.  B.  To 
calculate the percentage myelination it was necessary to exclude staining on oligodendrocyte cell 
bodies  and  to  focus  solely  on  the  myelin  sheathes.    To  achieve  this,  myelin  sheathes  were 
manually highlighted using Adobe Photoshop ® (Adobe systems) (blue).  The highlighted area was 
quantified using a macro within Image J. For each image percentage myelination was expressed 
as the total number of myelin pixels/ total number of SMI-31 pixels (based on Sorenson et al, 
2008).   
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2.7 Immunoglobulin Purification 
2.7.1 Protein G chromatography 
Antibodies  were  purified  using  1ml  HiTrap  protein  G  fast  flow  columns  (GE 
Healthcare) following manufacturers instructions.   
Briefly samples were diluted in binding buffer and particulates were removed by 
filtration using a 0.45µm filter prior to loading.  Samples and buffers were added 
using a 10ml syringe at a flow rate of 1ml/min taking care to prevent introducing 
air into the column.     
After washing with 10ml of binding buffer to remove the ethanol-based storage 
buffer the sample was passed through the column, which was then rinsed with a 
minimum of 5ml until the absorbance of the eluate at 280nm had fallen to that 
of diluted binding buffer.  The flow through was retained in the event that not 
all antibody binds to the column.  Bound antibody was eluted using 8ml elution 
buffer collected sequentially in 2ml fractions that were neutralised immediately 
by  addition  of  100µl  of  1M  Tris-HCl,  pH  9.0.    Protein  Concentrations  were 
determined by absorbance at 280nm using a nanodrop 1000 spectrophotometer 
(Thermo scientific).   
2.7.2 Generation of Fab fragments 
Fab  fragments  were  generated  using  Pierce  ®  Fab  Preparation  kit  following 
manufacturer’s instructions.   
1mg/ml purified IgG was incubated with immobilised papain for 4 hours at 37°C.  
After digestion, fragments were retrieved by centrifugation at 5000 x g for 1 min 
and the resin was washed with PBS.  Fab fragments were isolated via protein-A 
chromatography and their purity was assessed by SDS-PAGE.    
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2.7.3 Purification  of  patient-derived  Nfasc155  specific 
autoantibodies 
Purification and characterisation of Nfasc specific antibodies was performed in 
collaboration with Dr. A. Arthur (University of Glasgow). 
Recombinant  rat  NF155  (rrNfasc)  (500µg)  (R&D  Systems)  was  bound  to  an 
activated  NHS  column  (GE  Healthcare)  according  to  the  manufacturer’s 
instructions. Plasmapheresis samples were diluted with PBS, filtered and brought 
to  pH  7  before  were  run  over  rNfasc  immunosorpbent  columns  at  4°C.  After 
extensive washing with PBS, bound antibody was eluted with 0.1M glycine pH 2.7 
and immediately neutralized using 1M Tris pH 9. The presence of anti-rNfasc 
antibodies  and  their  isotype  was  confirmed  by  ELISA,  whilst  antibody 
concentrations were determined using a Nanodrop spectrophotometer (Thermo 
Scientific). 
2.7.3.1  Isotype usage of the Nfasc specific repertoire  
Purified human anti-Nfasc155 antibodies were diluted 1:500 in PBS and specific 
binding rat Nfasc155 detected using anti-human IgG1 (Zymed), IgG2 (Zymed), 
IgG3  (Zymed),  IgG4  (Zymed)  or  IgM  (Dako)  reagent  conjugated  to  alkaline 
phosphatase. 
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2.8 Using  myelinating  cultures  to  detect  complement 
dependent antibody mediated injury 
2.8.1 Preparation of fresh rat serum 
To obtain fresh sera, SD rats were exsanguinated by cardiac puncture with a 
10ml syringe and 21G needle.  The blood was allowed to clot on ice and once 
clotted the serum was isolated by centrifugation at 2000 g for 10 min at 4°C.  
Sera was stored at -80°C in small aliquots to avoid freeze thawing.  To heat 
inactivate the complement, sera was incubated at 56°C in a water bath for 30 
min.   
2.8.2   Antibody treatment of myelinating cultures 
2.8.2.1  Complement dependent assay 
To investigate complement dependent antibody mediated injury.  Cultures were 
treated  after  28  days  in  vitro  to  allow  for  axonal  establishment  and  robust 
myelination.  Purified antibodies were used at a concentrations indicated in the 
text.    Fresh  rat  serum  was  added  as  a  source  of  complement  at  a  final 
concentration of 1% and cells were incubated at 37°C/ CO2 until fixation.  In 
each  case  cells  were  labelled  by  ICC  and  axonal  density  and  extent  of 
myelination quantified as described previously.        
To  elucidate  whether  antibody  mediated  effects  were  dose  dependant 
myelinating  cultures  were  treated  with  varying  concentrations  of  antibody 
(10µg/ml,  1µg/ml,  100ng/ml,  50ng/ml  and  10ng/ml),  1%  FRS  was  used  as  a 
source of complement and cells were incubated overnight (~16hrs) at 37°C/7% 
CO2 until fixation and ICC.   
To determine the time scale in which injury occurs; myelinating cultures were 
treated with 10µg/ml antibody and taken at specific time intervals (as denoted 
in  the  text),  1%  FRS  was  used  as  a  source  of  complement  and  cells  kept 
incubated at 37°C/7% CO2 until fixation and ICC.   63 
2.8.2.2  Complement independent assay 
To investigate the pathogenic potential of autoantibodies in the absence of 
exogenous complement, myelinating cultures were treated at concentrations 
indicated in the text from 12 DIV, 18 DIV or 24 DIV.  Antibodies were reapplied 
with each media change until 28 DIV.   
2.9 Clinical Studies:  Identification of pathogenic 
autoantibodies in MS patients.   
2.9.1 Patient samples 
Samples  were  collected  from  patients  at  the  Southern  General  Hospital 
(Glasgow,  UK),  University  of  Heidelberg  (Heidelberg,  Germany)  and  the 
University  Clinic  Grosshardern  (Munich,  Germany).    Clinically  definite  MS  was 
defined using  the  Poser  or  McDonald  criteria  (Poser et  al.,  1983).    Each  site 
collected samples using a protocol approved by their Institutional Review Board, 
and informed consent was obtained from all subjects.  Samples were stored at -
80°C in aliquots.  Inclusion criterion for use in the study was positive for an 
antibody response to Nfasc155 as tested by ELISA. 
2.9.2 Treatment  of  myelinating  cultures  with  patient-derived 
autoantibodies 
After 28 DIV immunopurified Nfasc-specific immunoglobulins were added to the 
cultures at the concentrations indicated in the text in the presence or absence 
of fresh rat sera as a source of complement (final concentration 1%). Additional 
control cultures were treated with antibody alone or in combination with heat 
inactivated serum as additional controls.   
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Table 2.3 Clinical data of patient cohort selected for study 
Plasma samples were obtained from patients undergoing therapeutic plasma exchange (PEx).  The 
patients were broadly divided into two groups, those diagnosed with multiple sclerosis (MS) and 
those diagnosed with other neurological diseases OND.  Plasma samples were screened by ELISA 
for Nfasc autoantibody responses and the patients which tested positive were used in this study.   
Abbreviations: RRMS: relapsing remitting MS, SPMS: secondary progressive MS, PPMS: primary 
progressive MS, SPN: Sensory motor polyneuropathy, CIDP: chronic idiopathic polyneuropathy, 
GBS:  Guillian-Barre  syndrome,  ISAN:  Idiopathic  sensory  ataxic  neuropathy,  MG:  Myasthenia 
Gravis.    
 
Patient ID  Gender Age Diagnosis Time from onset at TPX
MS1 F 26 MS (Marburg) 8 years
MS2 F 42 RRMS 25 years
MS3 M 45 RRMS  0 years
MS4 F 49 RRMS 7 years
MS5 M 29 SPMS 5 years
MS6 F 49 RRMS 11 years
MS7 F 31 RRMS 7 months
MS8 F 51 RRMS N/A
MS9 F 43 RRMS N/A
MS10 M 46 RRMS N/A
MS11 F 42 RRMS N/A
MS12 F 42 RRMS N/A
MS13 F 40 RRMS N/A
MS14 M 33 RRMS N/A
MS15 F 53 RRMS N/A
MS16 F 58 RRMS N/A
MS17 F 57 PPMS N/A
MS18 F 56 PPMS N/A
MS19 M 47 PPMS N/A
MS20 F 28 PPMS N/A
OND1 M 38 SPN 9  years
OND2 F 49 GBS <1 month
OND3 F 55 GBS <1 month
OND4 M 24 GBS <1 month
OND5 M 62 CIDP 14  years
OND6 F 55 CIDP 20  years
OND7 M 79 CIDP 4  years
OND8 M 71 ISAN <1 month
OND9 F 62 MG 5  years
OND10 F 63 CIDP 8  years
HC1  F 45 N/A N/A
HC2 F 31 N/A N/A
HC3 M 46 N/A N/A
HC4 F 33 N/A N/A
HC5 F 27 N/A N/A
HC6 F 28 N/A N/A
HC7 F 32 N/A N/A
HC8 F 50 N/A N/A
HC9 F 31 N/A N/A
HC10 M 80 N/A N/A
HC11 F 24 N/A N/A
HC12 M 57 N/A N/A
HC13 F 37 N/A N/A    
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2.10 Statistics 
In order to determine whether immunocytochemical data obtained for axonal 
density and myelination followed a normal distribution, raw data was assessed 
using  the Lilliefors Test for Normality (Lilliefors, 1967) using software provided 
by  the  European  mirror  service  (Professor  Hossein  Arsham,  University  of 
Baltimore, 
http://www.mirrorservice.org/sites/home.ubalt.edu/ntsbarsh/Business-
stat/otherapplets/Normality.htm).  Using this test we determined that our data 
“likely follows a normal distribution”. 
Due to the distribution of the data, values from treatments and controls were 
compared using a parametric method namely the students T-test.  When directly 
comparing raw data values, probability values were calculated using the paired 
students T-test (two tailed) (Microsoft Excel).  In majority of cases, raw data 
was standardised and expressed as a percentage of control values.  In this case 
the paired T-test was not appropriate; therefore p values were calculated using 
the one-sample heteroscedastic T-test (Microsoft Excel).   
In each instance statistical significance was denoted with * when p<0.05 and ** 
when  p<0.001.    For  antibody  mediated  effects  on  axons  and  myelin/glia,  p 
values obtained were comparable between analyses of raw or standardised data 
[Table 2.4]. 
All data was plotted as the mean of three independent experiments performed 
three times in triplicate +/- standard error of the mean, unless stated otherwise.   
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Table 2.4:  Calculation of probality values using the students T-test- comparison of raw and 
standardised data 
Data values were taken from table 4.2.  Myelinating cultures (28 DIV) were treated overnight in the 
presence  of  complement  with  10µg/ml  of  Z2  (anti-MOG,  demyelinating),  A12/18.1  (pan-Nfasc, 
axopathic and demyelinating) or an IgG2a control (no effect to axons or glia).   P values from raw 
data values for axonal density and myelination were calculated using a paired two-tailed T-test.  In 
some cases data was standardised and expressed as a percentage of control values.  In these 
examples  p  values  were  calculated  using  a  one-sample  heteroscedastic  T-test.    In  each  case 
antibody mediated effects on axons and glia were highly significant and p values were comparable 
regardless of the data set analysed or statistical test used.  Values shown are the average of three 
independent experiments performed in triplicate ± S.E.M.   
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3  Characterisation of in vitro myelinating cultures 
3.1 Introduction  
The purpose of this chapter is to describe the in vitro myelinating cultures used 
in  this  study  and  demonstrate  their  validity  as  a  representative  model  of 
myelination.  This characterisation is a prerequisite if this in vitro system is to 
be  used  as  a  tool  to  detect  pathogenic  antibody  responses.    If  myelinating 
cultures are to provide a valid screening strategy it is crucial they replicate the 
structural and molecular organisation of the CNS in vivo.  The advantage of using 
such  a  co-culture  system  over  homogenous  cell  populations  such  as  pure 
oligodendrocyte  cultures  is  that  although  oligodendrocytes  are  capable  of 
extending myelin like membranous sheets in vitro, in the absence of neurons 
they  cannot  assemble  myelin  sheathes.    However  in  the  myelinating  culture 
model it is possible to obtain myelin sheathes with similar properties to that of 
compact CNS myelin in vivo including formation of higher order structures such 
as paranodal loops and nodes of Ranvier (Thompson et al., 2006, Sorenson et al., 
2008).   
If  this  myelinating  culture  model  was  to  provide  a  routine  screen  for 
demyelinating autoantibodies it was important to determine the reproducibility 
of the system by investigating the variation between cultures from the same 
preparation and between myelinating cultures from different preparations.  In 
order to generate a reliable model it must be proven to be robust, reproducible 
and statistically sound.   
Characterisation  was  also  necessary  to  determine  appropriate  time  points  to 
assay  antibody  dependent  effects.    To  do  this  was  important  to  initially 
determine at which stages in vitro are the antigens of interest expressed.   
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The aims of this chapter are: 
•  To  analyse  the  cytoarchitecture  of  the  myelinating  cultures  and 
determine similarities between this model and the in vivo CNS.    
•  To determine when various antigens are expressed and their localisation 
in vitro.   
•  To  determine  the  reproducibility  of  the  system  and  it  suitability  as  a 
potential screening strategy in which to detect pathogenic autoantibody 
responses.    
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3.2 Results 
To  investigate  in  vitro  development  of  myelinating  cultures,  they  were 
characterised by immunofluorescence microscopy at key stages namely 9, 12, 
18, 24 and 30 DIV. 
3.2.1 Neurite extension and axonal ensheathment 
Neurons derived from the embryonic rat spinal cord consist of a heterogeneous 
population of neuronal cell types and neural progenitors (Nornes et al., 1974).   
We  can  measure  neuronal  development  and  axonal  extension  that  occurs 
throughout  the  culture  period  by  measuring  increases  in  phosphorylated 
neurofilament expression by immunocytochemistry using the monoclonal SMI-31 
[Figure 3.1A].  After 9 DIV the astrocyte monolayer is covered by clusters of 
neurons  that  have  already  begun  to  extend  neurites  which  by  12  DIV  cover 
approximately  50%  of  the  surface  of  the coverslip.    Axonal  density  begins  to 
plateau at approximately 65-70% between 18 DIV to 24 DIV [Figure 3.1B].   
Oligodendrocyte  maturation  and  the  onset  of  myelination  were  followed  by 
measuring MBP immunoreactivity [Figure 3.1A].  MBP
+ cells are not present at 
earlier culture stages but a small number begin to appear 12 DIV. After 12 days 
in  culture  insulin  is  omitted  from  the  culture  media  in  order  to  promote 
oligodendrocyte progenitor differentiation maturation rather than proliferation 
(Thompson et al., 2006).  After insulin withdrawal there is an increase in the 
number of MBP expressing cells but by day 18 little axonal ensheathment. By 24 
DIV  we  observe  substantial  axonal  ensheathment  and  myelination  by  MBP
+ 
oligodendrocytes.  Once myelination has begun the process is relatively rapid as 
the  number  of  MBP
+  myelin  sheathes  effectively  triples  over  the  final  6  day 
period [Figure 3.1C].  MBP
+ sheathes also expressed PLP and quantification of 
PLP staining gave a similar result.  PLP was subsequently used for all future 
quantification.   70 
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Figure 3.1: Axonal density and myelination increase over time. 
A:    Immunochemistry  of  myelinating  cultures  over  a  30  day  culture  period.    Neurites  were 
visualised using SMI-31 (phosphorylated neurofilament: red) and myelin/ oligodendrocytes were 
stained for myelin basic protein (MBP: green) (10X magnification).  Cultures were stained at 9 (i), 
12 (ii), 18 (iii), 24 (iv) and 30 DIV (v).   Myelin sheathes also expressed PLP in addition to MBP 
(vi) (PLP: red, MBP: green) (40X magnification) B: Axonal density was calculated by measuring 
the number of SMI-31+ pixels per field of view (10X magnification).  For each time point a minimum 
of 30 images were analysed.  Neurofilament staining was visible at nine DIV where a small number 
of  axons  are  developing.    By  12  DIV  a  dense  network  of  neurites  is  formed.    Axonal  density 
increases to its maximum by 18 DIV.  Values plotted are quantification of immunocytochemical 
data from three independent experiments performed in triplicate (mean ± S.E.M).  C: Myelination 
was quantified by calculating the percentage of myelinated axons in each image.  For each time 
point a minimum of 30 images were analysed.  Myelination usually occurs between days 20-22 and 
by 24 DIV there is a substantial amount of axonal ensheathment.  Once myelination has begun the 
process is relatively rapid as the number of myelin sheathes effectively triples over the final 6 day 
period.    Values  plotted  are  quantification  of  immunocytochemical  data  from  three  independent 
experiments performed in triplicate (mean ± S.E.M).   71 
 
3.2.2 Differentiation of the oligodendrocyte lineage 
Myelination  is  a  tightly  regulated  process  in  which  oligodendrocyte  precursor 
cells (OPCs) differentiate into oligodendrocytes which extend processes and can 
ensheath  appropriate  axons.    OPCs  differentiate  into  mature  myelinating 
oligodendrocytes through a defined path with various stages.  Each cell subtype 
expresses a set of characteristic surface markers that can be used to determine 
their  state  of  differentiation.    Immature  OPCs  were  detected  using  NG2 
(chondroitin sulphate proteoglycan) (Dawson et al., 2000; Stallcup., 1981), late 
OPCs/ pre- oligodendrocytes were labelled with O4 monoclonal antibody (Bansal 
et al., 1992, Sommer and Schachner, 1981), which recognises sulphatide.  PLP 
staining was used to visualise oligodendrocytes; however it must be noted that 
the anti-PLP antibody used in this study also binds to DM20, an isoform of PLP, 
expressed  by  pre-OLG  populations  prior  to  PLP  expression  (Yamamura  et  al., 
1991).  Mature oligodendrocytes were defined as expressing MOG on the cell 
surface (Scolding et al., 1989) [Figure 3.2A].   In the early stages of development 
large  numbers  of  oligodendrocyte  precursor  cells  (OPCs)  can  be  detected  by 
immunocytochemistry  [Figure  3.2B].    Between  9  and  12  days  in  culture,  the 
majority of oligodendrocyte lineage cells present are NG2
+, but after insulin is 
withdrawn from the culture medium (arrow) the number of NG2
+ cells rapidly 
declines.    By  the  end  of  the  culture  period  only  a  small  proportion  of  NG2 
expressing cells remain.  Cells labelled by the O4 antibody include a subset of 
OPCs  (which  co-express  NG2),  pre-oligodendrocytes  and  oligodendrocytes; 
therefore  there  are  a  high  proportion  of  O4
+  cells  at  each  timepoint  culture 
however  the  cell  types  recognised  will  shift  from  OPCs  through  pre-
oligodendrocyte towards a mature myelinating oligodendrocyte phenotype as the 
culture progresses.   Mature oligodendrocytes are not present within the first 12 
days in culture [Figure 3.2B]; however after insulin withdrawal (arrow) there is 
an increase in the number of MOG expressing cells correlating with the onset of 
myelination.  The number of PLP/DM20 expressing cells follows a similar trend 
although  in  greater  number  due  to  the  number  of  pre-oligodendrocytes  and 
immature oligodendrocytes labelled.  All oligodendrocytes expressing MOG also 
express PLP and MBP.    
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Figure 3.2: Differentiation of the oligodendrocyte lineage within the myelinating cell culture 
system. 
A:    OPCs  express  NG2  chondroitin  sulphate  proteoglycan  (i)  and  as  they  mature  into  pre-
oligodendrocytes they begin to express sulphatide (04) (ii).  All oligodendrocytes express PLP (iii) 
(although  it  must  be  noted  that  PLP  antibodies  also  bind  to  DM20  expressed  by  pre-OLG 
populations).  MOG is a marker of terminal oligodendrocyte differentiation and commitment to a 
myelinating phenotype (iv).  B:  NG2
+ positive cells (purple line) are most abundant in the earlier 
culture stages reaching a maximum at ~12 DIV and decreasing at later stages.  Cells expressing 
O4 (blue line) arise also in the earlier stages and continue to increase in number as the culture 
progresses.  Arrow denotes day of insulin withdrawal from the media.  C: PLP
+ cells (red line) 
appear in large numbers the intermediate and late stages of development coinciding with the onset 
of myelination.  MOG expressing (green line) cells are most abundant in the final stages correlating 
with the terminal maturation of oligodendrocytes and enhanced myelination.  All values plotted are 
the mean of three independent experiments performed in triplicate (± S.E.M).   
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3.2.3 Microglial development 
In order to determine whether there were a population of resident microglia 
within  the  in  vitro  culture  system,  cultures  were  analysed  by 
immunocytochemistry at several stages of growth using two microglia markers; 
CD11b/c and MHC-II.   
At the earlier stages of development there are a number of CD11b/c
+ cells with a 
round  morphology.    However  as  the  cultures  mature  CD11b/c  and  MHC-II 
expressing  microglia  increase  in  number  and  they  adopt  a  more  classical 
branched morphology and demonstrate a larger amoeboid shape [Figure 3.3].  
The phagocytic potential of these microglia cells will be demonstrated in the 
next chapter.   
 
 
 
 
 
 
 
 
 
Figure 3.3: Microglia are present in every stage of culture development.   
A:  In  early  stages  of  culture  (<12  DIV)  the  microglia  present  have  a  rounded  morphology  (i) 
(CD11b/c: red) as the cells mature they adopt a more classical branched morphology expressing 
both MHC-II (ii) (green) and CD11b/c (iii) (red) (63X magnification).  B: Quantification of microglia 
numbers shows a steady increase throughout culture development.  Values plotted as the mean of 
from three independent experiments performed in triplicate (± S.E.M).   
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3.2.4 Development of axo-glial junctions 
3.2.4.1  Neurofascin expression in vitro 
The  neurofascins  play  key  roles  in  axo-glial  interactions  and  node  of  Ranvier 
formation  (Zonta  et  al.,  2008).  Neurofascin  exists  as  two  major  isoforms; 
Nfasc155 expressed by glia and Nfasc186 expressed by neurons and axons.  
Live  immunocytochemistry  using  a  rabbit  polyclonal  antibody  specific  for 
Nfasc155 detects Nfasc155 expression on the surface of oligodendrocytes at the 
cell body on along their processes [Figure 3.4A].  Fixation with Bouin’s fixative 
and  permeablisation  reveals  Nfasc155  staining  at  paranodal  domains  and 
cytoplasmic  staining  within  oligodendrocytes.    In  contrast  a  rabbit  polyclonal 
specific for Nfasc186 only clearly stained nodes of Ranvier with no binding to 
oligodendrocytes  or  myelin.  Staining  live  with  A12/18.1,  a  pan  specific 
monoclonal, revealed not only oligodendrocyte and nodal staining, but also on 
the surface of a subset of neurons [Figure 3.4B]. 
To investigate changes in Nfasc gene expression RT-PCR was performed on cDNA 
samples generated from RNA extracted from myelinating cultures at 9, 12, 18, 
24 and 30 DIV.  Nfasc155 expression [Figure 3.4C] follows a similar time course 
as oligodendrocyte maturation.  Fold change in gene expression was calculated 
by the comparative Ct method (Livak et al., 2001) with gene expression values 
for 9 DIV used as the base line.   There is no change in Nfasc gene expression 
between days 9 and 12.  However from day 12 there is a rise in Nfasc155 gene 
expression  increasing  steadily  as  the  culture  progresses  reaching  a  3  fold 
increase after 30 DIV.  In contrast Nfasc186 expression increases by 2 fold from 
day 9 to day 12 there is no change in Nfasc186 expression between day 12 and 
18.    From  the cells  present  at these  timepoints  (mainly  OPCs  and  no  myelin 
formation)  this  increase  in  Nfasc186  is  due  to  neuronal  Nfasc186  expression.  
Nfasc186  gene expression increases  sharply  once  myelination has  begun  (post 
day 18) due to increased Nfasc186 protein expression by the axon at the AIS and 
at the node of Ranvier.   75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Neurofascin expression in vitro  
A: Live staining for Nfasc155 (green) demonstrates surface expression by oligodendrocytes at the 
cell  body  and  processes  (PLP:  red)  with  intense  staining  at  the  tip  of  the  cell  process  (40X 
magnification).    B:  Live  staining  for  Nfasc155/186  using  a  pan-specific  monoclonal  (A12/18.1) 
revealed Nfasc186 expression on a subset  of PGP9.5
+ neurons at the soma (red), axon  initial 
segment and at the node of Ranvier (63X magnification).   C: RNA was purified from myelinating 
cultures at 9, 12, 18, 24 and 30 DIV and cDNA created.  Subsequent RT-PCR analysis of gene 
expression revealed that mRNA levels for both Nfasc155 and Nfasc186 continually increase over 
time in culture from 6 DIV.  Nfasc155 expression increases from 12 DIV and increases gradually as 
myelination proceeds (i).  Nfasc186 expression increases from day 6 as the neuronal population 
expands and after 18 DIV there is a large increase in Nfasc186 expression coinciding with the 
onset of myelination (ii).  Fold change values calculated in comparison to day 9 gene expression 
(±S.D).  ß-actin was used as housekeeping gene.       
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3.2.4.2  Molecular organisation of the node of Ranvier  
In order to assess whether myelin sheathes formed in the cultures reproduced 
the characteristics to  in vivo compact myelin and whether myelin internodes 
were bridged by typical nodes of Ranvier an immunocytochemical approach was 
adopted.      Myelinating  oligodendrocytes  in  vitro  assemble  paranodal  loops 
expressing  both  Caspr  and  Nfasc155.    These  paranodal  domain  flank  nodal 
regions where Nfasc186, ankyrin G and voltage gated sodium channels (NaV) are 
clustered.    Myelinating  cultures  are  capable  of  forming  nodes  of  Ranvier 
between myelinated segments that are “typical” of those described in vivo with 
respect to their molecular composition [Figure 3.5].  In however in this culture 
system the formation of “heminodes” is much more common.  At the heminode 
there is clustering of Nfasc155 and Caspr at the end of PLP
+ myelin sheathes but 
no detectable axonal expression of Nfasc186 or NaV [Figure 3.5B].   
 
 
 
 
 
 
Figure 3.5: Nodes of Ranvier formed in vitro are representative of those formed in vivo.   
A: Node of Ranvier between  two myelin internodes (PLP, red) visualised by  Nfasc186 (green) 
staining bounded by paranodal Caspr staining (blue) (100x magnification) (i).  Node of Ranvier 
between two myelin internodes (PLP, green) visualised by staining of the voltage gated sodium 
channel  (red)  bounded  by  Nfasc155  at  the  paranode  (blue)  (100x  magnification)  (ii).    Node  of 
Ranvier between two myelin  internodes (PLP,  green) visualised  by staining for ankyrinG (blue) 
bounded by Caspr at the paranode (red) (100x magnification) (iii).  B:  Staining showing a node of 
ranvier and a “hemi” node.  Heminodes consist of paranodal Caspr (i) and Nfasc155 (ii) but no 
expression of voltage gated sodium channel or Nfasc186.    
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3.3 Discussion  
In  vitro  myelinating  cultures  provide  a  model  which  reproduces  the  cellular 
composition and molecular organisation observed in vivo CNS.  However it must 
be  noted  that  this  dissociated  cell  system  is  a  developmental  model  of 
myelination  and  does  not  reproduce  the  3D  cytoarchitecture  as  seen  in 
myelinated  tracts  in  vivo.    Nevertheless,  individual  sheathes  form  paranodal 
loops and heminodes as defined by Nfasc155 and Caspr immunoreactivity and 
between myelin internodes nodes of Ranvier are formed where Nfasc186, NaV 
and AnkG are clustered.  Furthermore this system provides a cell based assay in 
which to determine the effects of a molecule of interest on myelination and 
axonal survival.     
The advantage of using this rat-derived system over the mouse equivalent is the 
number  of  coverslips  (individual  cultures)  one  can  generate  from  a  typical 
preparation.  One litter of P1 neonatal rats and one pregnant E15.5 SD rat (~12-
15 embryos) will generate approximately 140 coverslips/ individual cultures.  In 
contrast  one  pregnant  mouse  E13.5  (~6-8  embryos)  will  only  generate  only  a 
third of this number.  Using mouse-derived cultures could be used to confirm the 
specificity  of  the  target  such  as  using  MOG  knockout  mice  against  anti-MOG 
antibody  responses.    However  for  the  myelinating  culture  system  to  be  used 
routinely as a model to detect pathogenic autoantibody responses it must be 
statistically  reproducible  both  between  individual  coverslips  within  a  single 
preparation but also between coverslips from different preparations.  Within a 
batch of cultures the amount of myelination and the approximate axonal density 
remain relatively reproducible between coverslips [Table 3.1].   
There is little variation in axonal density between either coverslips of the same 
batch  or  between  preparations  (Cv<10%).    Myelination  is  much  more  variable 
(CV>10%).    Myelinating  cultures  were  checked  by  immunocytochemistry  and 
microscopy the day before use and cultures with <2% myelinated axons were 
discarded.   
 
 78 
Table 3.1: Variations between preparations of myelinating cultures at 28 DIV 
Values  for  axonal  density  and  the  percentage  of  myelinated  axons  were  calculated  from  six 
independent batches of myelinating cultures generated over a six week period.  Values plotted as 
the mean from three coverslips per preparation ± standard deviation (SD).      
   
 
 
 
 
 
 
The major advantage of this system is that images can be taken from coverslips 
randomly  and  subsequently  analysed  in  a  semi-automated  fashion  to  give 
quantitative data.  However it must be noted that quantifying the number of 
myelinated axons by highlighting individual myelin sheathes and discriminating 
between myelin and oligodendrocyte processes can be subjective depending on 
the  individual  performing  the  analysis.    When  quantifying  cell  numbers  it  is 
difficult  to  obtain  and  accurate  figure  when  many  cells  are  grouped  closely 
together.  One possible way to overcome this is to take Z stacks and quantify 
only those cells in that plane of focus.   
I  considered  other  culture  models  in  addition  to  the  dissociated  cell  culture 
models established here in Glasgow.  One such model was the organotypic slice 
culture model.   Organotypic slice cultures (OSCs) typically consist of neonatal 
murine  CNS  explants  (such  as  the  hippocampus  or  cerebellum),  which  are 
maintained in culture for several weeks (Stoppini et al., 1991).  Such systems 
have been used for a wide range of applications from measuring the effects of 
long  term  addition  of  a  particular  substance  (review:  Peña.  2010)  such  as 
investigating  the  effects  of  neuroactive  drugs  (Drexler  et  al.,  2010),  growth 
factors  (review:  McAllister  et  al.,  1999)  and  studies  regarding  antibody 
demyelination and subsequent remyelination (Harrer et al., 2009). 
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The  advantage  of  such  a  system  is  that  the  3D  architecture  seen  in  vivo  is 
conserved  in  culture  [Figure  3.6].    OSCs  are  therefore  ideally  suited  to 
electrophysiological studies and have been used to expand our understanding of 
action potential propagation and synaptic transmission (Maletic-Savatic et al., 
1999,   Shi et al., 1999).  The use of such as system has become an increasingly 
powerful tool with the incorporation of various transgenic mouse strains from 
auto fluorescent cells for enhanced imaging (review: Hechler et al., 2006) or the 
use of knockouts to investigate the mechanistics of a molecule of interest.  I 
considered using OSCs as the model screening strategy for my thesis and spent 
two  weeks  in  the  laboratory  of  Professor  N.  Goebels  (University  of  Zurich, 
Switzerland) learning the methodology.  I discovered that the system was not 
without  its  drawbacks.    It  would  require  many  animals  and  be  very  labour 
intensive  to  produce  enough  slices  each  week  for  a  routine  high  throughput 
screening protocol and the slices require more maintenance in comparison to 
dissociated cell systems.  The slices are also more sensitive to environmental 
changes and may spontaneously die in culture due to small media pH changes or 
hypoxia.   
 
 
 
  
Figure 3.6: 3D architecture of white matter tracts in cerebellar slice cultures. 
3D architecture of myelinated tracts in OSCs created from GPF-PLP transgenic mice (PLP; green, 
neurofilament; red) (20X magnification).  OSCs were created and images taken whilst visiting the 
lab of Prof. N Goebels in collaboration with Dr. M Harrer (Zurich).   
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Characterising the rat dissociated myelinating cultures allowed me to determine 
the best time point in which to investigate antibody mediated injury in vitro.  I 
decided for future experiments to add antibody at day 28.  This was based on 
the cellular and biological composition of the cultures at this time point.  Axonal 
density  is  well  established  with  a  substantial  amount  of  oligodendrocyte 
maturation and myelin formation with nodes of Ranvier [Figure 3.7].   Usually 
the cells begin to decline after 30-35 days in culture and therefore it is crucial 
to use the cultures whilst they remained “healthy”. 
Through  understanding  which  cell  populations  are  present  at  this  later  time 
point and which molecules are expressed by these cells together with what is 
already known about autoantibody mediated pathogenesis in MS.  We can begin 
to compile a  list of candidate autoantigens  in  which to investigate  using  our 
system.   81 
 
Figure 3.7: Summary of mature myelinating cultures after 28 DIV. 
Myelinating cultures consist of a many different cell types after 28 days in culture.  There is a well 
established  populations  of  neurons  (red,  PGP9.5)  extending  many  neurites  (SMI-31,  blue,  10X 
magnification) (i).  These axons eventually become myelinated by endogenous oligodendrocytes 
expressing  wide  variety  of  typical  markers  (PLP,  green;  SMI-31  red)  (63X  magnification)  (ii).  
These  oligodendrocytes  arise  from  a  pool  of  oliogodendrocyte  precursor  cells,  which  are  still 
present in small numbers even in mature cultures (O4, red, 63X magnification) (iii).  Myelinated 
internodes formed within the system form heminodes and are also bridged by characteristic nodes 
of  Ranvier  (iv).    Within  these  myelinated  cultures  it  must  be  noted  that  there  is  a  substantial 
populations of astrocytes (GFAP, green, 10X magnification (v) and microglia (CD11b/c, red, 40X 
magnification) (vi).      
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4  Validation of myelinating cultures as a model to 
detect pathogenic autoantibody responses. 
4.1 Introduction 
In the previous chapter myelinating cultures were described as an in vitro model 
with cellular and molecular composition of the CNS in vivo which reproduces the 
structural organisation of myelin internodes and nodes of Ranvier.  The purpose 
of this chapter is to build on this and to describe the experiments undertaken to 
demonstrate that this model can be adapted to reproduce antibody mediated 
CNS  injury.    From  the  previous  chapter  and  what  is  known  about  antibody 
mediated effects in animal models of MS we can compile a list of candidate 
autoantigens to investigate in order to validate our model as a tool to screen 
patients for the presence of axopathic and/or demyelinating antibody responses 
[Table 4.1].   
Table 4.1: Summary of candidate MS autoantigens and their localisation in vitro 
Summary of key autoantigens implicated in MS autoantibody responses.  Localisation of these 
antibodies  within  myelinating  cultures  was  determined  using  well  characterised  monoclonal 
antibodies.  Antibody binding to myelinating cultures was determined either live (without fixation or 
permeablisation) (L) or post fixation with 4% PFA and permeablisation with 0.5% Triton X-100 (P) 
[+: strong staining, ++: enhanced staining, --: no staining] 
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From what is already known about antibody mediated pathogenesis in MS and 
EAE we decided to investigate complement dependent antibody mediated injury 
(although complement independent effects will be discussed in a later chapter).  
This was for a number of reasons: 
1.  In  antibody  mediated  demyelinating  EAE  (ADEAE)  CNS  injury  is 
complement dependent.  In animals with ADEAE there is extensive deposition of 
C9 in white matter tracts (Linington et al., 1989).  However it has also been 
reported that antibody mediated injury in vivo is associated with an antibody 
dependent cellular cytotoxicity mechanism, where antibody binding makes the 
target  vulnerable  to  attack  from  other  immune  cells  such  as  macropahges 
(Brosnan et al., 1981).  Therefore we will focus on acute antibody mediated 
effects.   
2.  There is a correlation of deposition of complement activation products 
and  immunoglobulins  in  MS  lesions  (Lucchinetti  et  al.,  2000;  Prineas  et  al., 
1981).  
3.  In paediatric MS and ADEM there is strong evidence implicating a role of 
pathogenic  α-MOG  autoantibodies  in  disease  pathogenesis  (McLaughlin  et  al., 
2009, Di Pauli et al., 2010).   
4.  From  a  technical  standpoint  using  a  single  time  point  will  reduce  the 
amount of antibody required for screening and therefore will conserve patient 
samples.    
The aim of this chapter is to determine the validity of our in vitro system as a 
model  of  antibody  mediated  CNS  injury  and  therefore  must  fulfil  certain 
criterion: 
•  Antibody mediated injury in vitro must correspond to published data with 
respect to antigen specificity, accessibility and activity.   
•  Injury  must  reproducible  and  readily  detectable  at  low  antibody 
concentrations as reported in other autoantibody mediated diseases (Myathenia 
Gravis [α-AChR] is ~10-20nM) (Lindstrom et al., 1976).   84 
4.2 Results  
4.2.1 Antibody mediated injury in vitro is complement dependant 
and antigen specific  
To  determine  the  validity  of  our  in  vitro  myelinating  culture  model  as  a 
potential  screening  strategy  to  detect  pathogenic  autoantibody  responses  we 
performed  a  series  of  experiments  using  well  characterised  monoclonal  and 
polyclonal reagents directed against a multitude of CNS antigens some of which 
have been reported previously and implicated in the pathogenesis of EAE and MS 
[Table 4.2].  Throughout this initial study, myelinating cultures (28 DIV) were 
incubated overnight with 10µg/ml antibody in the presence of 1% fresh rat serum 
(FRS) as a source of complement.  Targets expressed at the outer lamellae of 
the myelin sheath such as myelin oligodendrocyte glycoprotein (Z2, 8-18C5) and 
sulphatide (O4) were readily accessible for antibody binding and complement 
deposition  resulting  in  a  complete  loss  of  PLP
+  myelin  sheathes.    In  contrast 
targeting a cytosolic myelin antigen such as myelin proteolipid protein (PLP) or 
myelin basic protein (MBP) resulted in no loss of myelin due to the inability of 
the antibody to bind to its target.   
Using live immunochemistry we can detect Nfasc155 staining on the surface of 
oligodendrocytes and their processes. Nfasc155 expressed at paranodal domains 
is  not  accessible  to  antibody  binding  without  permeablisation.    Targeting 
Nfasc155  with  a  Nfasc155  specific  anti-sera  mediates  complement  dependent 
loss of all PLP
+ myelin sheathes.  In the previous chapter we demonstrated that 
Nfasc186  is  expressed  by  the  axon  at  the  node  of  Ranvier  and  axon  initial 
segment.    Targeting  myelinating  cultures  with  a  Nfasc186  specific  anti-sera 
mediated  a  selective  loss  of  myelinated  axons  (~10%  of  total  axons)  and 
subsequent loss of myelin sheathes.  Live immunochemistry using A12/18.1 (pan-
Nfasc specific mAb) revealed in addition to the Nfasc155 and Nfasc186 staining 
observed with the specific anti-seras, staining on the cell body of a subset of 
neurons.    Treatment  of  myelinating  cultures  with  A12/18.1  resulted  in  a 
dramatic  loss  of  ~40%  of  all  axons  (both  myelinated  and  unmyelinated)  and 
complete demyelination.    85 
TAG-1/contactin-2  is  a  recently  identified  autoantigen  highlighted  for  its 
potential to cause T cell mediated cortical pathology in vivo.  In our system 
TAG-1  is  buried  deep  within  the  juxtaparanodal  region  and  is  completely 
inaccessible  to  antibody  binding  without  fixation  and  permeablisation.  
Therefore it was not surprising that incubation of myelinating cultures with two 
TAG-1  specific  monoclonal  Abs  (4D7,  3.1C6)  did  not  mediate  complement 
dependent injury to axons nor glia. The pathological effects of these antibodies 
in  vitro  were  complement-dependent  and  antigen-specific,  as  demonstrated 
using heat inactivated sera and appropriate isotype or species specific control 
antibodies. 
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Table 4.2: Using myelinating cultures as a model of autoantibody mediated injury 
Using our in vitro myelinating cultures we are able to detect selective antigen specific effects using 
a series of monoclonal reagents.  Myelinating cultures were treated overnight in each case with 
10µg/ml antibody in the presence of 1% fresh rat sera as a source of complement.    Targeting an 
extracellular myelin antigen, such a MOG or sulphatide in the presence of complement results in 
complete and selective demyelination.  In contrast targeting an cytosolic antigen such as PLP or 
MBP unable to mediate complement dependent demyelination in vitro.  Antibody mediated effects 
were  complement  dependent  and  antigen  specific.    Values  shown  are  an  average  of  three 
independent experiments performed in triplicate ± S.E.M.  P values obtained using the suitable 
statistical test were comparable between raw data or values standardised to the control (* p<0.05, 
**p<0.01 T-test).   
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70 ± 4.1
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Axon density
(% SMI-31+ / total field)
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4.2.2 MOG: the classic target for autoantibody mediated injury  
In EAE it has been demonstrated that MOG specific antibodies drive antibody 
mediated  demyelination  and  exacerbate  disease  (Linington  et  al.,  1988).    In 
paediatric  MS  and  ADEM  there  is  strong  evidence  suggesting  that  α-MOG 
autoantibodies have a key role in disease pathogenesis (McLaughlin et al., 2009, 
Di Pauli et al., 2011).  However in classical adult onset MS the issue remains 
controversial.     
The accessibility of MOG on the outer lamellae of the myelin sheath makes it an 
obvious candidate for antibody mediated injury.  To model anti-MOG mediated 
injury in vitro there are many MOG specific monoclonals available most of which 
recognise the extracellular Ig-like domain (Breithaupt et al., 2008).   For this 
thesis I used the monoclonal antibody Z2; a well defined anti-MOG monoclonal 
antibody  generated  by  Piddlesden  et  al,  (1993).      In  this  study  the  authors 
extensively characterised this antibody both in vitro and in vivo.  Z2 is mouse 
IgG2a and therefore is an excellent complement-fixing antibody.  This makes Z2 
an ideally candidate mAb to use in this initial proof of principle study [Figure 
4.1].   
Overnight treatment with 10µg/ml Z2 in the presence 1% FRS  as a source of 
complement results in a selective and complete loss of PLP
+ myelin sheathes and 
total loss of MOG immunoreactivity.  Injury is restricted to the oligodendrocyte 
and myelin sheathes as there is no detectable effect on axonal survival [Figure 
4.1A].    Antibody  treatment  in  the  absence  of  1%  rat  serum  as  a  source  of 
complement  mediated  no  detectable  injury  when  compared  to  untreated 
controls  and  at  higher  magnification  individual  oligodendrocytes  can  be  seen 
extending several processes and maintaining multiple myelin internodes [Figure 
4.1B].  This  antibody  mediated  demyelination  was  a  complement  dependent 
phenomenon  as  no  pathogenic activity  was  detected in cultures  treated  with 
either antibody alone, 1% FRS alone or after heat inactivation (56°C for 30 min) 
of the complement source.  [Figure 4.1C].   
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Figure 4.1: MOG: The classic target for autoantibody mediated injury 
A: Overnight antibody treatment the presence of fresh rat sera as a source of complement (1%) 
induced complete demyelination and loss of oligodendrocytes but leaving an intact bed of axons (i).  
High magnification images (100x) show the lysis of oligodendrocytes after treatment with an MOG 
specific monoclonal antibody in the presence of complement (PLP: green, DAPI: blue) (ii).  B: In 
contrast, treatment of myelinating cultures with 10µg/ml Z2 (MOG-specific monoclonal antibody) in 
the  absence  of  1%  FRS  does  not  induce  axonal  injury  as  visualised  by  intact  SMI-31 
(phosphorylated neurofilament) staining (red) or demyelination visualised with PLP (green) (10x 
magnification) (i).  High magnification (63X) images show oligodendrocytes are unaffected after 
overnight treatment with Z2 in the absence of a source of complement (ii).   C: Pathology observed 
was  both  antibody  mediated  and  complement  dependant  further  confirmed  by  various  control 
conditions such as heat inactivation of complement and addition of normal rat sera in the absence 
of  antibody.    Values  shown  are  an  average  of  three  independent  experiments  performed  in 
triplicate ± S.E.M    (* p<0.05, **p<0.01; T-test).   
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4.2.2.1  Time course of complement dependent demyelination mediated by 
MOG specific antibodies 
To visualise MAC pore formation it was not possible to use Z2 (both Z2 and α-
MAC  antibody  are  mIgG2a).    Therefore  for  this  experiment  I  used  8-18C5, 
another α-MOG monoclonal that is of the IgG1 isotype (Linington et al., 1988).  
Most  importantly  8-18C5  is  capable  of  fixing  complement  and  mediating 
demyelination in our myelinating culture system (described above). 
Two hours after addition of 10µg/ml 8-18C5 and 1% FRS, MAC pore formation can 
be seen on the surface of PLP
+ oligodendrocytes and myelin sheathes [Figure 
4.2A].  At this time point oligodendrocytes and myelin sheathes remain intact.  
However  MAC  pore  formation  on  the  oligodendrocyte/myelin  surface  is 
accompanied by a disruption in MOG distribution on the outer surface of the 
myelin sheath which can be detected as early as 2 hours after antibody addition 
[Figure 4.2B]. 
To plot the time course of α-MOG antibody mediated injury myelinating cultures 
were treated with 10µg/ml Z2 with 1% FRS.  Cultures were fixed at key intervals 
and stained for PLP, SMI-31 and MOG.   
Analysis of PLP staining demonstrates that despite injury to the outer surface, 
the myelin sheath remains stable and attached to the axon until 3.5 hours after 
addition.    The  first  signs  of  PLP  loss  are  detected  after  3  hours  and 
demyelination  is  complete  within  4  hours.    Demyelination  does  not  have  a 
detrimental  effect  on  axonal  survival  as  detectable  by  measuring  SMI-31 
immunoreactivity  [Figure  4.3A].    Complete  destruction  of  compact  myelin  is 
preceded by injury to the outer surface of the myelin sheath.  To monitor the 
fate of bound antibody at the myelin surface; cultures were washed, fixed (4% 
PFA)  and  incubated  with  the  appropriate  fluorochrome  conjugated  secondary 
antibody.  Within 30 minutes of addition we can detect Z2 bound to the surface 
of intact myelin sheathes and oligodendrocytes.  Within one hour of addition we 
can detect a loss of Z2 immunochemistry (~10%) and as injury progresses the 
amount of detectable Z2 immunoreactivity sharply declines.  After 3 hours Z2 
binding can be no longer detected on oligodendrocytes, myelin or myelin debris.  
This  loss  of  Z2  bound  at  the  myelin  surface  precedes  a  loss  of  MOG
+  myelin 90 
sheathes detected using 8-18C5.  Loss of all MOG reactivity (8-18C5 and Z2) was 
observed after 4 hours [Figure 4.3B].  In this series of experiments a rabbit pAb 
against neurofilament was used to label axons as 8-18C5 and SMI-31 are both 
mIgG1.   
 
 
 
 
 
 
 
 
 
 
Figure 4.2: MOG specific antibody mediated complement dependent myelin injury occurs 
within to hours via MAC deposition on the surface of oligodendrocytes and myelin 
A: Myelinating cultures were treated with 10µg/ml 8-18C5 in the presence of complement.  Two 
hours after antibody addition MAC (poly-C9) (green) (i) can be detected on the surface of PLP
+ 
oligodendrocytes and myelin (red) (ii-iii).  B: Treatment of myelinating cultures with 10µg/ml 8-
18C5 in the absence of complement does not induce demyelination.  Three hours after antibody 
addition; high magnification images (63X) of myelin show intact sheathes expressing both cytosolic 
PLP (red) (i) and MOG (Z2) on the outer myelin lamellae (green) (ii) (iii; merged image).    In 
contrast three hours after treatment with 10µg/ml 8-18C5 with 1% FRS as a source of complement 
shows that although the myelin appears intact with respect to PLP staining (red) (iv) there is major 
disruption of MOG localisation at the myelin surface (green) and the oligodendrocyte cell body (v) 
(vi; merged image).      
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Figure 4.3: Time course of anti-MOG antibody mediated complement dependent injury.  
A:  Demyelination occurs rapidly after antibody addition.  Analysis of PLP staining reveals that 
myelin sheathes remain relatively stable and attached to the axon until after ~4 hours in vitro after 
which the myelin is completely degraded (line).  Demyelination does not have a detrimental effect 
on axonal survival as detected by SMI-31 immunoreactivity (bars).   B: Complete destruction of 
PLP
+  myelin  sheathes  is  preceded  by  a  disruption  of  MOG  staining  at  the  myelin  surface.  
Significant  loss  of  MOG
+  immunoreactivity  can  be  detected  as  early  as  2  hours  after  antibody 
addition  as  detected  by  using  8-18C5  mAb.    Loss  of  bound  Z2  from  the  myelin  surface  is 
detectable  after  one  hour  after  antibody  addition.      Values  shown  are  an  average  of  three 
independent experiments performed in triplicate ± S.E.M.   
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4.2.2.2  Fate of myelin debris 
After complement mediated demyelination by the α-MOG response, PLP
+ myelin 
debris was found to be internalised by CD11b/c expressing microglia 4.5 hours 
after addition.  This was not seen in untreated cultures or in cultures treated 
with and isotype control antibody [Figure 4.4].   
There  reports  suggesting  that  antibody  mediated  injury  may  occur  by  ADCC, 
where  antibody  binding  to  the  target  leads  to  destruction  by  immune  cells.  
However  at  no  point  during  antibody  treatment  and  subsequent  injury;  were 
microglia  observed  making  direct  contact  with  the  damaged  myelin  sheath.  
Suggesting that microglia do not have an active role in driving demyelination in 
vitro  but  rather  serve  to  clear  myelin  debris  and  phagocytose  opsonised 
material. 
 
 
 
 
 
Figure 4.4: Uptake of myelin debris by microglia 
After α-MOG mediated demyelination myelin debris is internalised by resident microglial population 
(A).  This was not observed in non-demyelinated cultures (B) (PLP; green, CD11b/c; red, DAPI; 
blue) (63X magnification).   
 
 
 
 
 
PLP, CD11b/c, DAPI (nuclei) PLP, CD11b/c, DAPI (nuclei)93 
4.2.2.3  Summary  of  MOG  specific  antibody  mediated  complement 
dependent myelin injury   
In summary α-MOG mediated complement dependent injury occurs rapidly; the 
first signs of complement of activation and myelin disruption are detectable one 
hour after addition.  Substantial MAC deposition on the myelin surface can be 
detected  at  approximately  two  hours  after  antibody  addition,  leading  to  a 
reduction in MOG
 expression at the
 myelin surface.  Despite damage to outer 
lamellae  the  myelin sheathes  (PLP
+)  remain  stable  until  3.5  hours  where  the 
myelin rapidly degrades and demyelination is complete within 4 hours.  Residual 
PLP reactivity is associated with myelin debris, which is internalised by microglia 
[Figure 4.5].     
 
 
 
 
 
 
  
 
Figure 4.5: Summary of the time course of anti-MOG antibody mediated injury.   
MAC formation can be detected one hour after antibody addition reaching a peak at approximately 
2 hours after addition.  At this point there is a significant loss of MOG immunoreactivity (IR) at the 
surface of the myelin sheath.  Destruction of compact myelin occurs much later (3 hours after 
addition).    From  three  hours  after  addition  internalised  PLP
+  myelin  debris  can  be  detected  in 
microglia.   
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4.2.2.4  Complement  mediated  demyelination  by  a  MOG  specific  antibody 
has a limited effect on oligodendrocyte progenitor cells 
To  investigate  the  long  term  consequences  of  Z2  mediated  demyelination  I 
determined  changes  in  OPC  populations  post  treatment.    Immediately  after 
demyelination cultures were stained for NG2,
 a marker for OPCs and O4
 for late 
OPC pre-oligodendrocytes.  In cultures treated with an isotype control there is a 
population of NG2
 expressing cells and a mixed population of O4
+ cells including 
OPCs, pre-oligodendrocytes and mature oligodendrocytes with their associated 
myelin  sheathes  [Figure  4.6A].    After  Z2  mediated  demyelination  there  is  a 
complete  loss  of  O4
+  myelin  sheathes  accompanied  by  a  loss  of  mature 
oligodendrocytes  expressing  both  sulphatide  and  MOG  [Figure  4.6B].  
Quantification of cell numbers revealed the number of NG2
+ OPCs is unchanged 
after  demyelination;  there  is  a  small  reduction  of  O4
+  cells  which  can  be 
attributed to the loss of O4
+/MOG
+ mature oligodendrocytes [Figure 4.6C].   
To  determine  whether  these  remaining  OPCs  still  retained  their  ability  to 
differentiate  and  myelinate;  cultures  were  demyelinated  using  Z2  in  the 
presence of complement and after demyelination cells were washed extensively 
and placed back into culture with fresh media.  After 5 days in culture there was 
a  considerable  amount  of  myelin  formed  in  the  non-demyelinated  cultures 
[Figure 4.6D].  In demyelinated cultures there is a partial reconstitution of the 
mature PLP
+ oligodendrocyte pool and some myelination has taken place [Figure 
4.6E].  Analysis of immunocytochemical data reveals that after 5 days in culture 
the level of myelination is almost the level it was before demyelination [Figure 
4.6F].  This demonstrates that OPCs are spared after demyelination retain their 
functionality.  It also supports the previous observation that demyelination has 
no effect on axonal integrity as many axons remain permissible to myelination.    
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Figure 4.6:  Complement mediated demyelination by anti-MOG antibody has a limited effect 
on oligodendrocyte progenitors 
A:  At 28 DIV there is a residual population of NG2
+ and O4
+ OPCs.  It must be noted that mature 
oligodendrocytes and myelin are also labelled by the O4 antibody (20X magnification).  B:  At 28 
DIV cultures are  demyelinated  using  10µg/ml Z2 in  the presence of complement resulting in a 
complete loss of O4
+ myelin sheathes and a loss of mature oligodendrocytes expressing both MOG 
and  sulphatide  (NG2;  green,  O4;  red)  (20X  magnification).    C:  Comparison  of  cultures 
demyelinated using Z2 and those treated with an isotype control reveal that the numbers of NG2
+ 
OPCs are unchanged in response to demyelination there is a modest reduction in the number of 
O4
+ cells.  Values shown are an average of three independent experiments performed in triplicate ± 
S.E.M.  D:  At 30 DIV there was considerable myelin formed in the non-demyelinated cultures 
(SMI-31;  red,  MOG  green)  (10X magnification).    E:  Five  days  after  demyelination  there  was  a 
reconstitution  the  mature  oligodendrocyte  population  with  a  modest  amount  of  axonal 
ensheathment (SMI-31; red, MOG green) (10X magnification).  F:  Analysis of myelination after 
antibody treatment demonstrates that OPCs remain functional and capable of differentiating into a 
myelinating phenotype.  This also implies that there are no major axonal changes in response to 
demyelination as the remaining axons remain permissible to myelination.  Values shown are an 
average of three independent experiments performed in triplicate ± S.E.M.   
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4.2.2.5  Myelinating cultures provide a highly sensitive screening strategy in 
which to detect pathogenic MOG specific antibody responses   
In order to test the sensitivity of our system to detect pathogenic activity at low 
antibody concentrations a dose response study was performed.  Z2 was diluted 
across a concentration range from 10µg/ml to 10ng/ml.   
To determine the binding affinity of Z2 to myelinating cultures at sub-optimum 
concentrations used for immunochemistry a titration curve was plotted. Cultures 
were stained with 10µg/ml, 1µg/ml, 100ng/ml, 50ng/ml or 10ng/ml.  Cultures 
were imaged using immunofluorescence microscopy (10X magnification); images 
were  capture  using  the  same  exposure  thresholds  and  imaging  parameters 
defined using 10µg/ml cultures.  Analysis was performed using image J software 
using the same settings for each concentration (again thresholds were set using 
highest concentration).  At 10µg/ml approximately 45% of the total pixel number 
is Z2
+; as the concentration is lowered the number of Z2
+ pixels detected per 
field of view drops rapidly.  At concentration ranges below 100ng/ml it was not 
possible to visualise significant Z2 binding via immunocytochemistry [Figure 4.7].   
 
 
 
 
 
Figure  4.7:    Detection  of  Z2  binding  in  vitro  by  immunofluorescence  is  concentration 
dependent. 
A:    Staining  of  myelinating  cultures  (28  DIV)  with  10µg/ml  Z2  gives  a  strong  staining  of 
oligodendrocytes and myelin sheathes (i).  In contrast immunochemistry using 1µg/ml Z2 gives a 
much weaker staining (ii).  Black and white images were created using imageJ under the same 
exposure parameters and can be used to quantify the number of Z2
+ pixels per field of view (10X 
magnification).  B: Titration of Z2 over a concentration range 10µg/ml to 10ng/ml demonstrates that 
at  antibody  concentrations  below  100ng/ml  it  was  not  possible  to  detect  Z2  binding  by 
immunofluorescence microscopy.  Values shown are an average of three independent experiments 
performed in triplicate ± S.E.M.   
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Fortunately  our  model  is  far  more  sensitive  as  it  was  possible  to  detect 
significant  demyelinating  activity  at  antibody  concentrations  below  the 
detection threshold for immunofluorescence.  Significant demyelinating activity 
can be detected at antibody concentrations ≥50ng/ml [Figure 4.8].   
This  gives  our  system  a  great  advantage  over  other  cell  based  assay  system 
which relies solely on immunofluorescence as their mode of detection (either by 
FACS  or  microscopy).    In  this  paradigm  addition  of  50ng/ml  Z2  would  give  a 
“negative”  result however  using  our  system  we  can  still  detect  a  pathogenic 
antibody response.   
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Myelinating cultures provide a highly sensitive screening strategy in which to 
detect pathogenic α-MOG antibody responses   
A:  Treatment of myelinating cultures with 100ng/ml Z2 in the presence of complement mediates 
complete demyelination similar as that observed with treatment with antibody concentrations 100 
fold higher (SMI-31: red, PLP: green) (i).  In contrast treatment of myelinating cultures with 50ng/ml 
Z2 in the presence of complement mediates significant demyelination with a loss of ~50% total 
myelin  sheathes  (SMI-31:  red,  PLP:  green)  (ii).    Lowering  antibody  concentration  to  10ng/ml 
abolishes all demyelinating activity when compared to controls (SMI-31: red, PLP: green) (iii).  B: 
Dose  response  studies  show  that  α-MOG  mediated  demyelination  is  detectable  to  antibody 
concentrations  >50ng/ml.    Values  shown  are  an  average  of  three  independent  experiments 
performed in triplicate ± S.E.M.  C:  Axonal density was unaltered and equivalent across treatments 
when  compared  to  controls.    Values  shown  are  an  average  of  three  independent  experiments 
performed in triplicate ± S.E.M.   
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In  samples  of  unknown  antigen  specificity  one  way  to  determine  antibody 
binding  sites  at  low  antibody  concentrations  would  be  to  visualise  MAC 
deposition on the target.  To investigate this we treated myelinating cultures 
with  100ng/ml  8-18C5  and  stained  for  MAC  formation  2  hours  after  antibody 
addition.    At  this  low  concentration  we  can  only  detect  a  small  amount  of 
antibody  binding  by  immunochemistry  but  treatment  ultimately  results  in 
complete demyelination [Figure 4.9].  Unfortunately at this low concentration 
we  were  unable  to  detect  MAC  formation  as  seen  with  higher  antibody 
concentrations.    This  suggests  that  analysis  of  MAC  deposition  may  not  be  a 
useful  method  of  determining  sites  of  antibody  binding  in  samples  with  low 
antibody concentrations.   
 
 
 
Figure 4.9: Detection of MAC formation is dependent on antibody concentration  
In  contrast,  when  myelinating  cultures  were  treated  with  100ng/ml  8-18C5  in  the  presence  of 
complement, MAC (green) was not detected at the surface of oligodendrocytes or myelin (PLP; 
red) after 2 hours, although treatment ultimately leads to complete demyelination after 4 hours (63X 
magnification).   
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4.2.3 Nfasc: One molecule; two distinct pathologies? 
4.2.3.1  Nfasc  specific  antibodies  can  mediate  complement  dependent 
demyelination and axonal injury  
Recently a number of axoglial proteins have been implicated as potential MS 
autoantigens,  one  of  which  is  Nfasc  (Mathey  et  al,  2007).    In  this  study  the 
authors used the monoclonal antibody A12/18.1, which has a high affinity for the 
extracellular  domain  of  Nfasc186  and  Nfasc155,  the  target  moiety  is  shared 
between the isoforms however the exact epitope is unknown.  The authors also 
demonstrated the ability of this mAb to fix complement making it an excellent 
model Nfasc specific antibody to use in this proof of concept experiment.  To 
draw parallels between the MOG specific and Nfasc specific antibody responses 
we  characterised  the  α-Nfasc  response  using  a  similar  approach  as  described 
above for α-MOG responses.   
Overnight  treatment  of  myelinating  cultures  with  A12/18.1  in  the  presence 
complement  mediates  complete  demyelination  and  loss  of  mature  MOG
+ 
oligodendrocytes.  Antibody treatment also mediates a loss of both myelinated 
and  demyelinated  axons  (~40%  loss  of  total  axons)  accompanied  by  a  loss  of 
PGP9.5
+  neurons  [Figure  4.10A].    Antibody  mediated  CNS  injury  was  a 
complement dependent phenomenon as no pathogenic activity was detected in 
cultures  treated  with  either  antibody  alone  or  after  heat  inactivation  of  the 
complement source.  Demyelination was also antigen specific as the use of an 
isotype control antibody or 1% FRS in the absence of antibody was insufficient to 
induce injury [Figure 4.10B].   
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Figure  4.10:  Nfasc;  an  axo-glial  antigen  providing  a  potential  link  between  antibody 
mediated demyelination and axonal injury 
A: Myelinating cultures 28 days in vitro consist of a dense network of axons, some of which are 
myelinated  by  oligodendrocytes  (i).      Overnight  treatment  of  myelinating  cultures  with  10µg/ml 
A12/18.1 a pan-Nfasc specific monoclonal in the presence of 1% FRS as a source of complement 
induces  complete  demyelination  accompanied  by  a  significant  loss  of  both  myelinated  and 
unmyelinated axons (SMI-31; red, MOG; green) (ii).  Myelinating cultures 28 days in vitro have an 
abundant neuronal populations (PGP9.5; red), which extend axons (SMI-31; blue) (iii).  Axonal loss 
induced by A12/18.1 treatment is accompanied by a loss of neurons (PGP9.5; red, SMI-31; blue) 
(iv).    B:  Pathology  observed  was  both  antibody  mediated  and  complement  dependant  further 
confirmed by various control conditions such as heat inactivation of complement and addition of 
normal rat sera in the absence of antibody.  Values shown are an average of three independent 
experiments performed in triplicate ± S.E.M    (* p<0.05, **p<0.01; T-test).   
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4.2.3.2  Time course of A12/18.1 mediated complement dependent injury 
Similar to that  described above  for  the  MOG  specific  response;  to determine 
whether demyelination mediated by α-Nfasc antibody was due to acute injury 
caused  by  the  activation  of  the  complement  cascade  it  was  important  to 
determine the time scale in which antibody mediated complement dependent 
injury occurs.  To this end myelinating cultures were treated with 10µg/ml of 
A12/18.1 in the presence of 1% FRS as a source of complement.  Cultures were 
analysed at 30 minute intervals until 4 hours after antibody addition.   
Using A12/18.1, a pan specific monoclonal antibody recognising both Nfasc155 
and  Nfasc186,  induces  a  loss  of  both  myelinated  and  unmyelinated  axons 
accompanied with complete demyelination in a complement dependant manner.  
Demyelination precedes the axonal loss as there is a significant loss of myelin 
(~50%) at 3.5 hours after addition [Figure 4.11A] prior to a detectable significant 
reduction in axonal density [Figure 4.11B].  However after 4 hours both axonal 
injury and demyelination is complete.   
 
 
   
 
 
 
Figure 4.11: Time course of α-Nfasc mediated injury   
A:    Treatment  of  in  vitro  myelinating  cultures  with  10µg/ml  A12/18.1  (a  pan  Nfasc  specific 
monoclonal antibody) in the presence of 1% fresh rat sera induced complete loss of PLP
+ myelin 
sheathes within 4 hours of antibody addition.  Values plotted are an average of three independent 
experiments performed in triplicate ± S.E.M.  B:  Demyelination was accompanied by a significant 
axonal loss as detected by a loss on SMI-31
+ immunoreactivity.  This injury occurs in a similar time 
course  as  demyelination  as  significant  decreases  in  both  axonal  density  and  myelination  are 
detectable after 3.5hrs and are complete after 4 hours.  Values shown are an average of three 
independent experiments performed in triplicate ± S.E.M.   
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4.2.3.3   Targeting Nfasc reveals isoform specific effects on axons and glia 
As treatment of myelinating cultures with an antibody recognising both Nfasc 
isoforms is capable of mediating a dual pathology effecting neurons/ axons and 
oligodendrocytes  we  can  postulate  that  antibodies  recognising  Nfasc  may  be 
capable  of  mediating  two  distinct  pathologies  based  on  which  isoform  is 
targeted.    In  order  to  dissect  the  pathology  seen  using  the  pan  specific 
monoclonal  into  is  axonal/  neuronal  and  glial  components  we  used  two 
polyclonal antibodies one specific for the extracellular domain of Nfasc155 and 
the other specific for Nfasc186.   
 
In our system Nfasc155 is expressed exclusively by the oligodendrocyte processes 
and at the paranodal domain.  Treatment of myelinating cultures overnight with 
a  Nfasc155  specific  polyclonal  antibody  in  the  presence  of complement  were 
completely demyelinated with a significant reduction in the number of mature 
OLG
+  oligodendrocytes.    Demyelination  had  no  detrimental  effect  on  axonal 
integrity.  Nfasc186 immunochemistry is unchanged after demyelination with a 
Nfasc155 specific reagent when compared to controls [Figure 4.12A].  
 
Using a Nfasc186 specific polyclonal antibody expression within our system can 
be detected on the axon at the axon initial segment (AIS) and at the Node of 
Ranvier.    Targeting  myelinating  cultures  with  a  Nfasc186  specific  polyclonal 
antibody in the presence of complement mediates loss of only myelinated axons 
(~15%) with subsequent loss of myelin.  Antibody treatment has a minor effect 
on  the  number  of  mature  MOG
+  oligodendrocytes  (~10%)  but  this  was  just 
statistically significant (p=0.48, T-Test).  Neuronal Nfasc immunochemistry was 
present on the majority of neurons after axonal loss and subsequent myelin loss 
using a Nfasc186 specific reagent [Figure 4.12B].   
 
In contrast immunocytochemistry using A12/18.1 also reveals that in addition to 
the staining at the node and the AIS, Nfasc 186 staining on the neuronal soma. 
Treatment with A12/18.1 mediates major injury and subsequent loss of neurons, 
axons and oligodendrocytes. This injury is associated with a total loss of Nfasc 
immunoreactivity [Figure 4.12C].   
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Figure 4.12: Targeting Nfasc reveals isoform specific effects on axons and glia.   
A:  Targeting myelinating cultures with a polyclonal antibody specific for Nfasc155; the glial isoform 
expressed  at  the  oligodendrocyte  cell  surface  and  at  the  paranode.    Treatment  overnight  of 
myelinating  cultures  (28  DIV)  with  10µg/ml  Nfasc155  specific  antibody  induces  selective 
demyelination and loss of oligodendrocytes with no loss of axons (SMI-31; red, MOG; green) (10X 
magnification) (i).  Nfasc186 reactivity is retained after α-Nfasc155 meditated demyelination (Nfasc; 
green, PLP; red; SMI-31; blue) (10X magnification) (ii).  B:  In contrast treatment using 10µg/ml 
Nfasc186  specific  antibody  mediated  complement  dependant  loss  of  myelinated  axons  and 
subsequent  myelin  loss  accompanied  by  a  small  decrease  in  the  number  of  mature  MOG
+ 
oligodendrocytes    (SMI-31;  red,  MOG;  green)  (10X  magnification)  (i).    Nfasc  reactivity  on  the 
neuron is retained after treatment with Nfasc186 specific antibody (Nfasc; green, PLP; red; SMI-31; 
blue) (10X magnification) (ii).  C: Targeting both Nfasc155 and Nfasc186 simultaneously induces 
complete demyelination accompanied by a significant loss of both myelinated and unmyelinated 
axons (SMI-31; red, MOG; green) (10X magnification) (i).  This major loss of both axons and glia is 
associated  with  a  complete  loss  of  Nfasc  (Nfasc155  and  Nfasc186)  immunoreactivity  (Nfasc; 
green,  PLP; red;  SMI-31;  blue) (10X magnification)  (ii).  D:  Analysis of immunochemical data 
confirmed initial observations.  Values are plotted as a percentage of equivalent control cultures.  
Antibody  mediated  effects  were  complement  dependent  phenomenon  as  the  use  of  heat 
inactivated complement completely abolishes activity.     Values shown are an average of three 
independent experiments performed in triplicate ± S.E.M (* p<0.05, **p<0.01; T-test).   
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4.2.3.4  CNS injury by anti-Nfasc155 and anti-Nfasc186 antibodies is initiated 
by MAC deposition at the site of antibody binding 
To determine where MAC is deposited after treatment with either a Nfasc155 or 
a Nfasc186 specific reagent cells were fixed and stained for MAC two hours after 
addition  of  10  µg/ml  α-Nfasc155  or  α-Nfasc186  with  1%  FRS  as  a  source  of 
complement.   
Two hours after addition of α-Nfasc155 and 1% FRS, MAC formation was visible 
on the surface of PLP
+ oligodendrocytes and myelin sheathes [Figure 4.13A].  In 
cultures treated with Nfasc186 after two hours I could detect MAC deposition at 
the node of Ranvier [Figure 4.13B].  Unfortunately the isotype of the antibody 
used to visualise MAC (mouse IgG2a) is the same as A12/18.1 so could not be 
used  in  these  experiments.    As  the  Nfasc186  polyclonal  was  a  gift  (Prof  P. 
Brophy,  University  of  Edinburgh)  I  had  only  a  small  quantity  and  this 
unfortunately limited the number experiments I could perform. 
 
 
 
 
 
 
 
Figure 4.13: α-Nfasc 155/α-Nfasc186 antibody mediated complement dependent CNS injury 
occurs via MAC deposition on the surface of oligodendrocytes/and at the node of Ranvier 
respectively.   
A: Myelinating cultures were treated with 10µg/ml Nfasc155 in the presence of complement.  Two 
hours after antibody addition MAC (poly-C9) (green) (i) can be detected on the surface of PLP
+ 
oligodendrocytes  and  myelin  (red)  (ii-iii).    B:  Myelinating  cultures  were  treated  with  10µg/ml 
Nfasc186  in  the  presence  of  complement.    Two  hours  after  antibody  addition  MAC  (poly-C9) 
(green) (i) can be detected between PLP
+ myelin internodes (red) at the node of Ranvier (ii-iii) (63X 
magnification).   
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4.2.3.5  Time course of anti-Nfasc mediated complement dependent injury 
Similar to that described above for the α-MOG response; to determine whether 
demyelination mediated by α-Nfasc antibody was due to acute injury caused by 
the activation of the complement cascade it was important to determine the 
time scale in which antibody mediated complement dependent injury occurs.  To 
this  end  myelinating  cultures  were  treated  with  10µg/ml  of  α-Nfasc155 
polyclonal  antibody  in  the  presence  of  1%  FRS  as  a  source  of  complement.  
Cultures  were  analysed  at  30  minute  intervals  until  4  hours  after  antibody 
addition.   
Nfasc155  mediated  injury  occurs  rapidly  with  loss  of  PLP
+  myelin  sheathes 
initially detectable after 3.5 hours [Figure 4.14A].  Demyelination is complete 
within 4 hours after antibody addition.  Nfasc155 mediated demyelination is has 
no pathogenic effect on axonal survival [Figure 4.14B].   
 
 
 
 
 
 
   
Figure 4.14: Time course of α-Nfasc 155 mediated demyelination  
A:    Targeting  myelinating  cultures  with  10µg/ml  of  an  α-Nfasc155  polyclonal  antibody  induces 
complement mediated demyelination.  Loss of PLP
+ myelin sheathes is initially detectable 3.5 hours 
after  antibody  addition  and  demyelination  is  complete  within  4  hours.    Values  plotted  are  an 
average of three independent experiments performed in triplicate ± S.E.M.  B:  Nfasc155 mediated 
demyelination has no effect on axon integrity as detectable by changes SMI-31 immunoreactivity.  
Axonal density remains consistent throughout the treatment period.  Values plotted are an average 
of three independent experiments performed in triplicate ± S.E.M.  
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4.2.3.6  Nfasc specific antibody responses are detectable at ng/ml antibody 
concentrations  
To  determine  whether  our  myelination  culture  system  would  be  a  feasible 
screening strategy for detecting pathogenic antibody responses we set up a dose 
response to determine the sensitivity of the system.  Nfasc specific antibodies 
were  diluted  in  series  from  10µg/ml  to  10ng/ml  and  added  to  myelinating 
cultures in the presence of complement.   
Using  an  α-Nfasc155  specific  polyclonal  antibody  we  can  detect  pathogenic 
antibody responses at antibody concentrations ≥100ng/ml.  A small amount of 
demyelination can be detected in cultures treated with 50ng/ml however this 
was just statistically significant (p=0.48, T-test) [Figure 4.15A].  Axonal density 
as measured by SMI-31 immunoreactivity was unaltered and equivalent across 
treatments when compared to controls [Figure 4.15B].  
Using  A12/18.1,  a  pan-specific  monoclonal,  we  can  detect  demyelinating 
antibody responses down to antibody concentrations ≥50ng/ml [Figure 4.15C].  
However  the  axo-pathic  component  could  only  be  detected  at  antibody 
concentrations ≥100ng/ml [Figure 4.15D].    
These  results  are  similar  as  that  described  for  the  α-MOG  response  i.e.  at 
concentration  ranges  below  1µg/ml  it  is  not  possible  to  visualise  antibody 
binding via immunocytochemistry however pathogenic activity can be detected 
at much lower antibody concentrations.   
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Figure 4.15:  Myelinating cultures provide a highly sensitive screening strategy in which to 
detect pathogenic α-Nfasc antibody responses   
A: Dose response studies show that α-Nfasc155 mediated demyelination is detectable to antibody 
concentrations  >50ng/ml.    Complete  demyelination  was  observed  at  antibody  concentrations 
>100ng/ml.  Values shown are an average of three independent experiments performed in triplicate 
± S.E.M.  B:  Axonal density was unaltered and equivalent across treatments when compared to 
controls.  Values shown are an average of three independent experiments performed in triplicate ± 
S.E.M.  C:  Dose response studies show that A12/18.1 mediated demyelination is detectable to 
antibody  concentrations  >50ng/ml.  Values  shown  are  an  average  of  three  independent 
experiments  performed  in  triplicate  ±  S.E.M.    D:    A12/18.1  mediated  complement  dependent 
axonal injury is detectable at antibody concentrations >100ng/ml.  Axonal loss detected at cultures 
treated with 50ng/ml A12/18.1 and below were not statistically significant (p>0.05, T-test).  Values 
shown are an average of three independent experiments performed in triplicate ± S.E.M.   
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4.2.4 Complement  mediated  antibody  driven  CNS  injury  occurs 
by Fc activation of the classical pathway 
To determine whether antibody mediated complement dependent CNS injury is 
through  activation  of  the  classical  complement  cascade  via  the  Fc  region  I 
generated Fab fragments.  Fab fragments were produced by papain digestion of 
whole IgG (Z2 and A12/18.1) followed by protein A chromatography to separate 
Fabs from Fc domain.  Complete digestion and Fab purity was confirmed by SDS-
PAGE [Figure 4.16A].  Fabs purified from Z2 still retained there binding capacity 
as  detected  by  immunocytochemical  staining  on  both  myelin  and 
oligodendrocytes [Figure 4.16B].  Similarly Fab purified from A12/18.1 retained 
binding as seen with the whole antibody with binding at the node of Ranvier, 
neuronal soma and oligodendrocyte [Figure 4.16C].  No binding was detected in 
any of the purified Fc region preparations.   
When myelinating cultures are treated with 3.3µg/ml Z2 Fab fragments in the 
presence of complement no demyelination is detected.  Similarly treatment with 
purified Z2 Fc region had no effect on myelin or mature oligodendrocytes [Figure 
4.16D].            
In  the  case  of  A12/18.1,  which  can  mediate  complement  dependent  axonal 
injury  and  demyelination,  treatment  of  myelinating  cultures  with  3.3µg/ml 
A12/18.1 Fab does not induce axonal loss or demyelination.  Similarly treatment 
with purified A12/18.1 Fc domain mediated no detectable to axons, neurons or 
glia [Figure 4.16E]. 
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Figure 4.16: Complement mediated antibody driven CNS injury is Fc dependent 
A: SDS-PAGE analysis of IgG after papain digestion and protein A chromatography showing clear 
separation of Fab fragments from the Fc region.  Lanes: 1: Z2 protein A column eluate containing 
Fc regions and undigested IgG, 2: Z2 protein A flow through containing Fab fragments and Ig light 
chain, 3: A12/18.1 protein A column eluate containing Fc regions and undigested IgG, 4: A12/18.1 
protein A flow through containing Fab fragments and light chain.  B: Purified Z2 Fab fragments 
retain their binding activity.  Z2 Fab fragments bind to MOG on the surface of the myelin sheath 
and  to  oligodendrocytes  (inset)  (SMI-31;  red,  Z2  Fab;  green)  (10X  magnification).  C:    Purified 
A12/18.1 Fab fragments retain their binding activity.  A12/18.1 Fab fragments bind to myelinating 
cultures on neurons, oligodendrocyte and by the axon at the AIS and the node of Ranvier (SMI-31; 
blue, PLP; red, A12/18.1 Fab; green) (10X magnification).  D:  Overnight treatment of myelinating 
cultures  with 10µg/ml Z2 (whole IgG) in the presence of 1% FRS  as a source of complement 
mediates complete demyelination (black bar).  However addition of an equivalent concentration of 
either purified Z2 Fab fragments (grey bar) or Fc domain (white bar) in the presence of 1% FRS as 
a source of complement was insufficient to mediate demyelination.  Values shown are an average 
of  three  independent  experiments  performed  in  triplicate  ±  S.E.M.    E:    Overnight  treatment  of 
myelinating cultures with 10µg/ml A12/18.1 (whole IgG) in the presence of 1% FRS as a source of 
complement mediates complete demyelination and axonal injury (black bars).  However addition of 
an equivalent concentration of either purified Z2 Fab fragments (grey bars) or Fc domain white 
bars)  in  the  presence  of  1%  FRS  as  a  source  of  complement  was  insufficient  to  mediate 
demyelination or axonal injury.  Values shown are an average of three independent experiments 
performed in triplicate ± S.E.M.   
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4.2.5 Adsorption of IgG using purified compact myelin diminishes 
its pathogenic potential 
Using the myelinating culture model we have identified a number of pathogenic 
antibody responses that can induce complement mediated demyelination which 
in some cases may be accompanied by significant axonal injury.  To determine 
whether this effect is truly antigen specific I tried to remove the pathogenic 
antibody component using purified rat myelin.  Whilst one alternative to this 
approach would be to use recombinant antigens, in the case of Nfasc155 this 
would  be  extremely  expensive  and  Nfasc186  is  commercially  unavailable.    A 
recombinant antigen may lack the correct three dimensional structure or post-
translational modifications.   
Incubation with 1µg/ml IgG (A12/18.1, α-Nfasc155, Z2) with 2mg/ml total myelin 
protein  greatly  reduced  binding  to  rat  myelin  as  detectable  by  ELISA  when 
compared  to  antibody  binding  prior  to  adsorption  [Figure  4.17A].    This 
diminished  binding  was  accompanied  in  a  reduction  in  demyelinating  activity 
when 1µg/ml residual unadsorbed antibody was added to myelinating cultures in 
the presence of complement.  In the case of A12/18.1 where demyelination is 
accompanied  by  a  significant  axonal  loss,  this  axopathic  activity  was  also 
significantly reduced [Figure 4.17B].      
This  technique  is  extremely  useful  when  characterising  patient  samples  with 
unknown specificities.  Myelin adsorption may provide confirmation of antibody 
specificity especially in cases where antibody binding may not be visible using 
fluorescence microscopy.  Our model also allows us to determine the effect of 
myelin adsorption on the pathogenic activity and therefore we can determine 
whether antibodies generated against myelin are pathogenic.   
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Figure 4.17:  Adsorption of IgG using purified compact myelin diminishes its pathogenic 
potential 
A:  :    Adsorption  of  1µg/ml  IgG  (Z2,  α-Nfasc155,  A12/18.1)  with  2mg/ml  rat  myelin  resulted  in 
reduced binding to rat myelin as detected by ELISA.  Data plotted as mean OD (± S.E.M).  All 
reductions in IgG binding were statically significant (p<0.05, T-test).  B: Myelin adsorption of IgG 
resulted  in  a  marked  reduction  in  the  pathogenic  activity  when  compared  to  samples  prior  to 
adsorption.    Myelin  adsorption  lowered  the  amount  of  complement  dependent  demyelination 
detected in myelinating cultures in comparison to unabsorbed IgG.  In the one case of A12/18.1 
where axonal injury was also detected this was also significantly reduced after myelin adsorption.  
Values shown are an average of three independent experiments performed in triplicate ± S.E.M.   
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4.3 Discussion  
In this chapter it has been demonstrated that in vitro myelinating cultures can 
be used as a model of antibody mediated injury, which is: 
•  Antigen specific and dependent on antigen accessibility in vitro. 
•  Complement dependent through activation by Fc region and subsequent 
MAC deposition at sites of antibody binding. 
This model of antibody mediated injury is extremely effective.  The results seen 
are usually “all or nothing” i.e. antibody treatment mediates either complete 
demyelination or none.  This makes the data easy to interpret but provides no 
information on the variation or reproducibility of detecting antibody mediated 
injury using this model.  However using data obtained from the Z2 dose response 
curve, addition of 100ng/ml mediates an almost complete loss of myelin there is 
very little inter and intra variation (coefficient of variance= 6.6%).  In contrast 
using 50ng/ml Z2, which mediates ~50% demyelination the variability is much 
greater (32.2%).  Antibody mediated axonal injury is much less variable.  Using 
the  A12/18.1  dose  response  data,  where  antibody  treatment  mediates 
significant  axonal  injury  the  mean  coefficient  of  variance  from  three 
independent  experiments  is  much  lower  (5.1%  (100ng/ml);  3.1  %  (50ng/ml)) 
[Table 4.3].  From this we can conclude that antibody mediated injury in this 
system is fairly reproducible with respect to both inter and intra variability and 
therefore provides a relatively robust assay for antibody screening.   
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Table 4.3:  Variability of antibody mediated injury.   
Values were taken from a series of experiments performed three times.  Values shown are an 
average  from  three  coverslips  ±  standard  deviation.    Coefficient  of  variance  was  calculated  as 
standard deviation/ mean and expressed as a percentage.   
 
 
 
 
 
 
 
A major advantage of this system over other antibody detection strategies is that 
it is extremely sensitive and can detect pathogenic antibody activity at antibody 
concentration in the ng range.  Pathogenic activity can be detected using this 
system  at  antibody  levels  much  lower  than  the  detection  thresholds  of 
immunofluorescence.  For our model to be used as a valid screening strategy to 
detect pathogenic autoantibody responses in clinical samples it must be sensitive 
enough to detect low antibody titres.  In has been reported in the literature that 
patients with myasthenia gravis have α-AChR antibody titres ranging from 10-
20nM (Lindstrom et al., 1976).  In our model we can detect pathogenic antibody 
responses down to picomolar levels; this is extremely promising support for the 
viability of our model. 
Antibody mediated injury is highly specific and injury is confined to only cells 
expressing the antigen.  For example treatment using Z2 or α-Nfasc155 induces 
complement  mediated  demyelination  and  a  significant  loss  of  mature 
oligodendrocytes  with  a  notable  sparing  of  axons.    However  neurofilament 
staining is not the most sensitive technique to monitor subtle changes in axonal 
physiology.  Minor axonal changes in response to antibody treatment may also be 
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transient.  Further investigation is required to determine the effect of antibody 
mediated demyelination on the axon.     
It has been documented that rat serum can activate complement cascade and 
can  mediate  lysis  of  oligodendrocytes  in  culture  in  the  absence  of  antibody 
(Scolding  et  al.,  1989;  Wren  and  Noble,  1989).    Rat  oligodendrocytes  lack 
expression of CD59, a complement inhibitor that blocks MAC formation (Wing et 
al.,  1992;  Piddlesden  and  Morgan,  1993).    However  in  our  in  vitro  system 
addition of fresh rat serum in the absence of antibody has no pathogenic effect 
on oligodendrocytes or OPCs.  One explanation is that within the myelinating 
cultures  there  are  sufficient  levels  of  endogenous  complement  inhibitors 
preventing this autolytic effect.  Astrocytes and neurons are known sources of 
complement inhibitors (Rogers et al., 1996; Gasque et al., 2000) and are present 
in  myelinating  cultures  in  abundance.    Co-culturing  oligodendrocytes  in  close 
proximity to large numbers of neurons and astrocytes is sufficient to protect 
them from auto-lysis by complement.    
It has been reported that in the presence of complement activated microglia can 
mediate  oligodendrocyte  cell  death  and  uptake  of  debris,  which  is  antibody 
independent (Zajicek et al., 1992).  In cultures treated with either rat serum 
alone or in the presence of an isotype/CNS irrelevant antibody there was no 
detectable injury to oligodendrocytes.  This could be due to the activation state 
of microglia within the cultures.  The majority of microglia in untreated cultures 
are deemed “inactive” as they lack ED1/CD68 staining (Graeber et al., 1990).  
The  pathology  observed  using  our  model  is  antibody  driven  and  complement 
mediated phenomenon.  Therefore one can postulate that in the presence of low 
concentrations of fresh rat serum there is a must be a delicate balance between 
complement activation and inhibition and addition of a CNS specific antibody is 
sufficient to overcome this endogenous complement inhibition.  
Nfasc186 localisation within our myelinating cultures is also inconsistent with 
what  is  reported  in  vivo.    Using  A12/18.1,  a  pan-Nfasc  specific  monoclonal 
antibody, which binds to the extracellular domain of Nfasc155 and Nfasc186, 
reactivity  is  detected  on  the  axon  at  the  node  of  Ranvier  and  the  AIS.    In 
addition the antibody also labels Nfasc expressed on the surface of a subset of 115 
neurons  in  vitro.    This  neuronal  staining  was  not  detected  using  a  Nfasc186 
specific polyclonal antibody where Nfasc186 immunoreactivity was seen only at 
the AIS and the node of Ranvier.  Titration of these antibodies suggests that this 
neuronal Nfasc reactivity is not a staining artefact.    As myelinating cultures are 
a developmental system it is possible that this neuronal Nfasc expression is due 
to the recognition of an alternative Nfasc isoform which is not expressed in the 
adult CNS.  There are reports in the literature to support this and suggest that 
during development CNS neurons express an alternative intermediate isoform of 
Nfasc within the cell body prior to myelination (Burkarth et al., 2007).  This was 
identified as Nfasc166, a lower molecular weight isoform that lacks the fifth 
fibronectin-like region and precedes neuronal Nfasc186 expression (Pruss et al., 
2006).  Nfasc186 is not expressed by adult neurons apart from at the AIS and 
node of Ranvier however Nfasc186 is readily available for antibody binding at 
these sites (Mathey et al., 2007).   
There is also a discrepancy between Nfasc155 expression in vitro and reported 
expression in vivo.  Nfasc155 in our system is expressed on the surface of the 
oligodendrocyte at the cell body and along the cell process with staining at the 
paranodal  domain.    In  vivo  neurofascin  expression  by  oligodendrocytes  is 
transient  and  once  axonal  contact  is  made  gene  expression  falls  rapidly 
(Collinson et al., 1998).  Once myelination is complete expression Nfasc155 is 
sequestered to the paranodal loops (Tait et al., 2000; Charles et al., 2002) and is 
inaccessible  to  antibody  binding.    Lack  of  binding  of  our  Nfasc155  specific 
antibody to fully myelinated in vivo structures was demonstrated using the OSC 
system described in the previous chapter [Figure 4.18].  However that is not to 
say  that  Nfasc155  specific  antibody  responses  are  clinically  irrelevant  as 
Nfasc155 may be accessible in damaged myelin and therefore may exacerbate 
demyelination.  Nfasc155 may also become accessible to antibody binding during 
remyelination and therefore could disrupt lesion repair.   
Despite  these  caveats;  in  vitro  myelinating  cultures  provide  an  unbiased, 
extremely sensitive and statically reproducible model of antibody mediated CNS 
injury.  This model can be used as a tool to detect pathogenic autoantibody 
responses in patient samples of undefined specificity.  This will be demonstrated 
in the next chapter.   116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18: Nfasc155 is sequestered to the paranode in intact myelinated tracts in vivo and 
is inaccessible for antibody binding    
Nfasc155 (red) is not accessible to antibody binding in intact myelinated fibres in vivo (PLP; green, 
neurofilament; blue) (20X magnification).  OSCs were created and images taken whilst visiting the 
lab of Prof. N Goebels in collaboration with Dr. M Harrer (Zurich).   
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5  Identification of pathogenic antibody responses 
in Multiple Sclerosis  
5.1 Introduction 
Previously  we  demonstrated  that  the  myelinating  cultures  can  provide  an  in 
vitro system which reproduces the molecular and structural organisation of the 
CNS in vivo and have comprehensively demonstrated that this model provides a 
bioassay  which  can  be  used  to  quantify  complement  dependent  antibody 
mediated injury.  The previous chapters were necessary prerequisites building 
up to the main goal of this thesis, to determine whether or not MS is associated 
with a pathogenic autoantibody response.   
We are certainly not the first to attempt to address this question using a tissue 
culture based approach.  Studies describing the in vitro pathogenic properties of 
MS sera date back to the 1960s (Bornstein and Appel, 1965).  These early studies 
indicated  that  a  significant  number  of  MS  cases  were  associated  with  a 
serological factor capable of mediating demyelination in vitro (reviewed in Seil, 
1977  and  Caspary,  1977).    However  whether  this  factor  was  an  anti-myelin 
autoantibody  response  was  controversial.    The  use  of  in  vitro  myelinating 
cultures  to  model  demyelination  was  largely  abandoned  from  the  late-1980s.  
Our understanding of EAE pathogenesis lead to the long held assumption that MS 
was likely to be purely a T cell mediated disease, however the pathogenesis of 
MS  has  been  revealed  to be  far  more  complex.    Circumstantial  evidence has 
steadily accumulated implicating a role for autoantibodies.  Within the past 5 
years there have been reports supporting a strong association between α-MOG 
antibodies  and  paediatric  MS/ADEM  (McLaughlin  et  al.,  2009,  Di  Pauli  et  al., 
2010).  However despite immense effort, current opinion as to whether adult 
onset MS is associated pathogenic autoantibody responses remains divided.  This 
scepticism  mainly  stems  from  the  lack  of  formal  evidence  that  autoantibody 
associated with adult-onset MS actually pathogenic.   
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The main aim of this chapter is to address this question and use the myelinating 
cultures as a bioassay to:  
•  Determine whether the total IgG fraction purified from adult MS patient 
serum can mediate complement dependent demyelination and/or axonal injury 
in vitro.   
•  Investigate  the  potential  specificity  of  any  pathogenic  responses  with 
particular focus on Nfasc.    
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5.2 Results 
5.2.1 Detection of pathogenic antibody responses from patients 
with MS  
To determine whether the “in vitro demyelinating factor” previously reported in 
MS sera was due to an anti-myelin autoantibody response, total IgG was purified 
from MS patients (n=20), patients with other neurological diseases (OND; n=10) 
and healthy control donors (HC; n=13) by protein G chromatography.   
 
5.2.1.1  MS  patient  derived  IgG  mediates  complement  dependent 
demyelination and axonal injury 
Treating myelinating cultures with total IgG preparations from individual donors 
revealed a striking heterogeneity in their ability to mediate axonal loss and/or 
demyelination [Figure 5.1].   
 
At  100  µg/ml  IgG  preparations  from  50%  of  MS  cases  mediated  complete 
demyelination  reproducing  the  effects  observed  by  targeting  an 
oligodendrocyte/myelin specific antigen such as MOG or Nfasc155 [Figure 5.1A 
(ii)].  It must be noted that in two cases (MS5 and MS14) demyelination was also 
accompanied by varying degrees of axonal loss ranging from 22% to 34% of the 
total  number  of  axons.    This  pathology  is  similar  to  that  observed  after 
treatment with a pan-Nfasc specific monoclonal (A12/18.1) [Figure 5.1A (iii)].  
Within the MS group there is a trend suggesting that the pathogenic antibody 
responses  observed  are  associated  more  with  MS  patients  suffering  for  non-
steroid responsive relapses requiring plasmapheresis in comparison to patients 
with  more  the  classical  form  of  RRMS  or  PPMS  (P<0.05,  Fisher’s  exact  test) 
[Figure 5.1B].  These pathogenic effects were disease specific as no pathogenic 
effects were detected within the OND group or from samples taken from healthy 
controls [Figure 5.1C].  However the remaining 10 MS samples tested did not 
mediate a pathogenic effect or either axons or glia, however it is possible that 
not all antibodies are pathogenic as pathogenicity in this assay is dictated by 
several factors such as antigen localisation or the relative ability of the antibody 
to  fix  rat  complement.    To  address  the  possibility  that  the  concentration  of 120 
pathogenic  antibodies  was  below  the  bioassays  detection  threshold  in  some 
donors, the assay was repeated at an IgG concentration of 1 mg/ml. This failed 
to identify any additional donors with a pathogenic (axopathic/demyelinating) 
serum IgG response [Table 5.1]. 
 
In  all  cases  control  experiments  demonstrated  that  these  effects  were  an 
antibody-mediated complement-dependent phenomenon. Heat activation of the 
sera used as a source of complement abolished all antibody mediated effects 
and no loss of myelin or axons was observed after heat inactivation of the serum 
used as the source of complement. 
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Figure 5.1:  MS patient derived IgG mediates complement dependent demyelination and 
axonal injury at 100µg/ml.   
A:  A representative image of a myelinating culture after an overnight treatment with 100µg/ml IgG 
purified from patient MS6 (i), MS1 (ii) or MS5 (iii); resulting in a striking heterogeneity between 
patients [SMI-31: red, PLP: green, 10X magnification].   B: Summary of pathogenic potential of the 
IgG fraction from the 20 MS patient samples, 10 OND samples and 13 healthy controls.  Half of the 
MS samples tested mediated complete demyelination.  In two patients this was also accompanied 
by a loss of axons ranging from 22% to a loss of 34% of the total number of axons. No significant 
axopathic or demyelinating activity was detected in OND or healthy controls.  Antibody mediated 
effects were complement dependent phenomenon as heat inactivation of the FRS abolished all 
pathogenic activity.  Values shown are from one representative data set performed three times in 
triplicate ± standard deviation (*p<0.05, **p<0.01; T-test).   
A
B
 
    + active complement  - inactivated complement 
Patient ID  Diagnosis  % Axonal loss  % Myelin 
loss 
% Axonal 
loss 
% Myelin loss 
MS1  Marburg MS  2 ± 2.9  95 ± 3.5**  0 ± 2.4   5.2 ± 5.5 
MS2  RRMS  3 ± 2.6  96 ± 4.0**  2 ± 3.4  4.9 ± 5.0 
MS3  RRMS  4 ± 3.0  97 ± 2.2**  2 ± 1.9  3.2 ± 2.7 
MS4  RRMS  2 ± 2.1  98 ± 1.3**  4 ± 2.9  0 ± 3.3 
MS5  SPMS  34 ± 5.7**  92 ± 2.2**  1 ± 3.5  2 ± 2.4 
MS6  RRMS  2 ± 3.0  0 ± 0.5  0 ± 3.7  0 ± 1.0 
MS7  RRMS  3 ± 3.7  94 ± 2.0**  3 ± 3.7  4.9 ± 2.4 
MS8  RRMS  0 ± 2.2  0 ± 4.6  0 ± 2.4  0 ± 2.6 
MS9  RRMS  0 ± 2.0  0 ± 3.7  0 ± 2.8  0 ± 1.9 
MS10  RRMS  0 ± 2.3  0 ± 4.0  0 ± 2.9  0 ± 4.0 
MS11  RRMS  0 ± 2.1  95 ± 2.0**  0 ± 3.4  0 ± 2.0 
MS12  RRMS  0 ± 2.5  93 ± 1.7**  0 ± 4.8  0 ± 1.7 
MS13  RRMS  3 ± 2.4  1.5 ± 4.1  3 ± 2.6  0 ± 1.1 
MS14  RRMS  22 ± 3.5**  96 ± 3.2**  2 ± 3.5  0 ± 3.2 
MS15  RRMS  0 ± 2.1  3 ± 4.2  1 ± 2.3  3.4 ± 2.1 
MS16  RRMS  0 ± 2.2  94 ± 2.9**  1.6 ± 1.2  4.0 ± 1.9 
MS17  PPMS  0 ± 2.9  1.6 ± 4.0  1.4 ± 2.8  3.6 ± 1.4 
MS18  PPMS  0 ± 2.3  0 ± 4.5  2.5 ± 2.7  0 ± 4.5 
MS19  PPMS  0 ± 2.0  1.2 ± 4.3  4 ± 2.0  1.4 ± 4.5 
MS20  PPMS  1 ± 0.6  4.6  ± 4.0  1.9 ± 2.6  3.2  ± 4.6 
OND1  SPN  1.5 ± 2.5  2.4 ± 1.5  0 ± 3.5  0 ± 3.6 
OND2  GBS  0.8 ± 1.4  0 ± 3.4  0 ± 3.3  0 ± 4.2 
OND3  GBS  0 ± 4.1  3.3 ± 1.2  0 ± 3.2  0 ± 2.2 
OND4  GBS  1.5 ± 1.6  0 ± 2.2  0 ± 2.5  0 ± 2.5 
OND5  CIDP  2.5 ± 1.5  0 ± 6.0  0 ± 2.8  0 ± 2.6 
OND6  CIDP  0 ± 2.4  0 ± 1.3  0 ± 3.9  0 ± 2.9 
OND7  CIDP  0 ± 3.0  0 ± 2.4  0 ± 2.0  0 ± 2.8 
OND8  ISAN  1.1 ± 2.3  0 ± 4.0  0 ± 3.3  0 ± 4.4 
OND9  MG  1.6 ± 3.7  2 ± 5.2  0 ± 4.8  0 ± 2.6 
OND10  CIDP  0 ± 5.1  0 ± 3.2  0 ± 2.2  0 ± 3.8 
HC1  --  0.2 ± 2.5  1.3 ± 6.7  2.2 ± 2.5  2.3 ± 5.4 
HC2  --  1.2 ± 2.4  1.8 ± 5.2  3.4 ± 2.4  2.3 ± 3.1 
HC3  --  0.5 ± 2.6  1.1 ± 5.0  1.5 ± 2.6  3.1 ± 2.0 
HC4  --  0 ± 3.1  1.2 ± 4.3  1.3 ± 2.1  3.2 ± 3.2 
HC5  --  0.5 ± 4.4  1.8 ± 6.9  2 ± 2.6  2.8 ± 4.4 
HC6  --  0.5 ± 5.9  1 ± 3.8  2.2 ± 3.9  3 ± 3.3 
HC7  --  0 ± 2.2  0 ± 4.1  0 ± 3.1  0 ± 2.1 
HC8  --  0 ± 2.1  0.6 ± 4.4  0 ± 3.0  0 ± 3.4 
HC9  --  0.3 ± 3.0  0.7 ± 4.3  1.3 ± 1.0  0 ± 5.3 
HC10  --  0.4 ± 2.9  0.4 ± 3.8  0 ± 2.6  0 ± 4.1 
HC11  --  0 ± 2.7  0 ± 4.2  0 ± 1.8  0 ± 3.5 
HC12  --  0 ± 2.6  1.1 ± 4.1  0 ± 3.2  0 ± 4.2 
HC13  --  0.6 ± 4.0  0 ± 5.1  0 ± 3.0  0 ± 1.5 
SMI-31, PLP SMI-31, PLP SMI-31, PLP122 
Table 5.1:  Addition of patient derived IgG at 1mg/ml reveals no further pathogenic samples 
in comparison to addition at 100µg/ml.   
A: Summary of pathogenic potential of the IgG fraction from the 20 MS patient samples tested.  
50%  of  the  samples  tested  mediated  complete  demyelination.    In  two  patients  this  was  also 
accompanied by a loss of axons ranging from 18% to a loss of 30% of the total number of axons.  
B:  Summary of pathogenic potential of the IgG fraction from the 10 OND patient samples tested.  
No significant loss of axons or glia was detected even at 1mg/ml.  There was no difference in the 
activity of samples at 1mg/ml compared to 100µg/ml. Values shown are from one representative 
data set performed three times in triplicate ± standard deviation (*p<0.05, **p<0.01; T-test).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 ± 1.2 0 ± 1.9 OND10
0 ± 1.2 0 ± 2.2 OND9
2 ± 1.2 1 ± 1.4 OND8
0 ± 1.0 4.4 ± 1.2 OND7
0 ± 3.2 1 ± 2.5 OND6
0 ± 2.4 0 ± 2.2 OND5
0 ± 1.6 0 ± 1.0 OND4
1 ± 1.8 1.2 ± 2.6 OND3
1 ± 1.2 2 ± 1.8 OND2
1.5 ±2.3 0 ± 1.6 OND1
% Myelin
loss
% Axonal 
loss Patient ID
5 ± 3.1 2 ± 1.6 MS20
2 ± 3.3 2 ± 1.8 MS19
1 ± 4.0 1 ± 2.3 MS18
2.6 ±2.2 0 ± 2.9 MS17
100 ± 1.2** 0 ± 2.2 MS16
3 ± 2.8 0 ± 2.1 MS15
100 ± 1.6** 18 ± 1.3* MS14
3 ± 2.1 3 ± 2.4 MS13
100 ± 1.3** 0 ± 2.5 MS12
100 ± 1.5** 0 ± 2.1 MS11
2 ± 4.4 0 ± 2.3 MS10
0 ± 2.6 0 ± 2.0 MS9
0 ± 3.9 0 ± 2.2 MS8
100 ± 1.0** 3 ± 3.7 MS7
0 ± 1.2 2 ± 3.0 MS6
100 ± 1.0** 30 ± 6.4** MS5
100 ± 2.2** 0 ± 2.8 MS4
100 ± 2.4** 0 ± 1.0 MS3
100 ± 3.0** 4 ± 2.9 MS2
100 ± 4.5** 1 ± 1.9 MS1
% Myelin 
loss
% Axonal
loss Patient ID
A B
0 ± 1.2 0 ± 1.9 OND10
0 ± 1.2 0 ± 2.2 OND9
2 ± 1.2 1 ± 1.4 OND8
0 ± 1.0 4.4 ± 1.2 OND7
0 ± 3.2 1 ± 2.5 OND6
0 ± 2.4 0 ± 2.2 OND5
0 ± 1.6 0 ± 1.0 OND4
1 ± 1.8 1.2 ± 2.6 OND3
1 ± 1.2 2 ± 1.8 OND2
1.5 ±2.3 0 ± 1.6 OND1
% Myelin
loss
% Axonal 
loss Patient ID
5 ± 3.1 2 ± 1.6 MS20
2 ± 3.3 2 ± 1.8 MS19
1 ± 4.0 1 ± 2.3 MS18
2.6 ±2.2 0 ± 2.9 MS17
100 ± 1.2** 0 ± 2.2 MS16
3 ± 2.8 0 ± 2.1 MS15
100 ± 1.6** 18 ± 1.3* MS14
3 ± 2.1 3 ± 2.4 MS13
100 ± 1.3** 0 ± 2.5 MS12
100 ± 1.5** 0 ± 2.1 MS11
2 ± 4.4 0 ± 2.3 MS10
0 ± 2.6 0 ± 2.0 MS9
0 ± 3.9 0 ± 2.2 MS8
100 ± 1.0** 3 ± 3.7 MS7
0 ± 1.2 2 ± 3.0 MS6
100 ± 1.0** 30 ± 6.4** MS5
100 ± 2.2** 0 ± 2.8 MS4
100 ± 2.4** 0 ± 1.0 MS3
100 ± 3.0** 4 ± 2.9 MS2
100 ± 4.5** 1 ± 1.9 MS1
% Myelin 
loss
% Axonal
loss Patient ID
5 ± 3.1 2 ± 1.6 MS20
2 ± 3.3 2 ± 1.8 MS19
1 ± 4.0 1 ± 2.3 MS18
2.6 ±2.2 0 ± 2.9 MS17
100 ± 1.2** 0 ± 2.2 MS16
3 ± 2.8 0 ± 2.1 MS15
100 ± 1.6** 18 ± 1.3* MS14
3 ± 2.1 3 ± 2.4 MS13
100 ± 1.3** 0 ± 2.5 MS12
100 ± 1.5** 0 ± 2.1 MS11
2 ± 4.4 0 ± 2.3 MS10
0 ± 2.6 0 ± 2.0 MS9
0 ± 3.9 0 ± 2.2 MS8
100 ± 1.0** 3 ± 3.7 MS7
0 ± 1.2 2 ± 3.0 MS6
100 ± 1.0** 30 ± 6.4** MS5
100 ± 2.2** 0 ± 2.8 MS4
100 ± 2.4** 0 ± 1.0 MS3
100 ± 3.0** 4 ± 2.9 MS2
100 ± 4.5** 1 ± 1.9 MS1
% Myelin 
loss
% Axonal
loss Patient ID
A B123 
5.2.1.2  Dose response studies using patient IgG 
To  determine  the  sensitivity  of  our  bioassay  dose  response  studies  were 
performed  using  IgG  from  four  patients;  two  with  a  purely  demyelinating 
response at 100µg/ml (MS2 and MS4) and two with demyelination accompanied 
by some degree of axonal injury (MS5 and MS14). IgG was added to myelinating 
cultures (28 DIV) at 100µg/ml (667pM), 50µg/ml (333pM), 10µg/ml (67pM) and 
1µg/ml (6.7pM) with 1% FRS as a source of complement [Figure 5.2].   
For MS2 significant demyelination was detected at IgG concentrations ≥50µg/ml.  
In contrast pathogenic responses using IgG purified from patient MS4 were seen 
at concentrations as low as 10µg/ml.  In sample MS5 where demyelination was 
accompanied by axonal loss, reducing the IgG concentration to 50µg/ml resulted 
in  a  complete  loss  of  all  pathogenic  activity.    IgG  from  MS14  had  extensive 
axopathic activity at antibody concentrations ≥50µg/ml whereas demyelinating 
activity was still observed at ≥10µg/ml.    
 
Figure 5.2: Dose dependence of patient derived autoantibody mediated CNS injury.   
IgG  from  four  MS  patients  (MS2,  MS4,  MS5,  and  MS14)  known  to  contain  demyelinating  and 
axopathic activity was added to myelinating cultures at 100, 50, 10 and 1µg/ml in the presence of 
1% FRS as a source of complement (mean ± SEM, n = 3) (*p<0.05, **p<0.001, T-test).     A: 
Demyelinating activity in all cases was significantly reduced at 50µg/ml and was no longer detected 
at  1µg/ml.    B:  Axopathic  activity  present  in  samples  MS5  and  MS14  was  not  detected  at  IgG 
concentrations below 100µg/ml (mean ± SEM, n = 3) (*p<0.05, **p<0.001, T-test).   
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5.2.1.3  Pathogenic  IgG  components  purified  from  MS  patients  bind 
selectively to myelin 
Using  our  in  vitro  system  we  have  identified  a  demyelinating  IgG  response, 
therefore it was important to determine whether this activity can be attributed 
to the presence of myelin specific antibodies.   
 
Live  immunocytochemistry  of  myelinating  cultures  using  100µg/ml  human  IgG 
revealed a weak staining mainly restricted to the surface of the myelin sheath 
with minor staining on the oligodendrocyte cell body [Figure 5.3A].  There was 
no detectable staining on neuronal/axonal structures.  However high background 
levels seen using IgG on live cells may obscure relatively weak immunoreactivity.    
Antibody binding was only observed in those samples with demyelinating activity 
i.e.  (MS1-5  and  MS7)  and  was  not  detected  in  non-pathogenic  samples  (MS6; 
OND1-4; HC1-4) [Figure 5.3B].   
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Figure 5.3: IgG purified from MS patient plasma binds selectivity to myelin 
A:  Live  immunocytochemistry  using  100µg/ml  IgG  purified  from  MS  patients  (green)  revealed 
binding to PLP positive oligodendrocytes (red) (i-iii).  Binding is strongest at the myelin sheath/ cell 
process there is a weak staining on the oligodendrocyte cell body.  These structures stained with 
human  IgG  align  with  SMI-31
+  axons  (blue)  indicating  that  demyelinating  IgGs  are  capable  of 
binding to a component of the myelin sheath.  Images shown are from IgG purified from patient 
MS1 but identical staining patterns were observed using other MS patient IgG preparations.  B:  
Live immunochemistry using 100µg/ml IgG purified from donor HC7 demonstrated no binding to 
oligodendrocytes (i-iii) or axons (iv-vi). A similar lack of immunoreactivity was observed with all 
other non-pathogenic IgG samples.   
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5.2.1.4  Adsorption  of  patient  derived  IgG  using  purified  compact  myelin 
diminishes its pathogenic potential  
In order to determine whether these demyelinating responses were truly due to 
autoantibody responses directed against components of the myelin sheath we 
attempted  to  adsorb  the  pathogenic  IgG  component  using  highly  purified  rat  
CNS  myelin  and  used  our  myelinating  culture  system  to  detect  a  potential 
reduction in pathogenic activity.   Incubation of MS patient IgG (100µg/ml) with 
2mg/ml total myelin protein resulted in a decrease in total IgG in the samples as 
seen by SDS-PAGE [Figure 5.4A] and a significant reduction in detectable binding 
by ELISA to rat myelin and human MOG [Figure 5.4B].  This diminished binding 
was accompanied in a reduction in demyelinating activity of the IgG fraction in 
three of the six patients tested demyelinating activity was completely removed 
by myelin adsorption (MS1, MS3, MS5).  In the remaining samples pathogenicity 
was  greatly  reduced  ranging  from  a  64%  decrease  (MS7)  to  88%  decrease  in 
demyelinating potential (MS2) when compared to samples pre adsorption [Figure 
5.3C].  The retention of some residual demyelinating activity may be a result of 
incomplete  adsorption  of  pathogenic  component  or  an  indication  that  an 
element  of  this  demyelinating  response  does  not  recognise  a  component  of 
compact  rat  myelin.    Another  possibly  is  that  the  epitope  is  unavailable  or 
altered between purified myelin and the myelin generated in vitro.   
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Figure 5.4: Adsorption of patient derived IgG using purified compact myelin diminishes its 
pathogenic potential 
A: SDS-PAGE of IgG preparations post adsorption revealed a reduction in the total IgG present in 
the sample when compared to an non-adsorbed IgG control.  SDS-PAGE analysis also revealed 
that  the  remaining  IgG  is  intact  (~150KDa)  and  has  not  been  subjected  to  degradation  from 
endogenous proteases.   B:  Adsorption of 100µg/ml IgG purified from MS patients with 2mg/ml rat 
myelin resulted in reduced binding to rat myelin as detected by ELISA (Black bars non-adsorbed 
IgG, white bars IgG adsorbed with myelin).  Data plotted as mean OD (± standard deviation).  All 
reductions in IgG binding were statically significant (**p<0.01, T-test).  C:  Myelin adsorption of IgG 
samples purified from MS patients resulted in a marked reduction in the pathogenic activity when 
compared to samples prior to adsorption.  In the majority of cases myelin adsorption was lowered 
the amount of demyelination detected in myelinating cultures treated with 100µg/ml unbound IgG in 
the presence of 1% fresh rat sera as a source of complement.  In the one case where axonal injury 
was detected in the IgG preparation prior to absorption (MS5) this was also significantly reduced 
after myelin adsorption.  Values shown are from one representative data set performed three times 
in triplicate ± standard deviation (*p<0.05, **p<0.01; T-test).   
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5.2.1.5  Demyelination by human IgG has a limited effect on OPC survival  
Using this system we have been able to identify a set of MS patients that possess 
IgG  responses  capable  of  mediating  demyelination  and  destruction  of  mature 
MOG
+ and PLP
+ oligodendrocytes.   To determine whether these antibodies had a 
pathogenic  effect  on  oligodendrocyte  progenitor  cells  (OPCs)  we  determined 
changes in the NG2
+ and O4
+ populations post treatment [Figure 5.5].  From this 
we can determine that antibody treatment with either patient derived IgG or 
with the anti-MOG monoclonal Z2 had no effect on the number of NG2
+ cells 
when compared to isotype and untreated controls.  In 6 of 7 MS patients tested 
there was a complete loss of O4
+ myelin sheathes accompanied by a significant 
loss of O4
+ cells ranging from (24%-40%).  A similar effect was observed after 
demyelination  using  Z2  which  can  be  attributed  to  a  loss  of  mature 
oligodendrocytes and myelin sheathes that express both sulphatide and MOG.  
Therefore  we  can  predict  that  the  human  IgG  preparations  are  targeting 
epitopes expressed on the mature oligodendrocyte and myelin sheath and not a 
target expressed only by a subset of OPCs.  As when mature oligodendrocytes 
and OPCs are targeted simultaneously using the O4 monoclonal antibody there is 
a complete loss of myelin sheathes and 90% reduction in the total number of O4
+ 
cells.   
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Figure  5.5:  Treatment  of  in  vitro  myelinating  cultures  with  MS  patient  derived  IgG 
preparations has limited effect on oligodendrocyte precursor cells (OPCs).   
A:  Representative image (20X) taken from myelinating cultures treated with IgG from patient MS6 
(i) showing O4
+ OPCs, oligodendrocytes and their associated myelin sheathes (red).  Early OPCs 
are labelled using NG2 (chondroitin sulphate proteoglycans) (green).  Representative image (20X) 
taken from cultures treated with IgG purified from patient MS7 (ii) showing a complete loss of O4
+ 
myelin sheathes and a modest reduction in the total number of O4
+ cells.  There was not significant 
change in the number of NG2
+ OPCs when compared to controls.  This reduction is comparable to 
that seen when cultures are demyelinated with 10µg/ml Z2 (α-MOG mAb) (iii) due to the loss of 
mature  oligodendrocytes  and  myelin  sheathes  that  express  both  sulphatide  and  MOG.          In 
contrast when myelinating cultures are demyelinated with 10µg/ml O4 there is an almost complete 
loss of all O4 immunoreactivity (iv).  There is also a reduction in the amount of NG2 positive cells, 
resulting  from  the  loss  of  O4
+  and  NG2
+  double  positive  OPCs.    B:  Treatment  of  myelinating 
cultures with 100µg/ml MS patient derived IgG in the presence of complement results in a complete 
loss of O4 (α-sulphatide mAb) positive myelin sheaths and a significant reduction in the O4
+ cell 
population  (24-40%)  in  6  of  the  7  MS  patient  samples  tested.    Values  shown  are  from  one 
representative data set performed three times in triplicate ± standard deviation.   
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5.2.2 Nfasc: a potential specificity for pathogenic autoantibodies? 
5.2.2.1  Characterisation of the rrNfasc155 reactive repertoire 
Purification  and  characterisation  of  patient  derived  Nfasc155  reactive 
antibodies was performed by Dr A. Arthur (University of Glasgow).   
To  define  a  potential  specificity  for  these  observed  pathogenic  autoantibody 
responses,  we  screened  our  patient  cohort  for  Nfasc155  responses.    When 
screened  using  ELISA  18  of  the  20  MS  patients  possessed  significant  antibody 
titres  to  recombinant  rat  Nfasc155  (rrNfasc155),  with  7  patients  possessing 
particularly high titres (MS1-7).  However this response to rrNfasc155 was not 
unique to MS as responses were also detected with the OND group.   
 
We  isolated  the  Nfasc155-reactive  component  of  antibody  repertoire  by 
immunoaffinity chromatography using recombinant rat Nfasc155. The Nfasc155-
reactive immunoglobulin preparations contained varying proportions of IgM and 
IgG  antibodies,  IgG  levels  being  significantly  highly  in  samples  isolated  form 
patients  with  MS  than  those  with  other  neurological  diseases  (p<0.05).    This 
resulted in a significant difference the IgG:IgM ratio between the two groups.   
Isotype subclass usage was similar in both groups, predominately IgG1 and IgG2 
accompanied by low levels of Nfasc-specific IgG3 and IgG4 [Figure 5.6A]. The 
latter  was  significantly  higher  in  MS  patients  (p<0.05).      All  these  Nfasc155-
specific  immunoglobulin  preparations  recognised  both  glycosylated  and 
deglycosylated Nfasc155, although recognition of the peptide backbone varied 
significantly between individual patients [Figure 5.6B].  
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Figure 5.6: Characterisation of the Nfasc specific repertoire 
A: Nfasc responses were detected by ELISA in patients with MS (black bars) and patients with 
ONDs (grey bars).  When the isotype usages were quantified they was a significant difference 
between the two groups in the amount of total IgG present, the IgG to IgM ratio and the amount of 
IgG4  present  all  of  which  were  higher  in  the  MS  cohort.    However  there  were  no  significant 
differences  between  the  two  patient  groups  for  the  total  amount  of  IgM,  IgG1,  IgG2  or  IgG3.  
Values shown are an average of three independent experiments performed in triplicate ± standard 
deviation (* P<0.05, T-test).  B:  Western blot was performed to determine binding to Nfasc peptide 
epitopes rather than glycosylated moieties.  Patient derived Nfasc-specific antibodies were blotted 
against  200ng  glycosylated  and  500ng  deglycosylated  rNfasc.    With  the  exception  of  MS4, 
antibodies isolated from all the MS patients gave a strong ECL signal against both glycosylated 
and  deglycosylated  antigen  after  2  minutes  exposure.  Antibodies  from  patients  with  peripheral 
neuropathies gave a similar signal against glycosylated rNfasc, but the exposure time had to be 
increased to 20 minutes to demonstrate binding of these samples to the deglycosylated protein. 
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5.2.2.2  Patient  derived  rrNfasc155  antibodies  mediate  demyelination  and 
axonal injury in vitro 
Treating  myelinating  cultures  with  Nfasc155-specific  immunoglobulin 
preparations from individual donors revealed a striking heterogeneity in their 
ability  to  mediate  axonal  loss  and/or  demyelination.  Nfasc155-specific 
immunoglobulins isolated from all cases of MS mediated complement-dependent 
demyelination.  However in four cases this was also accompanied by variable 
degrees  of  axonal  loss  which  ranged  from  11%  to  39%  [Table  5.2A].  This 
axopathic  effect  was  attributed  to  cross-reactivity  of  Nfasc155-specific 
antibodies  with  epitopes  shared  with  Nfasc186,  as  demonstrated  previously.  
Demyelination induced by the Nfasc specific repertoire may not be strictly MS 
specific  as  a  demyelinating  response  was  also  detected  in  two  OND  patients 
(OND1: sensory motor polyneuropathy, OND3: GBS) [Table 5.2B].   
 
 
Table 5.2: Nfasc specific antibodies purified from MS patients mediate axonal and glial 
pathology in vitro.   
A:  Patient derived Nfasc155 specific autoantibodies are able to mediate demyelination in vitro.  In 
all seven MS cases tested we detected a strong demyelinating antibody response when added to 
myelinating cultures at 10µg/ml in the presence of 1% rat serum as a source of complement.  In 
four patients (MS1, MS5, MS6, MS7) we could also detect an axonal response resulting in axonal 
loss ranging from 11% to 39% of the total number of axons.  Values shown are an average of three 
independent  experiments  performed  in  triplicate  ±  standard  deviation  (*  P<0.05,  T-test).    B:  
Demyelinating responses were more common in the MS cohort but are not disease specific as we 
are able to detect demyelinating activity in two patients from the OND control group (OND1 and 
OND3).  Axonal pathology however was unique to the MS group.  Values shown are from one 
representative data set performed three times in triplicate ± standard deviation (*p<0.05, **p<0.01; 
T-test).   
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5.2.2.3  Nfasc155  can  provide  a  dominant  target  for  demyelinating  and 
axopathic autoantibody responses in MS  
The use of immunopurified antibodies formally demonstrates that components of 
the  Nfasc155-specific  autoantibody  repertoire  have  the  potential  to  mediate 
axonal injury and/or demyelination in vivo. However, this approach provides no 
indication as to whether this pathogenic response is a dominant component of 
the autoantibody repertoire. We therefore compared the pathogenic potential in 
vitro  of  total  IgG  fractions  prepared  from  patient  plasma  post-depletion  of 
Nfasc155  reactivity.    Using  our  immunopurification  method  we  are  able  to 
virtually  remove  all  Nfasc155  reactivity  from  the  plasma  [Figure  5.7A],  we 
subsequently collected this flow through and purified the residual IgG remaining 
in the plasma after Nfasc immunoabsorption.  In one particular case (patient 
MS5)  removal  of  the  Nfasc155-specific  repertoire  completely  abolished  the 
ability  of  the  IgG  fraction  to  mediate  any  pathogenic  effect  in  vitro  [Figure 
5.7B].  This  formally  identifies  Nfasc  as  a  dominant  target  for  pathogenic 
autoantibodies in this particular patient. This was not the case for the remaining 
patients,  as  depletion  of  the  Nfasc155  reactive  component  of  the  antibody 
repertoire had no significant effect its ability to mediate demyelination in vitro.  
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Figure 5.7: Nfasc155 can provide a major autoantigen for autoantibody responses in MS 
A:  Using  our  immunoabsorption  protocol  using  Nfasc155  we  are  able  to  remove  virtually  all 
Nfasc155 reactivity, as detected by ELISA.  We can see that there is a large amount of detectable 
Nfasc155  reactivity  in  the  starting  plasma  and  after  immunodepletion  binding  to  Nfasc155  is 
diminished (patient MS5).  B: For patient MS5 we purified the IgG fraction present in the column 
flow  through  after  the  removal  of  the  Nfasc155  specific  component.    This  was  then  added  to 
myelinating cultures at 100µg/ml in the presence of 1% rat serum as a source of complement.  In 
this  particular  patient  we  were  able  to  see  that  IgG  purified  from  plasma  prior  to  Nfasc155 
immunodepletion mediated both a striking demyelinating and axopathic response.  However after 
the removal of the Nfasc155 specific repertoire this activity was abolished, implicating Nfasc155 as 
the main autoantigen in this particular case.  However in the remaining patients the pathogenic 
activity was completely retained suggesting that Nfasc155 is not the key autoantigen driving these 
responses.  Values shown are from one representative data set performed three times in triplicate 
± standard deviation (*p<0.05, **p<0.01; T-test).   
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MS3 4 ± 3.0 97 ± 2.2** 4 ± 2.3 97 ± 2.0**
MS4 2 ± 2.1 98 ± 1.3** 3 ± 2.9 94 ± 1.8**
MS5 34 ± 5.7* 92 ± 2.4** 2 ± 3.0 0 ± 1.2
MS6 2 ± 3.0 0 ± 0 4 ± 3.4 0 ± 0
MS7 3 ± 3.7 94 ± 2.0** 2 ± 1.6 92 ± 2.2**135 
5.3 Discussion  
The use of in vitro CNS models to detect pathogenic activity in patient serum is 
not a novel concept.  The in vitro demyelinating potential of MS sera was first 
described over 50 years ago (Bornstein and Appel, 1965), an observation which 
was later confirmed by others (Hughes and Field, 1967; Lumsden, 1971; Bradbury 
et  al.,  1985).    However  whether  this  in  vitro  demyelinating  activity  was 
mediated  by  a  myelin-specific  autoantibody  response  remained  controversial 
(review:  Seil, 1977; Caspary, 1977).   
Recent studies have identified a plethora of potential autoantigens associated 
with MS; however most failed to determine whether these responses are actually 
involved  in  disease  pathogenesis.    In  order  to  address  this  question  we 
established  a  novel  in  vitro  screening  strategy  which  not  only  detects 
demyelinating and axopathic autoantibody responses but provides a quantitative 
readout of their pathogenic potential.  Using this model we can identify a subset 
of  MS  patients  who  possess  pathogenic  autoantibodies  capable  of  mediating 
axonal injury and/or demyelination.  This is the first formal demonstration that 
adult  onset  MS  is  associated  with  pathogenic  autoantibody  responses.    In 
contrast to earlier studies we demonstrated that these responses are specific for 
MS and not present in the OND or healthy controls (Bronstein and Appel., 1965; 
Hughes and Field 1967). 
Unfortunately due to the nature of this study and characterisation of clinical 
samples, coding of patient and control samples was not possible.  In order to 
prevent introducing any potential bias, future experiments should be performed 
in a blinded fashion.   
A number of studies have attempted to determine if there is any correlation 
between myelin specific antibody responses and the course of disease but this 
issue remains controversial (Berger et al., 2003; Kuhle et al., 2007).  Within our 
MS cohort we observed a trend suggesting that pathogenic antibody responses 
were  associated  with  patients  with  aggressive  onset  disease and  steroid non-
responsive relapses.  This suggests the exciting possibility that a correlation may 
exist  between  disease  severity  and  the  presence  of  a  pathogenic  antibody 136 
response.  Unfortunately the clinical data was not available in order for us to 
determine  whether  plasma  exchange  was  most  effective  in  patients  with 
pathogenic autoantibody reponses than seronegative patients.  This pilot study 
also lacks sufficient patient numbers to draw any solid conclusions regarding this 
point.  Studies of AQP-4 specific antibody titres in NMO demonstrated that there 
is a marked correlation between disease progression and pathogenic antibody 
titre (Jarius et al., 2010).   
Similar studies could be adopted to investigate many aspects of MS pathogenesis 
in which our model could be used as a potential readout of pathogenic antibody 
activity.    Further  clinical  investigations  using  this  model  will  be  discussed  in 
greater detail in the final chapter.    
We demonstrated that these pathogenic autoantibodies recognise a component 
of intact myelin.  Antibody binding was only observed in IgG preparations with 
pathogenic activity unlike previous studies which reported that human IgG can 
bind  non-specifically  to  myelin/oligodendrocytes  in  vitro  (Aarli  et  al.,  1975; 
Traugott  et  al.,  1979).    The  anti-myelin  reactivity  of  these  pathogenic 
autoantibodies was further confirmed when antibody adsorption using purified 
myelin was shown to significantly reduce pathogenic activity.  This is in contrast 
to studies described in the 1970s (Wolfgram and Duquette, 1976).  However the 
precise specificity of this pathogenic response remains unknown.  It is probable, 
given the complexity and immunopathological heterogeneity of MS that multiple 
targets may be involved, the identity of which may vary between patients.  In 
fact we have data to suggest this is the case as one of our patients developed 
pathogenic  autoantibody  responses  against  Nfasc155  and  depletion  of  this 
repertoire abolished all pathogenic activity (MS5), however Nfasc155 was not a 
dominant autogen in the rest of the cohort.   
From the data in this chapter we can make a number of assumptions about the 
antigen: 
•  It is accessible to bind antibody at the myelin surface. 
•  It  is  not  expressed  by  oligodendrocyte  precursor  cells  as  antibody 
treatment spares the majority of NG2
+ and O4
+ OPCs.       137 
•  Its expression is restricted to terminally differentiated oligodendrocytes.   
Potential  targets  that  satisfy  these  criteria  are  MOG  (Brunner  et  al.,  1989; 
Kroepfl et al., 1996), PLP (Hudson et al., 1989) and opalin (Yoshikawa et al., 
2008;  Kippert  et  al.,  2008).    Nothing  is  known  about  the  encephalitogenic 
potential  of  opalin  whilst  MOG  has  been  implicated  in  paediatric  MS/ADEM 
(McLaughlin et al., 2009; DiPauli et al., 2010).  Further investigation is required 
in order to identify the antigen recognised by these pathogenic antibodies and 
methods  by  which  the  candidate  autoantigens  may  be  identified  will  be 
discussed in a later chapter.   
Although our data are highly suggestive that the responses we detect in vitro 
may contribute to disease pathogenesis.  This has still to be confirmed in vivo.  
Classically this is achieved by passive transfer in an in vivo disease model.  In 
attempting to model antibody mediated effects in CNS disease most studies use 
cotransfer models in which patient-derived antibody is transferred into animals 
with EAE as in the case of NMO (Bradl et al., 2010).  Passive transfer of patient 
derived immunoglobulins from patients with NMO (Bradl et al., 2009); MG (Toyka 
et  al.,  1975)  or  neuromyotonia  (Shillito  et  al.,  1995)  reproduces  the  clinical 
features  of  these  diseases  in  experimental  animals.    Unfortunately  similar 
studies using MS immunoglobulins have been largely unsuccessful.  In a paper by 
Zhou et al. the authors identified a single patient with high anti-MOG antibody 
titres  which  bound  to  MOG  transfectants  with  high  affinity.    However  when 
immunoglobulin from this patient was transferred into rats with EAE the animals 
developed a very minor disease especially when compared to a MOG monoclonal 
antibody (Zhou et al., 2006).   
In this respect the study by Bradl et al. (2010) is particularly informative.  In this 
case animals had to be immunised with 10mg of NMO IgG in order to induce 
disease.  Similarly passive transfer of MG to mice required 10-11mg human IgG 
(Toyka  et  al.,  1975).    These  antibody  doses  required  to  induce  disease  are 
astonishingly high.  For example 10mg IgG is approximately 50% greater than the 
total circulating native IgG in the mouse (Santos, 1967).  Therefore there is a 
discrepancy between the amount of patient derived antibody needed to induce 
disease in rodents and the pathogenic antibody titres detected in patients. In MG 
patients,  AChR  antibody  titres  associated  with  disease  are  much  lower  (~10-138 
20nM) (Lindstrom et al., 1976).  This makes the bioassay an excellent screening 
strategy  to  detect  pathogenic  but  we  have  still  to  address  the  problem  of 
developing  relevant  in  vivo  models  to  investigate  the  effects  of  acute  and 
chronic exposure to MS autoantibodies.   
MS  was  long  described  as  a  disease  of  myelin  characterised  by  primary 
oligodendrocyte  loss  and  demyelination  but  with  relative  sparing  of  axons.  
However  it  is  known  understood  that  MS  lesions  are  also  associated  with 
profound  axonal  loss  (Trapp  et  al.,  1998).    Using  our  system  we  detected 
autoantibody  responses  which  can  mediate  axonal  injury,  an  observation  not 
previously reported.  A potential target for this axopathic response is Nfasc, in 
particular  Nfasc186.    Nfasc  was  first  reported  as  a  potential  autoantigen  by 
Mathey  et  al.  who  demonstrated  that  autoantibodies  against  Nfasc  could  be 
found  in  a  large  proportion  of  MS  patients.    The  authors  also  reported  that 
recognition  of  Nfasc186  exacerabates  disease  severity  in  EAE  due  to  axonal 
injury (Mathey et al., 2007).   
Using immunoaffinity chromatography we isolated the Nfasc155 specific antibody 
repertoire from MS and OND patients.  When added to myelinating cultures we 
observed  that  in  all  MS  cases  these  autoantibodies  mediated  complement 
dependent demyelination and in two cases this was accompanied by significant 
axonal injury.  We observed demyelination in only two OND samples.  Given that 
in  the  previous  chapter  we  demonstrated  that  a  Nfasc155  specific  anti-sera 
mediated complete demyelination this was not unexpected, and we attribute 
the limited axopathic effect to cross reactivity with Nfasc186.   
Unfortunately if was not possible to determine the site of antibody binding for 
this rrNfasc155 specific response.  We were unable to see specific binding to any 
particular structure in live cultures due to high levels of background staining and 
uptake of IgG aggregates by microglia.  It was also not possible to detect MAC 
deposition.  However as demonstrated in the previous chapter when myelinating 
cultures are treated with low doses of monoclonal antibody (such as 100ng/ml of 
8-18C5) we were unable to detect MAC deposition although treatment ultimately 
lead to complete demyelination.  This may be the case for our purified patient 
antibodies i.e. the pathogenic component may be present at concentrations too 
low to visualise by immunofluorescence.    139 
In one patient (MS5) removal of the rrNfasc155 reactive repertoire was sufficient 
to remove all pathogenic activity of the plasma IgG therefore in this patient 
there  is  a  dominant  pathogenic  antibody  component  which  recognises 
rrNfasc155.    Myelin  absorption  of  this  sample  significantly  depleted  the 
demyelinating  activity  therefore  part  of  this  response  must  be  myelin 
associated.    Axonal  injury  was  also  significantly  reduced  potentially  due  to 
adsorption  of  antibodies  recognising  both  Nfasc155  and  Nfasc186.    A  similar 
observation was reported in the previous chapter when A12/18.1 (pan-specific 
Nfasc  mAb)  was  adsorbed  with  rat  myelin  resulting  in  a  reduction  in  both 
demyelinating and axopathic activity.   
We must be cautious when drawing conclusions regarding Nfasc responses in MS.  
To immunopurify the Nfasc specific repertoire we used recombinant rat Nfasc155 
(rrNfasc155) this peptide was generated by a murine myeloma derived cell line 
(NSO) and therefore may contains post translational modifications not usually 
present  when  expressed  by  oligodendrocytes.    Western  blot  analysis  of  the 
purified antibody binding to rrNfasc155 or deglycosylated rrNfasc155 revealed 
that the majority of our purified antibody reacted primarily with glycosylated 
motifs  (especially  in  the  OND  group)  although  we  were  able  to  detect  some 
reactivity to the peptide backbone.  Therefore the antibody we purified is not 
homogeneous and must contain alternate specificities, some of which may be 
unrelated to Nfasc.  
Our bioassay focusses on complement dependent effects.  However in vivo there 
may be multiple pathogenic mechanisms.  Clearly it is not possible to reproduce 
all  adaptive  and  innate  mechanisms  within  our  in  vitro  model.    Using  this 
bioassay to model complement independent effects will be discussed in the next 
chapter.   
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6  Modelling chronic autoantibody mediated injury 
in the absence of complement. 
6.1 Introduction 
The previous chapters demonstrated that myelinating cultures can provide the 
basis of an in vitro screening strategy to detect antibodies that mediate acute 
complement dependent demyelination and axonal loss in vitro.  The decision to 
initially focus on complement-dependent mechanisms was driven by reports that 
they play an important role in the development of demyelinating lesions in EAE 
(Linington  et  al.,  1989;  Storch  et  al.,  1998)  and  the  immunopathology  of  MS 
lesions (Lucchinetti et al., 2000). 
However autoantibodies may also mediate demyelination and/or axonal injury 
via complement independent mechanisms.  These include:  
•  Antibody-dependent cellular cytotoxicity (ADCC).  
Recognition of antigen/antibody complexes by Fc-gamma receptors results in 
the  activation  of  cellular  components  of  the  innate  immune  system 
principally  NK  cells  and  polymorphonuclear  neutrophils.    This  triggers  a 
respiratory  burst  associated  with  the  generation  of  free  oxygen  species 
ond/or the release cytolytic proteins from intracellular granules.  Infiltrating 
neutrophils are prominent feature of some EAE models (Maatta et al., 1998; 
Zehntner  et  al.,  2005)  and  are  also  observed  in  fulminate  cases  of  MS 
(Johnson et al., 1990).   
•  Opsonisation and phagocytosis.  
Antibodies  bind  to  the  target  leading  to  Fc-gamma  receptor  mediated 
phagocytosis  of  the  antibody-antigen  complex  and  tissue  destruction.  
Demyelinating  lesions  in  both  MS  and  EAE  contain  numerous  phagocytes 
(macrophages and microglia) containing Ig and myelin debris (Genain et al., 
1999).  However whether this represents clearance of opsonised debris or a 
primary immune attack on CNS myelin is uncertain. 141 
•  Direct effect due to antibody binding.  
Antibody binding to the cell surface may mediate direct functional effects as 
demonstrated by the phosphorylation of cellular stress response proteins and 
cytoskeletal changes induced in oligodendrocytes by MOG-specific antibodies 
(Marta et al., 2003; 2005). 
Intriguingly  previous  studies  using  rodent  organotypic  myelinating  cultures 
reported  that  that  anti-myelin  antisera  inhibited  myelin  formation  in  vitro.  
There  are  reports  in  the  literature  that  MS  patient  serum  also  contains 
myelination  inhibitory  factors  although  this  issue  is  controversial  (Seil,  1977; 
Caspary et al., 1977).  We therefore decided to readdress this question using the 
myelinating  cultures  to  investigate  whether  either  MOG-  or  Nfasc-specific 
responses  would  have  any  pathogenic  effect  in  the  absence  of  exogenous 
complement.  
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6.2 Results 
6.2.1 MOG specific antibodies disrupt myelin formation in vitro  
To  determine  whether  MOG-specific  autoantibodies  are  able  to  effect  myelin 
formation in the absence of an exogenous source of complement, myelinating 
cultures were grown in the presence of mAb Z2 (10µg/ml) from either 12, 18 or 
24 DIV [Figure 6.1].  
As described in chapter 3, at 12 DIV these cultures contain very few MOG+ cells 
and no myelin.  Significant numbers of MOG+ oligodendrocytes and associated 
axonal ensheathment are only observed from 18 DIV onwards. Addition of Z2 
from either 12 or 18 DIV resulted in an almost complete block of myelination as 
assessed at 24 and 30 DIV [Figure 6.1A &B]. In contrast, the ability of Z2 to 
inhibit  myelination  when  present  from  24  DIV  onwards  was  partial.  This 
observation suggests that in the absence of a source of complement the mAb Z2 
inhibits the development of myelination competent oligodendrocytes, but does 
not  mediate  destruction  of  pre  existing  myelin  sheaths  [Figure  6.1C].  These 
antibody mediated effects on myelination were not associated with any changes 
in  axonal  density  as  assessed  by  SMI-31  immunoreactivity.  Furthermore,  no 
disruption  of  myelination  was  observed  when  cultures  were  grown  in  the 
presence of a control mouse IgG2a myeloma protein (10µg/ml).   
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Figure 6.1: MOG specific antibodies can block myelination in vitro.   
Myelinating cultures were incubated with 10µg/ml Z2 from 12 DIV (A), 18 DIV (B) or 24 DIV (C) 
until 30 DIV (antibody addition marked with an arrow).  Analysis of immunochemical data reveals 
that in all cases long term incubation with Z2 can block myelin formation in vitro.  In all cases 
axonal density was equivalent and unaltered in response to antibody treatment.  Values plotted are 
the average of three independent experiments performed in triplicate (± S.E.M), *p<0.05 **p<0.001 
(t-test).   
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6.2.1.1  Inhibition of myelination by MOG specific antibodies is concentration 
dependent 
To  determine  the  concentration  dependence  of  the  effect  of  mAb  Z2  on 
myelination  in  the  absence  of  an  exogenous  source  of  complement,  cultures 
were  treated  from  18  to  30  DIV  with  various  Z2  concentrations  ranging  from 
10µg/ml  to  1ng/ml  [Figure  6.2].    Axonal  density  and  myelination  were  then 
quantified as described previously. 
This experiment revealed that myelination in this culture system is very sensitive 
to the presence of this MOG-specific mAb.  Significant inhibition was observed at 
10ng/ml (66pM), which is lower than that required to obtain a similar degree of 
acute  antibody-mediated,  complement-dependent  demyelination  using  this 
antibody  in  vitro  (Chapter  4).  Myelination  in  this  culture  system  is  therefore 
highly  sensitive  to  the  presence  mAb  Z2,  being  detected  at  antibody 
concentrations  significantly  lower  than  those  reported  for  pathogenic 
autoantibody  responses  in  both  myasthenia  gravis  (Lindstrom  et  al.,  1976) 
autoimmune mediated epilepsy/neuromyotonia (Irani et al., 2010) 
 
 
 
 
 
 
Figure 6.2:  Disruption of myelination in vitro by MOG specific antibodies is concentration 
dependent. 
To  determine  the  antibody  concentration  range  required  to  inhibit  myelin  formation  myelinating 
cultures were treated from 18 DIV with various concentrations of Z2 (10µg/ml-10ng/ml) until 30DIV.  
Analysis  of  immunochemical  data  reveals  that  myelinating  cultures  are  extremely  sensitive  to 
antibody  treatment,  as  inhibition  of  myelin  formation  can  be  detected  down  to  antibody 
concentrations ≥ 10ng/ml.  In all cases axonal density was equivalent and unaltered in response to 
antibody treatment.  Values plotted are the average of three independent experiments performed in 
triplicate (± S.E.M), *p<0.05 **p<0.001 (t-test).   
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6.2.1.2  Inhibition of myelination by MOG specific antibodies is reversible  
To determine whether exposure to mAb Z2 results in an irreversible block in 
myelination, cultures were treated with 1mg/ml Z2 between 12 and 18DIV, after 
which they were washed extensively and cultured in the absence of antibody for 
a  further  12  days.  As  demonstrated  above  the  presence  of  Z2  from  12  DIV 
onwards  results  in  dramatic  reduction  myelination  as  assessed  by 
immunoreactivity for PLP. However, withdrawl of Z2 from 18 DIV was followed 
by a partial recovery indicating this antibody mediated effect is not necessarily 
permanent. Myelination in these cultures was approximately thirty percent of 
that seen in cultures treated with an isotype control mAb [Figure 6.3].  
 
 
 
 
 
   
 
Figure 6.3: Inhibition of myelination caused by MOG specific antibodies is reversible.   
To  determine  whether  the  block  of  myelin  formation  caused  by  MOG  specific  antibodies  is 
permanent, cultures were treated with 1µg/ml Z2 from 12 DIV and antibody was withdrawn from the 
media  at  18  DIV  and  cultured  normally  until  30  DIV.    Analysis  of  immunochemical  data 
demonstrates that at 24 DIV only a very small amount of has been myelin formed however by 30 
DIV  significant  myelination  has  taken  place.    In  all  cases  axonal  density  was  equivalent  and 
unaltered in response to antibody treatment.  Values plotted are the average of three independent 
experiments performed in triplicate (± S.E.M), *p<0.05 **p<0.001 (t-test). 
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6.2.2 Effects  mediated  by  Nfasc  specific  autoantibodies  in  the 
absence of complement  
6.2.2.1  Pan-Nfasc  antibodies  mediated  complement  independent 
demyelination and axonal loss 
As antibodies to Nfasc155 were reported to block myelination in vitro (Charles et 
al., 2002), it was anticipated that the pan-Nfasc mAb A12/18.1 would have a 
similar  effect.  This  hypothesis  was  tested  by  adding  A12/18.1  (10µg/ml)  to 
myelinating cultures from 12, 18 DIV and 24 DIV onwards.  In each case axonal 
density and myelination was determined as described previously [Figure 6.4].   
Surprisingly the presence of A12/18.1 from 12 or 18 DIV not only resulted in 
inhibition  of  myelination  but  also  decreased  SMI-31  immunoreactivity  by 
approximately half compared to control cultures.  This loss of SMI-31 positive 
structures was observed within six days of addition of A12/18.1, but was far less 
pronounced in those cultures treated from 24 DIV onwards.  In this case axonal 
loss  was  associated  with  an  inhibition  of  myelination  but  there  was  no 
concomitant loss of pre-existing myelin sheathes [Figure 6.4C].  This suggests 
that those axons/neurons that have already been myelinated are resistant to the 
complement-independent effects of A12/18.1.   
As previously demonstrated in chapter 4, antibody treatment in the presence of 
exogenous complement induces pronounced axonal loss and demyelination but 
no acute injury was detected after 16hrs in the absence of complement. 
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Figure 6.4: Nfasc specific antibodies can inhibit myelin formation and mediate axonal injury 
in the absence of complement.   
Myelinating cultures were incubated with 10µg/ml A12/18.1 from 12 DIV (A), 18 DIV (B) or 24 DIV 
(C)  until  30  DIV  (antibody  addition  marked  with  an  arrow).    Analysis  of  immunochemical  data 
reveals that in all cases long term incubation with A12/18.1 can block myelin formation in vitro 
(green line).  Strikingly inhibition of myelination is accompanied by a loss of axons, which can be 
detected after 6 days of antibody addition (red line).  Early antibody addition (from 12 DIV or 18 
DIV) mediates a significant loss of axons (~40%) and complete block of myelination.  Antibody 
addition much later (24 DIV) mediates axonal injury and block of myelination however to a much 
lesser  extent  than  in  earlier  treatments.    Values  plotted  are  the  average  of  three  independent 
experiments performed in triplicate (± S.E.M), *p<0.05 **p<0.001 (t-test).   148 
6.2.2.2  Concentration dependence of A12/18.1 mediated effects 
The concentration dependence of effects mediated by A12/18.1 in the absence 
of  exogenous  complement  on  axons  and  myelination  were  investigated  by 
treating myelinating cultures with 10µg/ml to 1ng/ml of antibody from 18 DIV 
onwards and then quantifying myelination and axonal density twelve days later 
(30 DIV) [Figure 6.5]. Significant inhibition of myelin formation was observed at 
mAb  concentrations  >  50ng/ml,  whilst  significant  axonal  loss  was  on  at 
concentrations  >100  ng/ml  indicating  the  latter  is  less  sensitive  to  the 
complement independent effects of the pan-Nfasc antibody.   
6.2.2.3  Effects mediated by A12/18.1 are irreversible  
To  determine  whether  the  effects  of  A12/18.1  on  axonal  survival  and 
myelination were reversible myelinating cultures were treated with 1µg/ml of 
the antibody between 12 and 18 DIV. The cultures were then washed extensively 
to remove unbound antibody and cultured for a further 12 days in the absence of 
A12/18.1. Quantification of axonal loss and myelination revealed that unlike the 
effect of the MOG-specific mAb Z2 on myelination, axonal loss and failure of 
myelination induced by A12/18.1 were irreversible [Figure 6.6]. The failure of 
these cultures to exhibit any evidence of myelination suggests early treatment 
with the antibody eliminates all potentially myelination competent axons.   
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Figure  6.5:    In  vitro  effects  mediated  by  Nfasc  specific  antibodies  are  concentration 
dependent. 
To determine the antibody concentration range required to inhibit myelin formation, myelinating 
cultures  were  treated  from  18  DIV  with  various  concentrations  of  A12/18.1  (10µg/ml-1ng/ml).  
Analysis  of  immunochemical  data  reveals  that  myelinating  cultures  are  extremely  sensitive  to 
antibody treatment as inhibition of myelination can be detected down to antibody concentrations ≥ 
10ng/ml.    Axonal  loss  was  less  sensitive  however  axopathic  activity  remains  at  antibody 
concentrations  ≥  100ng/ml.    Values  plotted  are  the  average  of  three  independent  experiments 
performed in triplicate (± S.E.M), *p<0.05 **p<0.001 (t-test).   
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Figure 6.6: Pathogenic effects on axons and glia mediated by Nfasc specific antibodies are 
irreversible.    
To determine whether pathology caused by Nfasc specific antibodies is permanent cultures were 
treated with 1µg/ml A12/18.1 from 12 DIV and antibody was withdrawn from the media at 18 DIV 
and cultured normally until 30 DIV.  Analysis of immunochemical data demonstrates that there is no 
recovery of myelination (A) or any replenishment of axons (B) at 24 DIV or 30 DIV.  Values plotted 
are  the  average  of  three  independent  experiments  performed  in  triplicate  (±  S.E.M),  *p<0.05 
**p<0.001 (t-test).   
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6.2.3 Complement independent activity of patient derived IgG in 
vitro 
The  observation  that  antibodies  recognising  axons  and/or  myelin  can  have 
profound complement independent effects on myelination and axonal survival 
promoted us to reassess the concept that some MS patients develop myelination 
inhibiting  autoantibody  responses  (review:  Seil  et  al.,  1977).  Purified  IgG 
preparations from seven patients (MS1-7) were added to myelinating cultures 
from 18 DIV onwards at a concentration of 50µg/ml.  Analysis of the extent of 
myelination revealed that twelve days later six of the seven IgG preparations 
had inhibited myelination to varying extents [Figure 6.7A], whilst one (MS5) had 
also induced a fifty percent reduction in SMI-31 immunoreactivity [Figure 6.7B]. 
No pathogenic effect was observed when cultures were treated with either a 
patient  derived  IgG  preparation  that  exhibited  no  complement-dependent 
effects in vitro (MS6) or a commercially available IgG preparation obtained from 
healthy donors.  
 
 
 
 
 
 
 
 
 
 152 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: In the absence of complement, long term incubation with IgG purified from MS 
patients can inhibit myelination and mediate axonal injury in vitro. 
At 18 DIV myelinating cultures were incubated with 50µg/ml IgG purified from MS patients until 30 
DIV.  Myelin/ oligodendrocytes were stained for PLP and axons labelled using SMI-31.  Analysis of 
immunochemical  data  reveals  that  six  of  seven  samples  tested  were  able  to  inhibit  myelin 
formation in vitro (A).  One patient (MS5) also exhibited axopathic activity  leading to a loss of 
approximately 40% of total axons (B).  Pathogenic activity was not seen in cultures treated with 
control IgG preparations (hIgG).  Values plotted are the average of two independent experiments 
performed in triplicate (± S.E.M), *p<0.05 **p<0.001 (t-test). 
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6.3 Discussion 
This  chapter  demonstrates  that  autoantibody  responses  directed  against 
myelinated  axons  can  mediate  profound  complement-independent  effects  in 
vitro,  as  demonstrated  by  the  ability  of  a  MOG-specific  mAb  to  inhibit 
myelination and a pan-Nfasc mAb to induce axonal loss.  The antibody-mediated 
effect  on  myelination  exhibited  significant  intra  and  inter  assay  variability 
(Cv=36%) [Table 6.1A], but was significant compared to parallel cultures treated 
with an irrelevant mAb of the same isotype down to a concentration of 10ng/ml 
(Figure 6.2).  Axonal loss induced by mAb A12/18.1 was less variable (Cv= 10.6%) 
[Table  6.1B]  but  compared  to  antibody-mediated  inhibition  of  myelination 
required  higher  concentrations  of  antibody  only  being  significant  at 
concentrations > 50ng/ml.  
Table 6.1: Variability of complement independent MOG specific antibody mediated injury  
Values shown are an average from three coverslips ± standard deviation after standardising to 
control values.  Coefficient of variance was calculated as standard deviation/ mean and expressed 
as a percentage. 
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Unfortunately  due  to  time  constraints  I  was  unable  to  characterise  the 
mechanisms  responsible  for  these  antigen-specific  effects  on  myelination  and 
axonal  survival.  A  number  of  obvious  experiments  using  Fab  and  F(ab)2` 
antibody  fragments  would  help  elucidate  the  relative  importance  of  Fc 
dependent effector pathways and the microglial cell response, as well as the 
effects of antigen cross-linking at the cell surface.  It will also be important to 
determine  that  the  observed  effects  are  not  dependent  on  low  levels  of 
endogenous  complement  components  produced  by  the  cultures  themselves 
(Stevens et al., 2007; Thomas et al., 2000). 
It is already known that treatment of cultured oligodendrocytes with a MOG-
specific mAb is sufficient to trigger an influx of calcium and active the MAPK/Akt 
signalling  pathways  (Marta  et  al.,  2003).    Activation  of  these  pathways  is 
associated with cell survival and regulation of apoptosis in other systems (Datta 
et  al.,  1997;  Bonni  et  al.,  1999)  and  is  implicated  in  regulation  of  OPC 
differentiation  (Chew  et  al.,  2010).    The  most  obvious  effect  on  cultured 
oligodendrocytes  was  retraction  of  processes  and  loss  of  myelin  like  sheets.  
These effects were independent of MOG partitioning into lipid rafts, but if the 
bound antibody was cross-linked at the cell surface not only did MOG partition 
into lipid rafts, but stress response proteins and elements of the cytoskeleton 
were also phosphorylated (Marta et al., 2005).  Our in vitro studies suggest that 
whilst these effects inhibit myelination they do not have a detrimental effect on 
pre-existing myelin sheaths (Figure 6.1, 24 DIV).  Moreover, the effect in the 
cultures  was  not  permanent.  We  speculate  that  this  is  due  to  the  continued 
presence of MOG- OPCs that once the antibody is removed, can still differentiate 
into myelinating oligodendrocytes.  However in the absence of data on the fate 
of MOG+ cells following antibody treatment we can not exclude the involvement 
of a pre-existing pool of mature oligodendrocytes. 
A  previous  report  indicated  that  Nfasc155-specific  antibodies  can  also  inhibit 
myelination  and  in  this  case  the  antibody  is  believed  to  act  by  blocking  the 
interaction of Nfasc155 with Caspr/contactin complexes on the axonal surface 
(Charles et al., 2002).  It was assumed the pan-Nfasc mAb A12/18.1 would mimic 
this effect, but in this case failure of myelination was secondary to irreversible 
axonal loss.  Why this occurs remains obscure.  One possibility is that microglial 
activation by bound antibody may trigger an oxidative burst, the release of pro-155 
inflammatory cytokines or disrupt local glutamate homeostasis, all of which may 
lead to neuronal cell death (Matute et al., 2011; Gehrmann et al., 1995; Mrak 
and Griffith, 2005).   
The  demonstration  that  patient-derived  antibodies  mediate  similar  effects 
suggests  that  complement-independent  effector  mechanisms  could  play  a 
significant role in the immunopathogenesis of MS.  However the observation that 
antibody exposure can result in an irreversible loss of some neurons may have 
far wider implications.  Our results clearly indicate the developing CNS contains 
a subset of neurons including those destined to produce myelination-competent 
axons that are susceptible to injury by Nfasc-specific antibodies.  If present in 
pregnant mothers we suggest that these antibodies may cross the placenta to 
eliminate  Nfasc+  neurons  in  the  developing  foetus.  This  could have  profound 
consequences not only with respect to the immediate post natal period but also 
into  adulthood  due  to  perturbed  white  matter  tract  development.    This 
hypothesis  warrants  further  investigation  as  there  is  increasing  evidence  that 
white  matter  tract  abnormalities  are  associated  with  a  number  of  important 
psychiatric conditions including schizophrenia (Kubicki et al., 2007; Peters et al., 
2010) but the underlying mechanisms are completely unknown.   
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7  General Discussion 
Over  the  past  50  years  circumstantial  evidence  has  accumulated  suggesting 
autoantibody-dependent  mechanisms  are  involved  in  the  pathogenesis  of  MS, 
however their clinical significance remains controversial.  This is largely because 
of the lack of formal evidence that patients develop pathogenic autoantibody 
responses  that  actively  participate  in  lesion  formation.    The  demyelinating 
potential  of  some  MS  sera  was  first  demonstrated  in  vitro  in  the  1960s,  but 
doubts  were  then  raised  as  whether  this  was  actually  an  antibody-mediated 
phenomenon  (review:  Caspary,  1977).  These  pioneering  attempts  using 
myelinated CNS tissue cultures to identify pathogenic autoantibodies in patient 
sera were ultimately abandoned due to combination of factors including:   
•  The presence of antibody-independent myelinotoxic factors in some sera. 
•  The lack of objective measures to determine myelin/axonal loss. 
•  The  identification  of  demyelinating  responses  in  patients  with  other 
neurological diseases. 
The  broad  aim  of  this  thesis  was  to  exploit  subsequent  advances  in  tissue 
culture,  antibody  purification  and  imaging  techniques  to  develop  a  reliable 
bioassay  that  can  be  used  to  determine  whether  MS  is  associated  with  a 
pathogenic autoantibody response against myelinated axons.  
This goal was achieved and the bioassay used to demonstrate the presence of 
demyelinating  and  in  a  small  number  of  cases  axopathic  autoantibodies  in 
patients with MS. 
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7.1 Myelinating  cultures  as  a  tool  to  screen  for  the 
presence  of  pathogenic  autoantibodies  in  clinical 
samples- a critical reappraisal.  
In  order  for  myelinating  cultures  to  be  used  as  a  reliable  tool  to  identify 
demyelinating  and/or  axopathic  autoantibodies  in  clinical  samples  they  must 
satisfy a number of criteria, in particular: 
•  They must reproduce the structural organisation of myelinated fibres in 
the CNS. 
•  Variability in axonal density and myelination should be minimal. 
•  Large numbers of cultures should be available for intermediate to high 
through put screening studies. 
•  Analysis must be rapid and based on objective measures.  
As described in chapters 3 and 4 the myelinating cultures clearly satisfy these 
criteria. They are characterised by the presence of numerous compact myelin 
sheaths associated with paranodal axo-glial junctional complexes and nodes of 
Ranvier that reproduce the topological organisation of these structures in vivo.  
Moreover large numbers of cultures can be prepared at any one time (~ 150 – 
200/E15 litter) that exhibit limited variability with respect to axonal density and 
myelination.  This  makes  them  suitable  for  use  in  high  throughput  screens  to 
identify  pathogenic  autoantibodies  in  clinical  samples.  However  data  analysis 
while semi automated remains labour intensive; for example to analyse the 43 
sera described in chapter 5 required acquiring and analysing approximately 8000 
images.  The reproducibility of the assay suggests the number of images/cultures 
used in the analysis can be reduced significantly, but nonetheless the current 
method of outlining myelin sheaths by hand is extraordinarily time consuming. 
This problem is being addressed by designing an algorithm that will differentiate 
intact  myelin  sheaths  from  immunoreactive  myelin  debris  and  cell  bodies. 
Ultimately  the  aim  is  to  develop  this  into  a  program  that  will  automatically 
process two colour immunofluorescent images and generate total pixel data and 158 
calculated myelin densities automatically.  This will not circumvent the time 
required to acquire the images in the first place and visual inspection of the 
cultures is important to control for pathogenic effects that may not be picked up 
by an automated program.   
The  other  major  limitation  of using  this culture  system to detect  pathogenic 
autoantibodies  is  that  it  is  derived  from  rodent  not  human  tissue.  Ideally  it 
would  be  preferable  to  use  myelinating  human  cultures,  but  to  attempt  this 
using  primary  human  tissue  would  be  both  ethically  and  technically  taxing. 
However recent advances in generating human neurons and glia derived from 
adult (Othman et al., 2011) and embryonic CNS tissue (Satoh et al., 1994; Jana 
et al., 2007), as well as various stem cell populations suggests that generating a 
humanised myelinating culture model may be feasible in the near feature. 
One possible alternative to using this dissociated myelinating culture system in 
order  to  identify  pathogenic  autoantibodies  are  organotypic  slice  cultures 
derived from post-natal cerebellum or spinal cord. These have the advantage 
that they reproduce the three dimensional architecture of white matter tracts in 
the  adult  CNS,  but  suffer  from  several  limitations  with  respect  to  their 
suitability as a screening tool to identify pathogenic autoantibodies. The major 
drawbacks are that only a limited number of cultures (6 - 8) can be generated 
from each donor, there is significant slice to slice variation in myelination and 
that whilst these cultures reproduce the three dimensional architecture of white 
matter  this  it  self  restricts  diffusion of  antibody  to  its  target  (Harrer  et al., 
2009).  However these organotypic cultures provide a powerful in vitro model in 
which to study remyelination not possible dissociated cell systems (Zhang et al., 
2011).   
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7.2 The significance of identifying pathogenic 
autoantibody responses in patients with MS  
The possibility that autoantibodies contribute to the immunopathogenesis of MS 
has been discussed for many years, but the specificity of this response remains 
unknown.    The  results  described  in  this  thesis  suggest  why  this  remains  a 
complicated  issue.    Quite  simply  it  appears  that  pathologically  relevant  i.e 
demyelinating or axopathic responses are restricted to a subset of patients and 
may  actually  be  relatively  rare  in  patients  with  typical  relapsing  remitting 
disease.  If this is the case, then any strategy that screens patients at random 
using  either candidate  antigen  or  proteomics  based  approaches  is  unlikely  to 
succeed, a problem that will be exacerbated if there are multiple pathogenic 
targets (review: Reindl et al., 2006).  The formal demonstration that pathogenic 
autoantibody  responses  specific  for  myelin-associated  antigens  are  present  in 
certain patients will stimulate a new generation of far more focused studies to 
define  their  specificity.    The  results  presented  in  this  thesis  suggest  these 
demyelinating and/or axopathic autoantibody responses are a specific feature of 
MS,  as  these  activities  were  not  detected  in  IgG  preparations  obtained  from 
patients  with  other  neurological  diseases  (mainly  Gullian-Barré Syndrome  and 
chronic idiopathic demyelinating polyneuropathy) or healthy controls.  Our study 
focussed purely on the pathogenic properties of patient-derived IgG.  A number 
of studies have reported MS specific IgM responses against a number of antigens 
in  particular  MOG  (review:  Reindl  et  al.,  2006).  Therefore  screening  of 
alternative immunoglobulin isotypes using our bioassay may be informative.   
It  may  be  anticipated  that  these  responses  may  ultimately  not  prove  to  be 
strictly  MS  specific,  as  pathogenic  MOG-specific  autoantibodies  have  been 
implicated in the pathogenesis of demyelination in ADEM, whilst neuron-specific 
autoantibodies are implicated in a number of other neurological diseases. 
However, the real significance of this study lies in the implications it has with 
respect to improving the clinical management of MS.  The demonstration that 
antibody-dependent  mechanisms  are  involved  in  other  diseases  such  as 
myasthenia gravis and NMO has resulted in rapid improvements in diagnosis and 
treatment.  However it is too early to say whether this will also be the case for 160 
MS  patients  found  to  be  seropositive  for  axopathic  and/or  demyelinating 
antibodies,  but  complement  inhibitors,  high  dose  IgG,  plasma  exchange  and 
immunoabsorption  are  just  some  of  the  treatments  now  used  to  suppress 
antibody-mediated effects in other diseases.  
Which of these treatments may be most appropriate to use in MS patients will 
depend  on  precisely  how  these  autoantibodies  contribute  to  disease 
pathogenesis.  The focus of this study was complement-mediated effects, but we 
cannot rule out a role for ADCC mediated by microglia or infiltrating monocytes 
and NK cells.  Moreover, in concordance with previous studies (Bornstein and 
Raine, 1970) antibodies can also inhibit myelination and mediate axonal injury in 
the absence of an exogenous source of complement in vitro, but further studies 
are required to assess the potential relevance of these complement independent 
effects in patients. 
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7.3 Future Directions 
The  demonstration  that  some  patients  with  MS  develop  axopathic  and/or 
demyelinating autoantibody responses raises two immediate questions: 
•  What is the clinical significance of this response? 
•  Which antigens are targeted by these pathogenic responses?  
 
7.3.1 Clinical studies 
Although this pilot study investigated only a small number of patients, a trend 
was  detected  indicating  that  pathogenic  autoantibody  responses  were  most 
prevalent  in  patients  with  steroid  non-responsive  relapses.    This  observation 
suggests that in certain patients these antibodies may have evolved to become 
the  dominant  mechanism  responsible  for  acute  neurological  deficits  in  these 
patients at this particular stage of disease.  However whilst severe steroid non-
responsive  relapses  are  relatively  rare,  neuropathological  studies  can  be 
interpreted  as  indicating  antibodies  are  involved  in  lesion  formation  in  the 
majority of patients (Lucchinetti et al., 2000).  
To resolve this dichotomy the following clinical studies should be carried out: 
•  Determine the frequency of pathogenic responses in patients with respect 
to disease duration and clinical subtype e.g. RRMS compared to SPMS etc. 
•  Investigate the prognostic significance of these pathogenic autoantibody 
responses.    Long  term  studies  including  regular  MRI  scans  and  clinical 
investigations will determine if the presence of a high pathogenic antibody titre 
is predictive of a poor prognosis. 
•  In  patients  with  severe  steroid  non-responsive  relapses  investigate  the 
relationship  between  the  presence/titre  of  pathogenic  autoantibodies  and 
clinical response to plasma exchange or other treatments that target antibody-
mediated effects. 162 
•  Investigate  potential  correlates  between  lesion  immunopathology  and 
axopathic and/or demyelinating serum autoantibody responses in patients where 
lesion biopsies are available.  
7.3.2 Identification of target antigens 
Although  a  pathogenic  autoantibody  response  can  now  be  identified  in  some 
patients its specificity is unknown.  One approach to resolve this question is to 
use immobilised recombinant antigens to selectively deplete IgG preparations of 
antibody  recognising  defined  candidates  such  as  MOG  or  Nfasc.    In  one  case 
(MS5) the axopathic and demyelinating IgG response was completely absorbed by 
recombinant rat Nfasc155, however in the remaining patients this was not the 
case.  It is therefore unlikely that Nfasc155 is a dominant target for pathogenic 
autoantibodies in MS.  Indeed in the absence of evidence that the antibodies 
isolated from this patient bind Nfasc155 in situ the role of this autoantigen in 
disease pathogenesis must be discussed with care.  An alternative approach is to 
use the bioassay to identify populations of seropositive and negative patients 
and  then  use  a  proteomics  based  approach  to  identify  potential  candidates 
(review: Fathman et al., 2005). 
The  classical  method  relies  on  2D-polyacrylamide  gel  electrophoresis  and 
resolves proteins based on their molecular weight and isoelectric point.  Spots of 
interest are then digested enzymatically and the resulting peptides analysed by 
mass  spectrometry.  However  some  proteins  are  readily  resolved  by  2D  gel 
electrophoresis  or  are  present  in  the  gels  at  levels  below  the  techniques 
detection threshold. More recently “shotgun” proteomics approaches have been 
introduced  in  which  the  composition  of  immune  complexes  formed  when  IgG 
preparations  are  incubated  with  a  relevant  target  is  analysed  by  mass 
spectrometry (review: Kinoshita et al., 2006).  The demonstration that isolated 
myelin will absorb pathogenic antibodies present in some patients indicates this 
approach may be applicable to MS.  However it should be stressed this technique 
will not identify a specific target, but rather produce a hierarchy of “hits” for 
each donor.  These will not only (hopefully) include the relevant target(s) but 
also any other molecules that remain associated with the target in the immune 
precipitate plus other non-specific contaminants. It will therefore be important 163 
to screen a significant number of patients and define strategies to select and 
validate potential candidates.  
An alternative is microarray based screening of antigen libraries in which IgG 
from patients and appropriate controls are screened against either a panel of 
suspected  antigens  or  the  entire  proteome  expressed  and  deposited  on 
microarray  slides.    Disease  specific  biomarkers  are  identified  by  comparing 
patient  data  to  controls  [Figure  7.1].  This  approach  has  been  used  to  some 
notable success in other autoantibody mediated diseases including autoimmune 
pancreatitis (Frulloni et al., 2009), alopecia (Lueking et al., 2003), rheumatoid 
arthritis  (Lueking  et  al.,  2003).    A  number  of  disease  specific  biomarkers  in 
ovarian  (Hudson  et  al.,  2007)  and  prostate  cancer  (Wang  et  al.,  2005)  and 
Alzheimer’s  disease  (Reddy  et  al.,  2011)  have  also  been  identified  using  this 
method.  However, this methodology may fail to detect pathologically relevant 
responses to conformation dependent targets.  Moreover, it is also necessary to 
establish validation techniques for each candidate. The importance of this was 
demonstrated by the study reported by Kanter et al. in 2006 that used a lipid 
microarray to screen for disease associated antibody responses in MS.  This study 
identified  a  disease  associated  response  to  sulphatide  and  then  used  the 
sulphatide-specific mAb O4 to validate the pathogenic potential of this response.  
It was notable that the pathogenic antibodies identified in the course of this 
project were clearly not sulphatide specific as they spared large numbers of O4+ 
cells in the myelinating cultures.   
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Figure 7.1: Comparative screens of case and control serum to identify disease biomarkers. 
The  Y-shaped  figures  represent  IgG  antibodies.  The  figure  depicts  hypothetical  binding  of  an 
antibody  present  at  high  levels  in  an  autoimmune  serum  sample,  but  not  in  a  healthy  serum 
sample, binding to three  molecules on a microarray. After probing  with a fluorescently labelled 
secondary antibody, this would produce a much higher intensity at these three spots on the array 
(indicated  in  by  red  boxes)  after  exposure  to  the  autoimmune  serum  sample  than  the  healthy 
control serum sample.  Figure adapted from Reddy et al. 2011.   
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7.4 Final Conclusions 
Autoantibodies have been implicated in the pathogenesis of MS for many years. 
The data presented in this thesis provides formal evidence that this response 
actually exists by identifying axopathic and/or demyelinating autoantibodies in a 
subset  of  MS  patients.  This  is  an  extremely  important  observation  which 
enhances our conceptual understanding of the pathogenesis of MS and certainly 
warrants further investigation. Identifying autoantibody responses specific to MS 
will have great implications in the clinical management of the disease ranging 
such as their use as diagnostic or prognostic markers. From the results of studies 
on  the  role  and  clinical  significance  of  AQP-4  specific  antibodies  in  NMO  we 
predict that this will be a complex undertaking. However I am confident that 
advances in laboratory techniques, as well as our conceptual understanding of 
the disease will clarify the role of antibody-dependent mechanisms in MS within 
the next ten years. 
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Appendix 
Materials 
All reagents were purchased from Sigma-Aldrich (Dorset, UK) unless otherwise 
stated. 
General buffers & solutions 
Phosphate buffered saline (10X) 
1.4M NaCl (80g) 
0.015M KH2PO4 (2g) 
0.027 KCl (2g) 
0.19M Na2HPO4.2H2O (29g) 
Made up to 1L with dH2O and diluted 1 in 10 for use. 
 
Sodium Hydroxide (1M) 
Dissolve 40g sodium hydroxide pellets in 1L distilled H2O. 
 
Hydrochloric acid (1M) 
Slowly add 88.8ml concentrated hydrochloric acid to 900ml 
distilled  H2O.    After addition of  acid  make  up  to  1L  with 
distilled H2O.   
 
Immunocytochemistry 
Paraformaldehyde solution (4%) 
Paraformaldehyde (4g) 
Add 1M NaOH until solution becomes clear.   
Make up to 100ml with 1x PBS and store in 5ml aliquots at -
20°C.   
 
Bouins fixative 
Saturated picric acid (30ml)  
Formaldehyde (10ml) 
Glacial acetic acid (2ml)  196 
0.5% Triton X-100 
Solubilise 0.5ml triton X-100 in 100ml distilled H2O and store 
at 4°C.  
 
Blocking Buffer 
1% Bovine serum albumin (1g)  
10% Normal Goat Serum (10ml) 
0.3M glycine (2.3g) 
Make up to 100ml with 1x PBS and stored in 5ml aliquots at -
20°C.   
 
ELISA 
Wash buffer 
0.05% Tween-20 (0.5ml)  
Make up to 1L with 1X PBS.   
 
Secondary antibodies 
Horseradish  peroxidase  conjugated  secondary  antibodies 
were purchased from Invitrogen (UK).    
 
Citric Acid (0.1M) 
Dissolve 21g sodium citrate in 1L distilled H2O. 
 
Sodium Phosphate (0.2M) 
Dissolve 28.4g in 1L distilled H2O.   
 
Substrate solution 
1 substrate tablet OPD  
28ml 0.1M Citric acid  
32ml 0.2M Na2HPO4  
Once the tablet has fully dissolved, add 20µl H2O2 to activate 
prior to use keep at 4°C and protect from light.   197 
Sulphuric acid (4M) 
Slowly add of 222ml concentrated sulphuric acid (95-98%) to 778ml of dH2O.   
 
SDS-PAGE 
Resolving gel buffer (4X) 
250ml 1.5M Tris pH 8.8  
10ml 10% SDS 
400ml dH2O 
10% SDS (w/v) 
Add 100g SDS in 900ml dH2O and heat to 68°C to dissolve the 
crystals.  Adjust to pH 7.2 with 1N HCl and make to 1L. 
 
10% APS (w/v) 
Add  1g  ammonium  persulphate  in  10ml  dH2O.    Store  at  -
20°C. 
 
Stacking gel buffer 
250ml 1.5M Tris pH 6.8  
10ml 10% SDS 
400ml dH2O 
 
Resolving gel (15%) 
5ml 40% acrylamide/bis solution 19:1 (Biorad, USA) 
2.5ml 4X resolving gel buffer 
2.39ml dH2O  
100µl 10% APS 
10µl TEMED 
 
Stacking gel (6%) 
1.3ml 40% acrylamide/bis solution 19:1 (Biorad, USA) 
2.5ml stacking buffer 198 
6.1ml dH2O 
 
Sample loading buffer (3X) 
2.4ml 1M tris-HCl pH 6.8 
3ml 20% SDS 
3ml 100% glycerol 
1.6ml β- mercaptoethanol 
0.006g bromophenol blue  
Store at 4°C.   
 
Running buffer (10X) 
30.3g Tris base 
144g glycine 
10g SDS 
Make up to 1L with dH2O 
 
Protein G affinity chromatography 
Binding buffer 
20mM NaH2PO4 (137g) 
Make  up  to  500ml  with  dH2O  and  adjust  to  pH7  using  1M 
NaOH.  
 
Elution Buffer  
0.1M glycine (75g) 
Make up to 500ml with dH2O and adjust to pH3 using 1N HCl. 
 
Tris-HCl (1M) 
Dissolve 60.5g tris base in 500ml with dH2O and adjust to 
pH9 using 1N HCl.   
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Primers 
Nfasc155 (Forward): 5`-CAGTGGAACCGCGTCTACTC 
Nfasc155 (Reverse): 5`- ACCACAACCATCTCCAGCTT 
Nfasc186 (Forward): 5`- TCTCCCTCAGTGCCAGGAC 
Nfasc186 (Reverse): 5`-TGGGATAGATGGGAACTGTTG 
ß-actin (Forward): 5`-TTGTAACCAACTGGGACGATATGG 
ß-actin (Reverse): GATCTTGATCTTGATGGTGCTGCTAGG 
 
Myelin purification 
Sucrose (0.32M) 
Dissolve  109.5g  of  sucrose  in  1L  distilled  H2O  with  1x 
protease inhibitor cocktail. 
 
Sucrose (0.80M)  
Dissolve  273g  of  sucrose  in  1L  distilled  H2O  1x  protease 
inhibitor cocktail.     
 
Cell culture stock solutions 
Poly-L-lysine 
25mg of poly-L-lysine hydrobromide  
Dissolve in 6.25ml sterile H2O.  Sterilise by filtering through 
a 0.22µ filter and store at -20°C in 66µl aliquots. 
For coating flasks/ coverslips add one aliquot/20ml.  Ensure 
flasks/coverslips are thoroughly rinsed and air dried before 
use.   
 
Collagenase 
Dissolve 20mg collagenase (Invitrogen, UK) to 20ml Leibovitz 
L-15 media (Invitrogen).  Sterilize using a 0.22µ filter and 
store at -20°C.   200 
 
SD (soybean trypsin inhibitor) 
Dissolve  13mg  trypsin  inhibitor  (soybean),  1mg  DNAse  I 
(bovine pancreas) and 75mg BSA fraction V in 25ml Leibovitz 
L-15  media  (Invitrogen).  Sterilize  using  a  0.22µ  filter  and 
store at -20°C.    
 
 
Glial cell culture media 
Neurosphere media 
Glucose (30%) 
Dissolve 30g of D-glucose to 100ml sterile H2O with constant 
stirring.  Filter sterilise through a 0.22µ filter and store at -
20°C.   
 
Sodium hydrogen carbonate (7.5%) 
Gradually dissolve 7.5g NaHCO3 to 100ml sterile H2O.  Filter 
sterilise through a 0.22µ filter and store at -20°C.     
 
DMEM/F12 (10X) 
Measure  400ml  sterile  H2O  in  to  a  sterile  1  litre  beaker. 
Dissolve 1 pot of DMEM powder (high glucose, Invitrogen), 
which usually makes up 5 litres and allow to fully dissolve.  
To this mix add 5 pots of F12 (usually 1L/pot) (Invitrogen).  
Bring final volume up to 500ml and filter through a 0.22µ 
filter and store at -20°C.   
 
Hepes (1M) 
Dissolve 23.8g HEPES and add to 80ml sterile H2O, once fully 
dissolved  bring  final  volume  up  to  100ml.    Sterilise  by 
filtration through a 0.22µ filter and store at -20°C.     
Putrescine 
Weigh 96.6mg putrescine and add to 100ml of sterile H2O 
once dissolved store in 25ml aliquots at -20°C.   201 
Selenium 
Dissolve 1mg sodium selenate in 1.93ml sterile H2O (3mM) 
and store at -20°C.   
Progesterone 
Dissolve 1mg progesterone in 1.59ml 95% ethanol and store 
at -20°C. 
 
Hormone mix (10X)  
Firstly prepare 1X DMEM/F12 as follows: 
10X DMEM/F12    25ml 
30% Glucose      5ml 
7.5% NaHCO3     3.75ml 
1M Hepes      1.25ml 
Sterile H2O      187.5ml 
To this solution add: 
250mg apo-human transferrin 
6.25ml human insulin (recombinant) 
25ml 600µM putrescine (final concentration 60µM) 
25µl 3mM sodium selenate 
25µl progesterone 
 
Epidermal growth factor (EGF) 
Dissolve 1mg of recombinant murine EGF (Peprotech) in 1ml 
of sterile H2O store at -20°C.  Use at a final concentration of 
4ng/ml (4µl EGF/ 20ml neurosphere media).     
 
Neurosphere media 
Neurosphere media 
Sterile H2O      185ml 
DMEM/F12 (x10)    25ml 
Hormone Mix (x10)    25ml 
30% Glucose      5ml 
7.5% NaHCO3     3.75ml 
1M HEPES      1.25ml 
L-Glutamine (200mM)  2.5ml 202 
Astrocyte growth media 
Astrocyte Media (DMEM + 10% FBS) 
DMEM (1g/L glucose, Invitrogen)    179ml 
Foetal bovine serum       20ml 
L-Glutamine (200mM)      1ml 
 
Plating media  
Plating Media 
DMEM (4.5g/L glucose)  50ml 
Horse Serum     25ml 
HBSS        25ml 
 
Differentiation media (DM)  
Biotin 
To make a 1mg/ml stock: dissolve 100mg biotin in 100ml 1M 
NaOH.  Dilute 1 in 100 with sterile H2O, filter using a 0.22µ 
filter and store at -20°C.  Use at a final concentration of 
10µg/ml.  
 
Hydrocortisone 
Dissolve  100mg  of  hydrocortisone  (H2O  soluble  form)  in 
27.6ml sterile H2O.  Dilute 1 in a 1000 by adding 20µl to 
19.88ml  of  sterile  H2O  to  create  a  10µM  stock.    Filter 
through a 0.22µ filter and store in 250µl aliquots at -20°C.   
 
Insulin 
Dissolve  100mg  insulin  (bovine  pancreas)  in  200ml  10mM 
HCl/H2O  (final  concentration  500µg/ml).    Filter  through  a 
0.22µ filter and store in 2ml aliquots at -20°C.  Use at a final 
concentration of 10µg/ml (1ml/ 50ml media). 
 
N1 supplement (100X) 
N1  supplement  containing:    0.5 mg/ml  human  transferrin 
(partially  iron-saturated),  0.5 µg/ml  sodium  selenite, 
1.6 mg/ml putrescine, and 0.73 µg/ml progesterone.  203 
Differentiation media 
Differentiation media + Insulin (50ml) 
DMEM (4.5g/L glucose)  47.25ml 
Biotin (1mg/ml)    50µl 
N1 Supplement (100X)  500µl 
Hydrocortisone (10µM)  250µl 
Insulin  (0.5mg/ml)    1ml 
 
Differentiation media – Insulin (50ml) 
DMEM (4.5g/L glucose)  48.2ml 
Biotin (1mg/ml)    50µl 
N1 Supplement (100X)  500µl 
Hydrocortisone (10µM)  250µl 
 
 
Hybridoma cell culture media 
Z2 and 8-18C5 hybridoma 
RPMI complete + 10% FBS 
RPMI (1640)        429.5ml 
Foetal bovine serum    50ml 
L-glutamine (200mM)    5ml 
Non-essential aas (100X)    5ml 
Penicillin/streptomycin    5ml 
Sodium Pyruvate (100mM)   5ml 
β- mercaptoethanol (50mM)  500µl 
 
 
 
A12/18.1 hybridoma 
DMEM complete + 10% FBS 
DMEM (4.5g/L glucose, Invitrogen)  424.5ml 
Foetal bovine serum      50ml 
L-glutamine (200mM)      5ml 
Non-essential aas (100X)      5ml 204 
L-Asparagine (2.5M)        5ml 
Sodium Pyruvate (100mM)     5ml 
Penicillin/streptomycin      5ml 
β- mercaptoethanol (50mM)    500µl 
 
Transfected cell media 
Untransfected HeLa cells 
DMEM complete + 10% FBS 
DMEM (4.5g/L glucose)      429.5ml 
Foetal bovine serum      50ml 
L-glutamine (200mM)      5ml 
Non-essential aas (100X)      5ml 
Sodium Pyruvate (100mM)     5ml 
Penicillin/streptomycin      5ml 
β- mercaptoethanol (50mM)    500µl 
 
 
Transfectants 
DMEM complete + 10% FBS with G418 
DMEM (4.5g/L glucose)      429.5ml 
Foetal bovine serum      50ml 
L-glutamine (200mM)      5ml 
Non-essential aas (100X)      5ml 
Sodium Pyruvate (100mM)     5ml 
Penicillin/streptomycin      5ml 
G418            5ml 
β- mercaptoethanol (50mM)    500µl 
 
 
 205 
Statistics 
All calculations were performed using Microsoft Excel.  Values were calculated 
using the formulae defined below;  
Mean 
 
Standard deviation 
 
Standard error of the mean (S.E.M) 
 
T-Test 
 
Coefficient of Variance 
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Myelin Quantification Macro (written by John Annan) 
//set the thresholds here 
thresh_red = 33; 
thresh_green = 79; 
thresh_blue = 128; 
 
//get the name of the open image, and the folder it came from 
iTitle=getTitle; 
imageDirectory = getDirectory("image"); 
print (imageDirectory); 
print ("Image name,Red Black,Red White,Green Black,Green 
White,Blue Black,Blue White") 
 
//build a list of all images in the folder 
fList=getFileList(imageDirectory); 
selectWindow(iTitle); 
run("Close"); 
 
//start the loop to open files 
for (i=0; i<fList.length; i++){ 
  //check that file is a valid image 
  if (endsWith(fList[i],"tif")) { 
  //if it is valid, open it 
  open(imageDirectory + fList[i]); 
 
  //build names of colour component images 
  iTitle=getTitle; 
  iTitleRed=iTitle + " (red)"; 
  iTitleGreen=iTitle + " (green)"; 
  iTitleBlue=iTitle + " (blue)"; 
 
 
  //split image into colour components 
  run("RGB Split"); 
 
  //get red and blue areas and threshold 
   
  string="image1=["+iTitleGreen + "] operation=AND 
image2=[" + iTitleBlue+"] create"; 
  run("Image Calculator...", string); 
  iTitleAND = getTitle; 
  setThreshold(thresh_blue, 255); 
  run("Threshold", "thresholded remaining black"); 
  run("Invert"); 
 
  //measure areas 
     getStatistics(area, mean, min, max, std, histogram); 
  n_blue_black=histogram[0]; 
  n_blue_white=histogram[255]; 
 
  //close windows 
  selectWindow(iTitleAND); 207 
  run("Close"); 
  selectWindow(iTitleBlue); 
  run("Close"); 
 
 
  //get red threshold 
  selectWindow(iTitleRed); 
  setThreshold(thresh_red, 255); 
  run("Threshold", "thresholded remaining black"); 
  run("Invert"); 
 
  //measure areas 
     getStatistics(area, mean, min, max, std, histogram); 
  n_red_black=histogram[0]; 
  n_red_white=histogram[255]; 
 
  selectWindow(iTitleRed); 
  run("Close"); 
 
  //get green threshold 
  selectWindow(iTitleGreen); 
  setThreshold(thresh_green, 255); 
  run("Threshold", "thresholded remaining black"); 
  run("Invert"); 
 
  //measure areas 
     getStatistics(area, mean, min, max, std, histogram); 
  n_green_black=histogram[0]; 
  n_green_white=histogram[255]; 
 
  selectWindow(iTitleGreen); 
  run("Close"); 
   
  //display results 
  print 
(iTitle+","+n_red_black+","+n_red_white+","+n_green_black+","
+n_green_white+","+n_blue_black+","+n_blue_white); 
 
  } 
} 
 